---
title: "Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence. Covers ABTECT-1, ABTECT-2, ABTECT maintenance, ABX464-103, ABX464-104, ABX464-101, and 9 further headings. 587 evidence topics quoted from 82 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 ABTECT-1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.1-2"></a>

###### Primary objectives for the FDA and for the EMA in the protocol

> “The primary/co-primary and key secondary efficacy endpoints will be analyzed separately for FDA and National Regulatory Authorities other than EMA.”
> “For the FDA and National Regulatory Authorities other than EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on clinical remission defined as:”
> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.1-3"></a>

###### Place of the trial in the phase 3 development plan

> “This study is part of a phase 3 clinical development program comprising two similar 8-week induction studies (ABX464-105 and ABX464-106), followed by a maintenance study (ABX464-107) to confirm the efficacy and safety of obefazimod in the short and long-term treatment of moderate to severely active UC in adults and adolescents from 16 to 18 years of age.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.1-4"></a>

###### Main objective in the EU Clinical Trials Information System record

> “Main objective To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [EU Clinical Trials Information System 2022-500535-36-01](https://euclinicaltrials.eu/ctis-public/view/2022-500535-36-01)

<a id="topic-3.1.1.1-5"></a>

###### Aim stated in the late-breaking abstract

> “Here we report efficacy and safety of two Phase 3, 8‐week, induction trials in adult pts with UC from ABTECT‐1 [ NCT05507203 ] and ABTECT‐2 [ NCT05507216 ].”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-11-16”
> “Primary Completion (Actual) 2025-06-24”
> “Study Completion (Actual) 2025-06-25”
> “First Posted 2022-08-18”
> “Results First Posted 2026-09-10”
> “Last Update Posted 2026-09-10”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 264 locations”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.2-3"></a>

###### Planned number of sites and potential countries in the protocol

> “Approximately 350 sites located worldwide will participate in the study.”
> “(List of potential countries: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Hungary, India, Italy, Korea, Netherlands, Poland, Portugal, Spain, Switzerland, Turkey, UK, Ukraine, USA)”
> “Recruitment period: Q3 2022 Q4 2024 (approx. 26 months)”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.2-4"></a>

###### Sites and countries of the two induction trials stated by the company

> “ABTECT-1 and ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients from over 600 participating clinical trial sites in 36 countries with the intent to satisfy regulatory requirements globally.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.2-5"></a>

###### Start of the phase 3 trials and first U.S. enrollment

> “We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active UC in October 2022, which consists of two induction trials (ABTECT-1 and ABTECT-2) and one ABTECT maintenance trial.”
> “Enrollment of the first patient under this program in the United States occurred on October 11, 2022.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.2-6"></a>

###### EU member states and trial dates in the EU Clinical Trials Information System record

> “Locations Netherlands, Poland, Austria, Italy, Germany, Spain, Greece, France, Portugal, Czechia, Hungary, Bulgaria, Belgium”
> “Start of trial 12/06/2023 End of trial 25/06/2025 Global end of trial 25/06/2025”

Source: [EU Clinical Trials Information System 2022-500535-36-01](https://euclinicaltrials.eu/ctis-public/view/2022-500535-36-01)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Triple”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.3-2"></a>

###### Periods, randomization ratio, and planned arm sizes in the protocol

> “This induction study is a multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of obefazimod given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response (lack of response, loss of response, or intolerance) to either conventional therapies and/or advanced therapies.”
> “As shown below, this study consists of a screening period of up to 4 weeks, an 8-week induction period followed by 4-week follow up period.”
> “On Day 1, eligible subjects will be randomized and allocated into three treatment arms according to ratio 1:1:2 as follows: Placebo: 153 subjects Obefazimod Daily dose 25 mg QD: 153 subjects Obefazimod Daily dose 50 mg QD: 306 subjects”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Randomization stratification factors

> “Randomization will be stratified according to the following factors: Subjects with inadequate response to advanced therapies [AT-IR subjects] (lack of response, loss of response or intolerance to advanced therapies (Yes/No) Subjects with concomitant oral corticosteroids at baseline (Yes/No)”
> “Previous discontinuation of an advance therapy for any reason other than inadequate response, e.g., pregnancy, economic reasons or termination of a clinical trial, will not be considered as AT-IR.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Endoscopy, central reading, and electronic diaries

> “During the screening period, a full colonoscopy will be performed for all subjects unless one has been performed within the last 3 months before screening.”
> “At Week 8, only a flexible sigmoidoscopy is required.”
> “Endoscopies will be centrally read.”
> “Biopsies will be centrally analyzed.”
> “e-Diaries will be used to collect stool frequency, rectal bleedings, nocturnal bowel movements, bowel urgency and fatigue NRS on a daily basis, as well as whether the subjects took the study treatment and the intake time.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Independent central review of video-recorded endoscopies stated by the company

> “Each of the trials were randomized, double-blind and placebo-controlled, using independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance trial (total 52 weeks), as recommended by the FDA.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.3-6"></a>

###### Entry into the maintenance trial after Week 8

> “In the randomized double-blind placebo-controlled study part [Part 1; placebo, obefazimod 25 mg, obefazimod 50 mg] for clinical responders at Week 8.”
> “In the double-blind multi-arm study part [Part 2; obefazimod 25 mg or obefazimod 50 mg] for non-clinical responders at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Rationale for the doses and the 8-week treatment duration in the protocol

> “The ABX464-103 phase 2b UC study has demonstrated that the 25 mg dose was also efficacious for induction with a safety profile comparable to placebo (except transient headaches generally reported during the first several days of treatment).”
> “The 100 mg dose showed similar efficacy to the 25 and 50 mg doses but with a higher incidence of most frequently reported TEAEs and was not selected for this”
> “After 16 weeks of treatment there were a limited number of patients who achieved a clinical response that was not observed at Week 8. Therefore, it is reasonable to define 8 weeks as the treatment duration for the induction study.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-8"></a>

###### Design stated in the late-breaking abstract

> “Pts were randomized 2:1:1 to Obe 50 mg QD (Obe‐50), Obe 25 mg QD (Obe‐25) or placebo (PBO) for 8 weeks.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”
> “Documented diagnosis of UC confirmed by endoscopy and histology.”
> “Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).”
> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.”
> “Subjects with primary sclerosing cholangitis or autoimmune hepatitis.”
> “Subjects on antidiarrheals including those working on motility (e.g., loperamide, diphenoxylate with atropine, etc.).”
> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Subjects with HIV infection.”
> “Subjects with a family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female).”
> “Subjects previously treated with ABX464.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.4-3"></a>

###### Minimum age by region in the protocol

> “Male or female (at birth) at least 16 years old, except in European Union (EU)/European Economic Area (EEA) and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.4-4"></a>

###### Definition of inadequate response to JAK inhibitors in the protocol

> “Inadequate response to JAK inhibitors (tofacitinib, filgotinib, upadacitinib) is defined as: i. Lack of response to an induction course; ii. Loss of response or recurrence of symptoms during maintenance course following primary response after induction course (discontinuation despite clinical benefit does not qualify); iii. Intolerance to JAK inhibitor treatment including (but not limited to) increase of serious infection, malignancies, deep venous thrombosis (DVT), or major adverse cardiac event (MACE).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.4-5"></a>

###### Eligibility summarized in the late-breaking abstract

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and administration in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| ABX464 50 mg | “Experimental: ABX464 50mg Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| ABX464 25 mg | “Experimental: ABX464 25mg Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| Placebo | “Placebo Comparator: Placebo Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| Intervention | “Administered once daily in the morning with food” |
| Other name of ABX464 | “Obefazimod” |

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.5-2"></a>

###### Capsule strengths and dosing instructions in the protocol

> “Depending on the treatment arm allocation, obefazimod or its matching placebo (capsules) 50 mg and 25 mg are administered once daily in a fed condition (ideally at the same time in the morning) for 8 weeks during the induction phase.”
> “25 mg regimen: 1 capsule of obefazimod 25 mg per day”
> “50 mg regimen: 1 capsule of obefazimod 50 mg per day”
> “1 capsule of placebo per day”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.5-3"></a>

###### Background ulcerative colitis therapy allowed during the trial

> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study), the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”
> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Doses and route stated by the company

> “The ABTECT-1 and ABTECT-2 induction trials are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint and its definition in the ClinicalTrials.gov record

> “Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8”
> “Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).”
> “Modified Mayo score is a composite measure of ulcerative disease activity consisting of three components: stool frequency, rectal bleeding and endoscopic subscores. Each component is scored from 0 (normal or inactive disease) to 3 (severe activity). The total range score ranges from 0 to 9, with higher scores indicating more severe disease activity.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.6.1-2"></a>

###### FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “Stool frequency subscore = 0 or 1”
> “Rectal bleeding subscore = 0”
> “Centrally read endoscopy subscore = 0 or 1 (score of 1 modified to”
> “exclude friability)”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-3"></a>

###### Reason the physician global assessment is excluded from the modified Mayo Score

> “The mMS is a composite endpoint consisting of rectal bleeding, stool frequency, and endoscopy subscores, adapted from the originally published Mayo Score. The previously used physician global assessment component is excluded to reduce subjectivity and focus the evaluation on the subject’s directly reported symptoms and directly observable endoscopic findings.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-4"></a>

###### FDA recommendations on entry criteria and central reading of endoscopy

> “Subjects should have a score of 5 to 9 on the modified Mayo Score (mMS),”
> “including an endoscopy subscore of at least 2.”
> “We recommend using centralized reading of endoscopies as the primary approach”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-5"></a>

###### Company statement that the endpoint and entry criteria follow FDA guidance

> “The inclusion criteria based on FDA guidance for moderately to severely active UC is active disease defined by a Modified Mayo Score ≥ 5 with (RBS) ≥ 1 and endoscopy subscore of 2 or 3 (confirmed by central reader).”
> “The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.6.1-6"></a>

###### Co-primary endpoints for the EMA: endoscopic improvement and symptomatic remission

> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission. The co-primary endpoints are defined as: o Proportion of subjects who achieve endoscopic improvement at Week 8 o Proportion of subjects with symptomatic remission at Week 8.”
> “Symptomatic remission is defined as SFS = 0 or 1 and RBS = 0.”
> “Endoscopic improvement is defined as MES = 0 or 1 (MES of 1 modified to exclude friability).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### Key secondary endpoints for the FDA

> “For the FDA and National Regulatory Authorities other than EMA, the key secondary efficacy objectives and endpoints are: To compare the efficacy of obefazimod versus placebo on endoscopic improvement. o Proportion of subjects who achieve endoscopic improvement at Week 8. To compare the efficacy of obefazimod versus placebo on clinical response o Proportion of subjects with clinical response at Week 8. To compare the efficacy of obefazimod versus placebo on HEMI. o Proportion of subjects with HEMI per Geboes scoring at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-8"></a>

###### Secondary endpoint definitions in the ClinicalTrials.gov record

> “Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.”
> “HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.6.1-9"></a>

###### Patient-reported and other secondary endpoints in the protocol

> “To compare the efficacy of obefazimod versus placebo on Bowel Urgency (BU). o Proportion of subjects with BU = 0 by visit in the subpopulation of subjects with BU at baseline.”
> “To compare the efficacy of obefazimod versus placebo on FACIT-Fatigue questionnaire. o Change from baseline in the FACIT-Fatigue at Week 8.”
> “To compare the efficacy of obefazimod versus placebo on IBDQ. o Change from Baseline in IBDQ total score and domain subscores at Week 8.”
> “To compare the efficacy of obefazimod versus placebo on EQ-5D-5L. o Change from baseline in EQ-5D-5L score by visit.”
> “To compare the efficacy of obefazimod versus placebo in WPAI. o Change from baseline in WPAI:UC score at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### Status of symptomatic remission under each regulatory protocol in the late-breaking abstract

> “Symptomatic remission was an “other secondary” endpoint, not multiplicity controlled, for the FDA protocol.”
> “Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned sample size in the protocol

> “Approximately 612 subjects will be randomized in this study.”
> “A total of 612 subjects (153:153:306) will allow the detection of a difference of at least”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 639”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants analyzed by arm in the posted results

| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Started | “318” | “161” | “160” | Not reported |
| Baseline (Full Analysis Set) | “318” | “160” | “158” | “636” |
| Primary and secondary endpoints (Full Analysis Set) | “318” | “160” | “158” | Not reported |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” | Not reported |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants randomized and treated in the late-breaking abstract

> “1272 pts were randomized and treated in ABTECT‐1 (636) and ABTECT‐2 (636).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants randomized across both induction trials stated by the company

> “Overall, 1,275 patients were randomized and 1,272 patients were treated in ABTECT-1 (N=636) and ABTECT-2 (N=636).”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Full Analysis Set and participants randomized but not dosed

> “The Full Analysis Set includes all randomized participants who received at least one dose of study drug. One participant in the ABX464 25 mg group and 2 in the placebo group were randomized but did not receive any dose of study drug.”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.7.2-2"></a>

###### Analysis sets in the statistical analysis plan

> “The Randomized Set includes all subjects who were randomized to study treatment.”
> “The FAS includes all randomized subjects who received at least one dose of study drug. Subjects will be analyzed according to the treatment group to which they were randomized (i.e., “as randomized”), regardless of the treatment received. The efficacy analysis will be based on the FAS.”
> “The Safety Set includes all randomized subjects who have received at least one dose of study drug. Subjects will be analyzed according to the treatment received (i.e., “as treated”).”

Source: [Abivax ABX464-105 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/SAP_001.pdf)

<a id="topic-3.1.1.7.2-3"></a>

###### Primary analysis method and testing sequence in the protocol

> “will be analyzed using a Cochran Mantel Haenszel test (CMH) test adjusting for AT-IR (yes/no) and baseline oral corticosteroid treatment (yes/no) as stratification factors, using the Full Analysis Set (FAS).”
> “If comparisons on primary endpoints for each dose are statistically significant, then, the testing procedure will continue through each of the key secondary endpoints in the prespecified order until an endpoint fails to reach statistical significance, after which all subsequent key secondary endpoints will be considered exploratory.”
> “Interim analysis: No interim analysis is planned.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Handling of intercurrent events and missing data in the statistical analysis plan

> “The Composite Strategy will be applied for each of the above IEs for the main analyses of all primary and key secondary estimands.”
> “For the supplementary analysis of all primary and key secondary estimands, a Treatment Policy approach will be applied for the above three IEs.”
> “In the main analysis of all binary responder-type endpoints, subjects with missing data, regardless of reason for missingness, will be considered as non-responders.”

Source: [Abivax ABX464-105 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/SAP_001.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Testing hierarchy and pooled analysis in the late-breaking abstract

> “Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.”
> “NRI is used for subjects with missing outcome at week 8 and subjects reporting any IE prior to week 8. % Difference is for Obe minus placebo and is based on estimated common risk difference using the Mantel‐Haenszel weights adjusting for the randomization stratification factors: inadequate response to advanced therapies (yes/no), baseline oral corticosteroids usage (yes/no), and region (Japan/rest of world) [ABTECT‐2 only].”
> “for pooled analysis, all p ‐values are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Participant flow by arm in the posted results

| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Started | “318” | “161” | “160” |
| Completed | “291” | “155” | “143” |
| Not completed | “27” | “6” | “17” |
| Adverse event | “18” | “0” | “6” |
| Lost to follow-up | “1” | “1” | “1” |
| Never dosed | “0” | “1” | “1” |
| Non-compliance with study drug | “2” | “0” | “0” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “0” | “1” |
| Withdrawal by subject | “4” | “4” | “7” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.1-2"></a>

###### Participants randomized but never dosed

> “One participant in ABX464 25 mg group was never dosed. Two participants in the placebo group were never dosed: One participant reason recorded for non-completion is "never dosed". One participant reason recorded for non-completion is 'adverse event" (the adverse event occurred before first dose administration).”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.1-3"></a>

###### Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons

| Disposition | Obefazimod 50 mg | Obefazimod 25 mg | Placebo |
| --- | --- | --- | --- |
| Participants who discontinued the study, n (%) | “54 (8.5)” | “23 (7.2)” | “31 (9.7)” |
| Adverse event, n (% of discontinuations) | “31 (57.4)” | “8 (34.8)” | “14 (45.2)” |
| Withdrawal by subject | “13 (24.1)” | “10 (43.5)” | “10 (32.3)” |
| Lack of efficacy | “2 (3.7)” | “2 (8.7)” | “1 (3.2)” |
| Lost to follow-up | “4 (7.4)” | “1 (4.3)” | “1 (3.2)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Percentages are calculated relative to the number of randomized pts (ie, N=636, 320, 319 for Obe-50, Obe-25, PBO, respectively).”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.1-4"></a>

###### Pooled ABTECT-1 and ABTECT-2: entry into the maintenance trial

> “Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the maintenance trial.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline characteristics by arm in the posted results

| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) | Total (n=636) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “42.7(14.3)” | “41.5(13.54)” | “43.1(13.59)” | “42.5(13.93)” |
| Age 65 years or older, participants | “25” | “12” | “11” | “48” |
| Female, participants | “129” | “56” | “66” | “251” |
| Male, participants | “189” | “104” | “92” | “385” |
| Asian, participants | “87” | “34” | “45” | “166” |
| Black or African American, participants | “5” | “3” | “2” | “10” |
| White, participants | “219” | “114” | “106” | “439” |
| Weight, kg, mean (SD) | “72.41(18.581)” | “72.58(17.269)” | “71.28(16.392)” | “72.17(17.713)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.98(7.348)” | “7.8(7.151)” | “7.51(7.761)” | “7.82(7.395)” |
| At least one prior advanced therapy inadequate response, participants | “149” | “70” | “69” | “288” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “22” | “15” | “15” | “52” |
| Modified Mayo Score, mean (SD) | “6.9(1.06)” | “6.8(1.04)” | “6.9(1.04)” | “6.9(1.05)” |
| Mayo endoscopic subscore 2, participants | “128” | “69” | “64” | “261” |
| Mayo endoscopic subscore 3, participants | “190” | “91” | “94” | “375” |
| Fecal calprotectin, µg/g, mean (SD) | “3768.46(6219.12)” | “2533.58(3761.06)” | “5390.53(9479.94)” | “3828.77(6729.81)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.2-2"></a>

###### Proportion with prior advanced therapy inadequate response in the late-breaking abstracts

> “In both trials, baseline demographics and disease characteristics were similar between groups; 45.3% and 49.3% of pts had inadequate response to one or more advanced therapies.”
> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.2-3"></a>

###### Pooled ABTECT-1 and ABTECT-2: endoscopic severity and prior JAK inhibitor failure

> “A total of 1272 patients were enrolled across the ABTECT trials, with approximately 60% being classified as having an endoscopic subscore of 3. Of the total pooled population, approximately 47% were classified as having a prior inadequate response to advanced therapy (‘AT-IR Yes’) with approximately 21% having failed to respond to a JAK inhibitor.”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-3.1.1.8.2-4"></a>

###### Pooled ABTECT-1 and ABTECT-2: baseline disease extent

> “Among randomized and treated pts in ABTECT trials, 280 presented with proctosigmoiditis, 474 with left-sided colitis, and 497 with extensive colitis.”

Source: [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669)

<a id="topic-3.1.1.8.2-5"></a>

###### Pooled ABTECT-1 and ABTECT-2: baseline disease duration

> “Of the 1272 randomized and treated pts in ABTECT trials, 250 pts had BDD<2, 662 pts had BDD2-10 and 360 pts had a BDD≥10.”
> “Baseline demographics and disease characteristics were overall equivalent between treatment groups, and comparable between BDD groups except a higher proportion of BDD2-10 and BDD≥10 pts having endoscopic score of 3 and prior inadequate response to advanced therapy vs BDD<2 pts.”

Source: [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748)

<a id="topic-3.1.1.8.2-6"></a>

###### Pooled ABTECT-1 and ABTECT-2: treatment exposure

| Exposure | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Duration of exposure, days, mean (SD) | “58.8 (12.62)” | “59.5 (11.14)” | “58.7 (11.14)” |
| Duration of exposure, days, median [min, max] | “60.0 [1, 106]” | “61.0 [4, 96]” | “61.0 [5, 102]” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary and key secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) | 25 mg minus placebo, % | 25 mg p-value | 50 mg minus placebo, % | 50 mg p-value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical remission (primary) | “2.5 (4)” | “23.8 (38)” | “21.7 (69)” | “21.4” | “p < 0.0001” | “19.3” | “p < 0.0001” |
| Clinical response | “28.5 (45)” | “65.6 (105)” | “61.0 (194)” | “37.2” | “p < 0.0001” | “32.6” | “p < 0.0001” |
| Endoscopic improvement | “5.7 (9)” | “37.5 (60)” | “33.3 (106)” | “32.0” | “p < 0.0001” | “27.8” | “p < 0.0001” |
| HEMI | “3.2 (5)” | “23.8 (38)” | “23.0 (73)” | “20.7” | “p < 0.0001” | “20.0” | “p < 0.0001” |
| Symptomatic remission | “17.7 (28)” | “42.5 (68)” | “41.2 (131)” | “24.9” | “p < 0.0001” | “23.7” | “p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-2"></a>

###### Participants meeting each endpoint at Week 8 in the posted results

| Endpoint at Week 8, participants | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) |
| --- | --- | --- | --- |
| Clinical remission per modified Mayo Score (primary) | “69” | “38” | “4” |
| Endoscopic improvement | “106” | “60” | “9” |
| Clinical response per modified Mayo Score | “194” | “105” | “45” |
| HEMI per Geboes | “73” | “38” | “5” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.3-3"></a>

###### Primary endpoint result stated by the company

> “Individually, ABTECT-1 showed a placebo-adjusted clinical remission rate of 19.3% (p<0.0001) and ABTECT-2 demonstrated 13.4% (p=0.0001), each at the 50 mg once-daily dose, with all key secondary efficacy endpoints being met.”
> “The 25 mg once-daily dose of obefazimod achieved the FDA primary endpoint of clinical remission at Week 8 in ABTECT-1 demonstrating a placebo-adjusted remission rate of 21.4%.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.8.3-4"></a>

###### Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=317) | Obefazimod 25 mg (N=319) | Obefazimod 50 mg (N=636) | 25 mg minus placebo, % | 50 mg minus placebo, % |
| --- | --- | --- | --- | --- | --- |
| Clinical remission | “4.4 (14)” | “17.6 (56)” | “20.8 (132)” | “13.2” | “16.4” |
| Clinical response | “30.9 (98)” | “59.6 (190)” | “62.1 (395)” | “28.6” | “31.2” |
| Endoscopic improvement | “7.9 (25)” | “29.8 (95)” | “34.4 (219)” | “21.9” | “26.6” |
| HEMI | “5.4 (17)” | “18.5 (59)” | “23.4 (149)” | “13.2” | “18.2” |
| Symptomatic remission | “19.9 (63)” | “37.9 (121)” | “40.7 (259)” | “18.1” | “21.0” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “In a pooled analysis, both Obe‐50 and Obe‐25 met all primary and secondary endpoints with nominal significance ( p < 0.0001) (Table 1).”
> “for pooled analysis, all p ‐values are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-5"></a>

###### Pooled ABTECT-1 and ABTECT-2: early symptomatic improvement from Week 1

> “In a pooled analysis of the Phase 3 ABTECT-1 and ABTECT-2 induction trials, both Obe-50mg and Obe-25mg produced reductions in rectal bleeding subscores and stool frequency subscores versus PBO starting from week 1 and reaching a nominally significant difference by week 2 (p-value <0.05)”
> “A greater proportion of patients receiving obefazimod (50mg or 25mg) versus PBO achieved symptomatic response from week 1 and symptomatic remission from week 2 increasing through week 8”

Source: [Abivax press release, ECCO 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod)

<a id="topic-3.1.1.8.3-6"></a>

###### Pooled presentation of both trials: miR-124 expression and serum IL-17A and IL-6 at Week 8

> “In both Phase 3 ABTECT induction trials, Obe-25mg and Obe-50mg significantly enhanced expression of miR-124 in blood (unadjusted p < 0.0001 vs. PBO) and in rectal and sigmoidal tissue (unadjusted p < 0.0001 vs. PBO) at week 8”
> “At week 8, Obe-25mg and Obe-50mg significantly reduced IL-17A levels in serum (unadjusted p < 0.0001 vs. PBO); Obe-25mg (p=0.0150 vs. PBO) and Obe-50mg (p=0.0039 vs. PBO) decreased IL-6 levels in serum”

Source: [Abivax press release, ECCO 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod)

<a id="topic-3.1.1.8.3-7"></a>

###### Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=69) | AT-IR-Yes 25 mg (N=70) | AT-IR-Yes 50 mg (N=149) | AT-IR-No placebo (N=89) | AT-IR-No 25 mg (N=90) | AT-IR-No 50 mg (N=169) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “1.4 (1)” | “8.6 (6)” | “14.1 (21)” | “3.4 (3)” | “35.6 (32)” | “28.4 (48)” |
| Endoscopic improvement | “4.3 (3)” | “14.3 (10)” | “22.1 (33)” | “6.7 (6)” | “55.6 (50)” | “43.2 (73)” |
| Symptomatic remission | “10.1 (7)” | “27.1 (19)” | “34.9 (52)” | “23.6 (21)” | “54.4 (49)” | “46.7 (79)” |
| HEMI | “1.4 (1)” | “5.7 (4)” | “12.8 (19)” | “4.5 (4)” | “37.8 (34)” | “32.0 (54)” |
| Clinical response | “21.7 (15)” | “52.9 (37)” | “54.4 (81)” | “33.7 (30)” | “75.6 (68)” | “66.9 (113)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “7.1 p = 0.0556” | “12.7 p = 0.0039” | “32.4 p < 0.0001” | “25.0 p < 0.0001” |
| Endoscopic improvement | “9.9 p = 0.0457” | “17.8 p = 0.0011” | “48.9 p < 0.0001” | “36.4 p < 0.0001” |
| Symptomatic remission | “17.0 p = 0.0108” | “25.0 p = 0.0001” | “31.0 p < 0.0001” | “23.2 p = 0.0003” |
| HEMI | “4.3 p = 0.1803” | “11.3 p = 0.0073” | “33.4 p < 0.0001” | “27.5 p < 0.0001” |
| Clinical response | “31.2 p = 0.0002” | “32.5 p < 0.0001” | “41.8 p < 0.0001” | “33.2 p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-8"></a>

###### Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=148) | AT-IR-Yes 25 mg (N=146) | AT-IR-Yes 50 mg (N=308) | AT-IR-No placebo (N=169) | AT-IR-No 25 mg (N=173) | AT-IR-No 50 mg (N=328) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “3.4 (5)” | “6.8 (10)” | “13.3 (41)” | “5.3 (9)” | “26.6 (46)” | “27.7 (91)” |
| Endoscopic improvement | “6.8 (10)” | “13.0 (19)” | “24.4 (75)” | “8.9 (15)” | “43.9 (76)” | “43.9 (144)” |
| Symptomatic remission | “12.8 (19)” | “26.7 (39)” | “36.0 (111)” | “26.0 (44)” | “47.4 (82)” | “45.1 (148)” |
| HEMI | “4.1 (6)” | “6.8 (10)” | “14.9 (46)” | “6.5 (11)” | “28.3 (49)” | “31.4 (103)” |
| Clinical response | “20.9 (31)” | “46.6 (68)” | “55.8 (172)” | “39.6 (67)” | “70.5 (122)” | “68.0 (223)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “3.5 p = 0.1728” | “10.1 p = 0.0009” | “21.3 p < 0.0001” | “22.4 p < 0.0001” |
| Endoscopic improvement | “6.4 p = 0.0687” | “17.8 p < 0.0001” | “34.9 p < 0.0001” | “34.9 p < 0.0001” |
| Symptomatic remission | “13.8 p = 0.0031” | “23.4 p < 0.0001” | “21.3 p < 0.0001” | “19.2 p < 0.0001” |
| HEMI | “2.9 p = 0.2785” | “11.1 p = 0.0005” | “21.7 p < 0.0001” | “24.7 p < 0.0001” |
| Clinical response | “25.6 p < 0.0001” | “34.9 p < 0.0001” | “30.7 p < 0.0001” | “28.2 p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-9"></a>

###### Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)

| Subset of AT-IR participants | Placebo, % (n/N) | Obefazimod 25 mg, % (n/N) | 25 mg minus placebo, % and p-value | Obefazimod 50 mg, % (n/N) | 50 mg minus placebo, % and p-value |
| --- | --- | --- | --- | --- | --- |
| Prior JAK inhibitor failure | “20.0 (7/35)” | “47.1 (16/34)” | “27.0 p = 0.0196” | “54.5 (30/55)” | “34.4 p = 0.0017” |
| 1 advanced therapy failure | “24.2 (15/62)” | “53.3 (24/45)” | “30.5 p = 0.0018” | “50.7 (76/150)” | “25.3 p = 0.0008” |
| 2 advanced therapy failures | “20.6 (7/34)” | “48.9 (22/45)” | “28.6 p = 0.0114” | “67.2 (43/64)” | “45.5 p < 0.0001” |
| 3 advanced therapy failures | “14.3 (4/28)” | “42.4 (14/33)” | “27.3 p = 0.0297” | “61.5 (32/52)” | “46.3 p < 0.0001” |
| 4 or more advanced therapy failures | “20.8 (5/24)” | “34.8 (8/23)” | “14.4 p = 0.2968” | “50.0 (21/42)” | “28.7 p = 0.0242” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “In the AT‐IR‐No subgroup, Obe‐50 and Obe‐25 performed similarly in the pooled analysis across efficacy measures.”
> “The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-10"></a>

###### Pooled ABTECT-1 and ABTECT-2: definition of inadequate response to advanced therapies in the subgroup analysis

> “ABTECT-1&2 pooled analysis; all p-values are nominal; AT-IR was defined as inadequate response, loss of response, or intolerance to advanced therapies including biologics, JAK inhibitors, and S1P modulators”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-3.1.1.8.3-11"></a>

###### Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease extent (post hoc, nominal p-values)

> “For this post-hoc analysis, pts were categorized by baseline disease extent as designated by investigator: proctosigmoiditis, left-sided colitis, or extensive colitis.”
> “In the pooled analysis, greater proportions of pts treated with Obe-25 and Obe-50 versus PBO achieved clinical remission in pts with proctosigmoiditis (Obe-25-PBO difference: 16.1%, p = 0.0009; Obe-50-PBO difference: 19.5%, p < 0.0001) and left-sided colitis (Obe-25-PBO difference: 21.1%, p < 0.0001; Obe-50-PBO difference: 23.6%, p < 0.0001), and met all other evaluated efficacy endpoints with nominal significance (Table).”
> “In pts with extensive colitis at baseline, greater proportions of pts treated with Obe-50 versus PBO achieved clinical response, symptomatic response/remission, endoscopic improvement, and HEMI with nominal significance.”

Source: [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669)

<a id="topic-3.1.1.8.3-12"></a>

###### Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease duration (post hoc, nominal p-values)

> “In a pooled analysis, a higher proportion of pts receiving Obe-25 or Obe-50 versus PBO achieved clinical remission across BDD subgroups (Obe-50-PBO difference: BDD<2: 20.6%; BDD2-10: 17.8%; BDD≥10: 12.5%; Obe-25-PBO difference: BDD<2: 13.6%; BDD2-10: 13.2%; BDD≥10: 13.0%) and met most endpoints across BDD subgroups with nominal significance (Table).”
> “A numerical trend of greater efficacy with shorter disease duration was observed.”

Source: [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Pooled ABTECT-1 and ABTECT-2: bowel urgency, nocturnal bowel movements, and fatigue at Week 8

> “Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.”
> “At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group”
> “47.6% of patients on 50mg obefazimod reported no nocturnal bowel movements (NBM) at week 8 compared to 24.7% in the placebo group”
> “In the 50 mg group 17.1% of patients reported fatigue remission as measured with the Fatigue Numerical Rating Scale (NRS) at week 8, compared to 7.7% in the placebo group”

Source: [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect)

<a id="topic-3.1.1.8.4-2"></a>

###### Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)

> “The IBDQ has four domains, scores range 32-224; higher scores=better QoL. Meaningful within patient change (MWPC) for IBDQ total score was defined as ≥ 16 point change and remission as ≥ 170 points.”
> “All p-values are nominal.”
> “1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1207 had IBDQ, 1137 had EQ-5D-5L Index and 1,180 had EQ-5D-5L VAS data at baseline.”
> “At baseline, pts had mean IBDQ total scores of 110.8, 110.8, and 109.7 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher mean IBDQ scores vs PBO: 161.9, 159.2, and 135.7 in the Obe-50, Obe-25 and PBO groups respectively (Obe-50:Δ25.97 and Obe-25:Δ22.33, p < 0.0001).”
> “At Week 8, a greater proportion of Obe-treated pts had a MWPC: 60.9% for Obe-50 and 56.9% for Obe-25 vs 39.8% for PBO (Obe-50:Δ21.20 and Obe-25:Δ17.07, p < 0.0001). More Obe-treated pts without IBDQ remission at baseline achieved IBDQ remission: 36.7% for Obe-50 and 33.2% for Obe-25 vs 19.6% for PBO (Obe-50:Δ17.13 and Obe-25:Δ13.56, p < 0.001).”
> “At baseline, mean EQ-5D-5L Index scores were 0.66, 0.64, and 0.63 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher EQ-5D-5L Index scores vs PBO: mean 0.82, 0.81, and 0.71 in the Obe-50, Obe-25 and PBO groups, respectively (Obe-50:Δ0.10 and Obe-25:Δ0.09, p < 0.0001).”
> “At Week 8, a greater proportion of Obe-treated pts had a MWPC on the EQ-5D-5L Index: 41.0% for Obe-50 and 38.9% for Obe-25 vs 28.5% for PBO (Obe-50:Δ12.59 and Obe-25:Δ10.36, p < 0.01).”

Source: [Baert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.098/8432840)

<a id="topic-3.1.1.8.4-3"></a>

###### Pooled ABTECT-1 and ABTECT-2: work productivity and activity impairment (WPAI:UC)

> “All p values are nominal.”
> “At baseline, 1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1153 pts had WPAI:UC data.”
> “At week 8, a smaller proportion of pts treated with Obe reported overall work impairment compared to PBO: 36.2% of Obe-50 pts and 34.6% of Obe-25 pts vs 47.8% of PBO pts (Obe-50: Δ-11.03, Obe-25: Δ-13.21, both p = 0.0002).”
> “At week 8, greater proportions of pts treated with Obe reported a MWPC on overall work impairment relative to PBO: 66.3% for Obe-50 and 71.8% for Obe-25 vs 56.9% of PBO (Obe-50: Δ9.64, p = 0.06; Obe-25: Δ15.13, p < 0.05).”

Source: [Tilg et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1109/8434071)

Additional sources: [Abivax press release, DDW 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-digestive-disease-weekr)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-emergent adverse events at Week 8 reported by the company

| Event, n (%) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) |
| --- | --- | --- | --- |
| Any TEAE | “84 (53.2%)” | “75 (46.9%)” | “189 (59.4%)” |
| TEAE leading to study drug discontinuation | “6 (3.8%)” | “0 (0.0%)” | “17 (5.3%)” |
| Serious TEAE | “3 (1.9%)” | “1 (0.6%)” | “14 (4.4%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “1 (0.3%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “1 (0.6%)” | “1 (0.6%)” | “2 (0.6%)” |

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.8.5-2"></a>

###### Serious adverse events, all-cause mortality, and adverse event time frame in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Any serious adverse event | “14/318 (4.40%)” | “1/160 (0.63%)” | “3/158 (1.90%)” |
| Myocardial infarction | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis acute | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Colitis ulcerative | “3/318 (0.94%)” | “0/160 (0.00%)” | “2/158 (1.27%)” |
| Pneumonia | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Appendicitis | “0/318 (0.00%)” | “1/160 (0.63%)” | “0/158 (0.00%)” |
| Prostate cancer stage I | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

> “Adverse Events Time Frame up to 12 weeks”
> “Adverse events reported here are treatment emergent adverse events”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.5-3"></a>

###### Non-serious adverse events at a 5% reporting threshold in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Any non-serious adverse event at 5% threshold | “90/318 (28.30%)” | “34/160 (21.25%)” | “28/158 (17.72%)” |
| Headache | “66/318 (20.75%)” | “25/160 (15.63%)” | “9/158 (5.70%)” |
| Nausea | “18/318 (5.66%)” | “5/160 (3.13%)” | “1/158 (0.63%)” |
| Anaemia | “10/318 (3.14%)” | “6/160 (3.75%)” | “9/158 (5.70%)” |
| Colitis ulcerative | “6/318 (1.89%)” | “0/160 (0.00%)” | “8/158 (5.06%)” |
| Arthralgia | “8/318 (2.52%)” | “1/160 (0.63%)” | “8/158 (5.06%)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.5-4"></a>

###### Adverse events in the late-breaking abstract

> “Proportions of pts who reported at least one TEAE in ABTECT‐1 were 59.4%, 46.9%, and 53.2% for Obe‐50, Obe‐25, and PBO, respectively.”
> “The most frequent TEAE was headache (Obe‐50: 20.8%–25.8%; Obe‐25: 14.5%–15.6%; PBO: 5.7).”
> “The headaches were mild, transient, short in duration and not a barrier to treat as evidenced by a low discontinuation rate of 0%–1.6%. No signal was observed for serious, severe, or opportunistic infections or malignancies.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.5-5"></a>

###### Pooled ABTECT-1 and ABTECT-2: integrated summary of treatment-emergent adverse events

| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Any TEAE | “383 (60.2)” | “156 (48.9)” | “161 (50.8)” |
| TEAE related to study drug | “226 (35.5)” | “86 (27)” | “55 (17.4)” |
| TEAE leading to study discontinuation | “30 (4.7)” | “6 (1.9)” | “13 (4.1)” |
| Serious TEAE | “20 (3.1)” | “7 (2.2)” | “10 (3.2)” |
| Malignancies | “1 (0.2)” | “0” | “0” |
| Serious, severe, or opportunistic infections | “4 (0.6)” | “1 (0.3)” | “1 (0.3)” |
| Headache | “148 (23.3)” | “48 (15.0)” | “18 (5.7)” |
| Nausea | “46 (7.2)” | “16 (5.0)” | “4 (1.3)” |
| Abdominal pain | “24 (3.8)” | “2 (0.6)” | “2 (0.6)” |
| Lipase increased | “27 (4.2)” | “9 (2.8)” | “7 (2.2)” |
| Time to onset of first headache, days, median | “1.0” | “1.0” | “7.0” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Prostate cancer stage I in a patient who received obefazimod for two weeks.”
> “the only opportunistic infection was aspergillosis in a placebo patient.”
> “To date, no safety signals have been observed related to either elevations in lipase or more specifically to pancreatitis.”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation

| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Ulcerative colitis | “7 (1.1)” | “2 (0.6)” | “7 (2.2)” |
| Headache | “7 (1.1)” | “1 (0.3)” | “0” |
| Vomiting | “4 (0.6)” | “1 (0.3)” | “0” |
| Nausea | “3 (0.5)” | “1 (0.3)” | “0” |
| Pancreatitis acute | “2 (0.3)” | “1 (0.3)” | “1 (0.3)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### Pooled ABTECT-1 and ABTECT-2: infection-related adverse events

| Infection, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Nasopharyngitis | “14 (2.2)” | “9 (2.8)” | “10 (3.2)” |
| Upper respiratory tract infection | “7 (1.1)” | “3 (0.9)” | “6 (1.9)” |
| COVID-19 | “6 (0.9)” | “4 (1.3)” | “1 (0.3)” |
| Influenza | “6 (0.9)” | “3 (0.9)” | “1 (0.3)” |
| Urinary tract infection | “5 (0.8)” | “2 (0.6)” | “0” |
| Pneumonia | “4 (0.6)” | “0” | “1 (0.3)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Rates of infection-related TEAEs among pts were very low, generally below 1% (Table 2). There was no signal for serious, severe, or opportunistic infections or malignancies in the ABTECT induction trials (Table 3).”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-8"></a>

###### Pooled ABTECT-1 and ABTECT-2: integrated safety abstract

> “Overall, 636 patients received Obe-50, 319 received Obe-25, and 317 received placebo (PBO).”
> “The most frequent TEAEs (≥ 3% in obe treated pts and greater than PBO) included headache, nausea, abdominal pain, and an increase in serum lipase. Headache TEAEs were mild, transient, short in duration (median: 2-3 days) and rarely led to discontinuation (0-1.1%). Serious, severe, or opportunistic infections or malignancies were rarely reported.”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-9"></a>

###### Pooled ABTECT-1 and ABTECT-2: headache and nausea rates reported at UEG Week 2025

> “In the pooled full data set across ABTECT 1 & 2, no signal for serious, severe, or opportunistic infections or malignancies was observed. The most commonly reported TEAEs were headache (6%-placebo, 16%-25mg, 24.1%-50mg) with <1% of headaches leading to study discontinuation (0.3% at 25mg; 1.1% at 50mg), and nausea (1.3% in placebo, 5.0% at 25mg, 7.2% at 50mg).”

Source: [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

<a id="topic-3.1.1.8.5-10"></a>

###### Headache: most frequent adverse event in the ABTECT induction trials

> “The most frequent TEAE was headache (obefazimod 50 mg: 20.8-25.8%; obefazimod 25 mg: 14.5-15.6%; placebo: 5.7%).”
> “The headaches were mild, transient, short in duration and not a barrier to treatment, as evidenced by a low discontinuation rate of 1.6%.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “The most commonly reported TEAEs were headache (6%-placebo, 16%-25mg, 24.1%-50mg) with <1% of headaches leading to study discontinuation (0.3% at 25mg; 1.1% at 50mg), and nausea (1.3% in placebo, 5.0% at 25mg, 7.2% at 50mg).”

Source: [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

> “Headache TEAEs were mild, transient, short in duration (median: 2-3 days) and rarely led to discontinuation (0-1.1%).”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-11"></a>

###### Integrated safety of the ABTECT induction trials

> “Overall, 636 patients received Obe-50, 319 received Obe-25, and 317 received placebo (PBO).”
> “Proportions of pts who reported at least one TEAE were 60.2%, 48.9%, and 50.8% for Obe-50, Obe-25, and PBO, respectively.”
> “The overall rates of serious TEAEs for pts were comparable across groups (Obe-50: 3.1%; Obe-25: 2.2%; PBO: 3.2%).”
> “TEAEs leading to study discontinuation occurred at similar rates across treatment groups (Obe-50, 4.7%; Obe-25, 1.9%; PBO, 4.1%).”
> “The most frequent TEAEs (≥ 3% in obe treated pts and greater than PBO) included headache, nausea, abdominal pain, and an increase in serum lipase.”
> “Serious, severe, or opportunistic infections or malignancies were rarely reported.”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-12"></a>

###### Adverse events of special interest in the phase 3 protocol

> “Headaches are frequently reported by subjects treated with obefazimod.”
> “The headache lasts more than 72 hours continuously (or is an intermittent headache with a continuous symptom free period < 12 hours) and is not relieved by painkillers for > 12 hours.”
> “Anemia will be reported as AESI if hemoglobin < 8 g/dL or if hemoglobin drops > 2 g/dL from baseline.”
> “An increase > 3.0 × ULN in liver transaminases (AST and/or ALT) with or without cholestasis or clinical symptoms”
> “Subjects will be monitored for the development of signs and symptoms of infection during treatment with obefazimod.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.8.5-13"></a>

###### Hepatic enzymes: protocol summary of clinical data

> “Based on nonclinical data, a DILIsym evaluation of obefazimod was conducted and concluded that there was no risk of the drug-induced liver injury (DILI) in these subjects.”
> “Analysis of ALT/AST changes in subjects treated with obefazimod, did not reveal any meaningful variation of the mean ALT/AST measurement throughout treatment nor an increased incidence of any liver function tests (LFTs).”
> “Sporadic cases of isolated alkaline phosphatase increase have been reported in subjects dosed with obefazimod.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: study limitations

- Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
- Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
- Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
- Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
- Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203); [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results); [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download); [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669); [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748); [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392); [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf); [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

<a id="heading-3.1.2"></a>

#### 3.1.2 ABTECT-2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.1-2"></a>

###### Primary objectives for the FDA and for the EMA in the protocol

> “For the FDA and National Regulatory Authorities other than EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on clinical remission defined as:”
> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Place of the trial in the phase 3 development plan

> “This study is part of a phase 3 clinical development program comprising two similar 8-week induction studies (ABX464-105 and ABX464-106), followed by a maintenance study (ABX464-107) to confirm the efficacy and safety of obefazimod in the short and long-term treatment of moderate to severely active UC in adults and adolescents from 16 to 18 years of age.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.1-4"></a>

###### Main objective in the EU Clinical Trials Information System record

> “Main objective To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-25”
> “Primary Completion (Actual) 2025-06-24”
> “Study Completion (Actual) 2025-07-15”
> “First Posted 2022-08-18”
> “Results First Posted 2026-09-10”
> “Last Update Posted 2026-09-10”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 262 locations”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.2-3"></a>

###### Planned number of sites and potential countries in the protocol

> “Approximately 350 sites located worldwide will participate in the study.”
> “(List of potential countries: Argentina, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Croatia, Czech Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Lithuania, Mexico, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, UK, Ukraine, USA)”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.2-4"></a>

###### EU member states and trial dates in the EU Clinical Trials Information System record

> “Locations Romania, Poland, Slovakia, Germany, Ireland, Lithuania, Italy, Croatia, Belgium, Bulgaria, France, Czechia, Hungary, Spain”
> “Start of trial 08/06/2023 End of trial 23/06/2025 Global end of trial 15/07/2025”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="topic-3.1.2.2-5"></a>

###### Sites and countries of the two induction trials stated by the company

> “ABTECT-1 and ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients from over 600 participating clinical trial sites in 36 countries with the intent to satisfy regulatory requirements globally.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Design in the ClinicalTrials.gov record

> “Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Triple”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.3-2"></a>

###### Periods, randomization ratio, and planned arm sizes in the protocol

> “This induction study is a multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of obefazimod given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response (lack of response, loss of response, or intolerance) to either conventional therapies and/or advanced therapies.”
> “As shown below, this study consists of a screening period of up to 4 weeks, an 8-week induction period followed by 4-week follow up period.”
> “On Day 1, eligible subjects will be randomized and allocated into three treatment arms according to ratio 1:1:2 as follows: Placebo: 153 subjects Obefazimod Daily dose 25 mg QD: 153 subjects Obefazimod Daily dose 50 mg QD: 306 subjects”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-3"></a>

###### Randomization stratification factors, including region

> “Randomization will be stratified according to the following factors: Subjects with inadequate response to advanced therapies [AT-IR subjects] (lack of response, loss of response or intolerance to advanced therapies (Yes/No) Subjects with concomitant oral corticosteroids at baseline (Yes/No) Region (Japan/Rest of world)”
> “Previous discontinuation of an advance therapy for any reason other than inadequate response, e.g., pregnancy, economic reasons or termination of a clinical trial, will not be considered as AT-IR.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Endoscopy, central reading, and electronic diaries

> “Endoscopies will be centrally read.”
> “Biopsies will be centrally analyzed.”
> “e-Diaries will be used to collect stool frequency, rectal bleedings, nocturnal bowel movements, bowel urgency and fatigue NRS on a daily basis, as well as whether the subjects took the study treatment and the intake time.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Entry into the maintenance trial after Week 8

> “In the randomized double-blind placebo-controlled study part [Part 1; placebo, obefazimod 25 mg, obefazimod 50 mg] for clinical responders at Week 8.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.3-6"></a>

###### Rationale for the 8-week treatment duration in the protocol

> “After 16 weeks of treatment there were a limited number of patients who achieved a clinical response that was not observed at Week 8. Therefore, it is reasonable to define 8 weeks as the treatment duration for the induction study.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”
> “To be eligible, adolescent subjects must weigh ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit.”
> “Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).”
> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record

> “Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.”
> “Subjects with primary sclerosing cholangitis or autoimmune hepatitis.”
> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Subjects with HIV infection.”
> “Subjects previously treated with ABX464.”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.4-3"></a>

###### Minimum age by region in the protocol

> “Male or female (at birth) at least 16 years old, except in European Union (EU)/European Economic Area (EEA), Israel, Serbia and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.4-4"></a>

###### Age range in the EU Clinical Trials Information System record

> “Age range 65+ years, 18-64 years”

Source: [EU Clinical Trials Information System 2022-500536-11-01](https://euclinicaltrials.eu/ctis-public/view/2022-500536-11-01)

<a id="topic-3.1.2.4-5"></a>

###### Eligibility summarized in the late-breaking abstract

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Arms and administration in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| ABX464 50 mg | “Experimental: ABX464 50mg Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| ABX464 25 mg | “Experimental: ABX464 25mg Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| Placebo | “Placebo Comparator: Placebo Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) for 8 weeks” |
| Intervention | “Administered once daily in the morning with food” |

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.5-2"></a>

###### Capsule strengths and dosing instructions in the protocol

> “Depending on the treatment arm allocation, obefazimod or its matching placebo (capsules) 50 mg and 25 mg are administered once daily in a fed condition (ideally at the same time in the morning) for 8 weeks during the induction phase.”
> “25 mg regimen: 1 capsule of obefazimod 25 mg per day”
> “50 mg regimen: 1 capsule of obefazimod 50 mg per day”
> “1 capsule of placebo per day”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.5-3"></a>

###### Background ulcerative colitis therapy allowed during the trial

> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study), the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”
> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint and its definition in the ClinicalTrials.gov record

> “Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8”
> “Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.6.1-2"></a>

###### FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “The previously used physician global assessment component is excluded to reduce subjectivity and focus the evaluation on the subject’s directly reported symptoms and directly observable endoscopic findings.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.2.6.1-3"></a>

###### Co-primary endpoints for the EMA and key secondary endpoints for the FDA

> “The co-primary endpoints are defined as: o Proportion of subjects who achieve endoscopic improvement at Week 8 o Proportion of subjects with symptomatic remission at Week 8.”
> “For the FDA and National Regulatory Authorities other than EMA, the key secondary efficacy objectives and endpoints are: To compare the efficacy of obefazimod versus placebo on endoscopic improvement. o Proportion of subjects who achieve endoscopic improvement at Week 8. To compare the efficacy of obefazimod versus placebo on clinical response o Proportion of subjects with clinical response at Week 8. To compare the efficacy of obefazimod versus placebo on HEMI.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### Secondary endpoint definitions in the ClinicalTrials.gov record

> “Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.”
> “HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned sample size in the protocol

> “Approximately 612 subjects will be randomized in this study.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 636”

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed by arm in the posted results

| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Started | “318” | “159” | “159” | Not reported |
| Baseline | “318” | “159” | “159” | “636” |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” | Not reported |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants randomized and treated in the late-breaking abstract

> “1272 pts were randomized and treated in ABTECT‐1 (636) and ABTECT‐2 (636).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis population in the posted results

> “Overall Number of Baseline Participants 318 159 159 636 [Not Specified] Baseline Analysis Population Description”

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.7.2-2"></a>

###### Analysis sets in the statistical analysis plan

> “The Randomized Set includes all subjects who were randomized to study treatment. The FAS includes all randomized subjects who received at least one dose of study drug. Subjects will be analyzed according to the treatment group to which they were randomized (i.e., “as randomized”), regardless of the treatment received. The efficacy analysis will be based on the FAS.”
> “The Safety Set includes all randomized subjects who have received at least one dose of study drug. Subjects will be analyzed according to the treatment received (i.e., “as treated”).”

Source: [Abivax ABX464-106 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Primary analysis method, region factor, and testing sequence in the protocol

> “will be analyzed using a Cochran Mantel Haenszel test (CMH) test adjusting for AT-IR (yes/no), baseline oral corticosteroid treatment (yes/no) and Region (Japan/Rest of world) as stratification factors, using the Full Analysis Set (FAS).”
> “The Region (Japan/Rest of world) factor will not be included in the primary analysis model for consistency with ABX464-105 but may be included in a sensitivity analysis.”
> “If comparisons on primary endpoints for each dose are statistically significant, then, the testing procedure will continue through each of the key secondary endpoints in the prespecified order until an endpoint fails to reach statistical significance, after which all subsequent key secondary endpoints will be considered exploratory.”
> “Interim analysis: No interim analysis is planned.”

Source: [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf)

<a id="topic-3.1.2.7.2-4"></a>

###### Handling of intercurrent events and missing data in the statistical analysis plan

> “The Composite Strategy will be applied for each of the above IEs for the main analyses of all primary and key secondary estimands.”
> “In the main analysis of all binary responder-type endpoints, subjects with missing data, regardless of reason for missingness, will be considered as non-responders.”

Source: [Abivax ABX464-106 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/SAP_001.pdf)

<a id="topic-3.1.2.7.2-5"></a>

###### Consequence of the 25 mg primary endpoint result for the testing hierarchy

> “Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.”
> “25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participant flow by arm in the posted results

| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Started | “318” | “159” | “159” |
| Completed | “291” | “142” | “145” |
| Not completed | “27” | “17” | “14” |
| Adverse event | “13” | “8” | “8” |
| Lack of efficacy | “2” | “2” | “1” |
| Lost to follow-up | “3” | “0” | “0” |
| Protocol violation | “0” | “1” | “2” |
| Withdrawal by subject | “9” | “6” | “3” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics by arm in the posted results

| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) | Total (n=636) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “41.4(13.64)” | “41.3(12.83)” | “41.6(14.68)” | “41.4(13.69)” |
| Age 65 years or older, participants | “19” | “6” | “16” | “41” |
| Female, participants | “138” | “60” | “58” | “256” |
| Male, participants | “180” | “99” | “101” | “380” |
| Asian, participants | “66” | “29” | “39” | “134” |
| Black or African American, participants | “6” | “3” | “4” | “13” |
| White, participants | “231” | “116” | “108” | “455” |
| Weight, kg, mean (SD) | “71.75(17.101)” | “73.37(16.050)” | “73.91(17.387)” | “72.69(16.919)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.74(7.193)” | “7.92(6.769)” | “7.75(6.503)” | “7.79(6.911)” |
| At least one prior advanced therapy inadequate response, participants | “159” | “76” | “79” | “314” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “33” | “19” | “20” | “72” |
| Modified Mayo Score, mean (SD) | “6.9(1.11)” | “7.0(1.04)” | “6.8(0.98)” | “6.9(1.06)” |
| Mayo endoscopic subscore 2, participants | “130” | “56” | “64” | “250” |
| Mayo endoscopic subscore 3, participants | “188” | “103” | “95” | “386” |
| Fecal calprotectin, µg/g, mean (SD) | “3759.05(7548.48)” | “4121.86(7081.92)” | “4499.81(8074.99)” | “4038.06(7569.95)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.2-2"></a>

###### Disease severity of the 25 mg group compared with ABTECT-1 stated by the company

> “In both trials, baseline demographics and disease characteristics were similar between groups; 45% and 49% of patients had inadequate response to one or more advanced therapies.”
> “A slightly more severe and refractory population were randomized to the 25 mg group in ABTECT-2 compared to ABTECT-1.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.2.8.2-3"></a>

###### Proportion with prior advanced therapy inadequate response in the late-breaking abstract

> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary and key secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) | 25 mg minus placebo, % | 25 mg p-value | 50 mg minus placebo, % | 50 mg p-value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical remission (primary) | “6.3 (10)” | “11.3 (18)” | “19.8 (63)” | “5.1” | “p = 0.1034” | “13.4” | “p = 0.0001” |
| Clinical response | “33.3 (53)” | “53.5 (85)” | “63.2 (201)” | “20.1” | “p = 0.0002” | “29.6” | “p < 0.0001” |
| Endoscopic improvement | “10.1 (16)” | “22.0 (35)” | “35.5 (113)” | “12.0” | “p = 0.0029” | “25.4” | “p < 0.0001” |
| HEMI | “7.5 (12)” | “13.2 (21)” | “23.9 (76)” | “5.7” | “p = 0.0932” | “16.4” | “p < 0.0001” |
| Symptomatic remission | “22.0 (35)” | “33.3 (53)” | “40.3 (128)” | “11.4” | “p = 0.0227” | “18.0” | “p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.”
> “Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.2.8.3-2"></a>

###### Participants meeting each endpoint at Week 8 in the posted results

| Endpoint at Week 8, participants | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) |
| --- | --- | --- | --- |
| Clinical remission per modified Mayo Score (primary) | “63” | “18” | “10” |
| Endoscopic improvement | “113” | “35” | “16” |
| Clinical response per modified Mayo Score | “201” | “85” | “53” |
| HEMI per Geboes | “76” | “21” | “12” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.3-3"></a>

###### Primary endpoint result for the 25 mg dose stated by the company

> “While the 25 mg dose did not achieve statistical significance for this endpoint in ABTECT-2, it achieved a pooled placebo-adjusted clinical response rate of 28.6%”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.2.8.3-4"></a>

###### Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=79) | AT-IR-Yes 25 mg (N=76) | AT-IR-Yes 50 mg (N=159) | AT-IR-No placebo (N=80) | AT-IR-No 25 mg (N=83) | AT-IR-No 50 mg (N=159) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “5.1 (4)” | “5.3 (4)” | “12.6 (20)” | “7.5 (6)” | “16.9 (14)” | “27.0 (43)” |
| Endoscopic improvement | “8.9 (7)” | “11.8 (9)” | “26.4 (42)” | “11.3 (9)” | “31.3 (26)” | “44.7 (71)” |
| Symptomatic remission | “15.2 (12)” | “26.3 (20)” | “37.1 (59)” | “28.8 (23)” | “39.8 (33)” | “43.4 (69)” |
| HEMI | “6.3 (5)” | “7.9 (6)” | “17.0 (27)” | “8.8 (7)” | “18.1 (15)” | “30.8 (49)” |
| Clinical response | “20.3 (16)” | “40.8 (31)” | “57.2 (91)” | “46.3 (37)” | “65.1 (54)” | “69.2 (110)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “0.7 p = 0.8529” | “7.6 p = 0.0652” | “9.5 p = 0.0659” | “19.4 p = 0.0004” |
| Endoscopic improvement | “3.5 p = 0.4675” | “17.7 p = 0.0015” | “20.3 p = 0.0016” | “33.1 p < 0.0001” |
| Symptomatic remission | “11.3 p = 0.0841” | “21.7 p = 0.0006” | “11.0 p = 0.1430” | “14.2 p = 0.0329” |
| HEMI | “1.8 p = 0.6596” | “11.0 p = 0.0197” | “9.3 p = 0.0805” | “21.8 p = 0.0002” |
| Clinical response | “21.0 p = 0.0043” | “36.8 p < 0.0001” | “18.8 p = 0.0165” | “22.2 p = 0.0008” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Treatment-emergent adverse events at Week 8 reported by the company

| Event, n (%) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) |
| --- | --- | --- | --- |
| Any TEAE | “77 (48.4%)” | “81 (50.9%)” | “194 (61.0%)” |
| TEAE leading to study drug discontinuation | “9 (5.7%)” | “8 (5.0%)” | “15 (4.7%)” |
| Serious TEAE | “7 (4.4%)” | “6 (3.8%)” | “6 (1.9%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “0 (0.0%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “0 (0.0%)” | “0 (0.0%)” | “2 (0.6%)” |

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.2.8.5-2"></a>

###### Serious adverse events, all-cause mortality, and adverse event time frame in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Any serious adverse event | “6/318 (1.89%)” | “6/159 (3.77%)” | “7/159 (4.40%)” |
| Colitis ulcerative | “2/318 (0.63%)” | “2/159 (1.26%)” | “3/159 (1.89%)” |
| Pancreatitis acute | “0/318 (0.00%)” | “1/159 (0.63%)” | “1/159 (0.63%)” |
| Pneumonia | “1/318 (0.31%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Uveitis | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Lipase increased | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Acute coronary syndrome | “0/318 (0.00%)” | “0/159 (0.00%)” | “1/159 (0.63%)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

> “Adverse Events Time Frame Up to 12 weeks”
> “Adverse events reported here are treatment emergent adverse events.”

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.5-3"></a>

###### Non-serious adverse events at a 5% reporting threshold in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Any non-serious adverse event at 5% threshold | “115/318 (36.16%)” | “40/159 (25.16%)” | “32/159 (20.13%)” |
| Headache | “82/318 (25.79%)” | “23/159 (14.47%)” | “9/159 (5.66%)” |
| Nausea | “29/318 (9.12%)” | “11/159 (6.92%)” | “3/159 (1.89%)” |
| Lipase increased | “19/318 (5.97%)” | “2/159 (1.26%)” | “4/159 (2.52%)” |
| N-terminal prohormone brain natriuretic peptide increased | “7/318 (2.20%)” | “3/159 (1.89%)” | “11/159 (6.92%)” |
| Anaemia | “12/318 (3.77%)” | “6/159 (3.77%)” | “11/159 (6.92%)” |

Source: [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results)

<a id="topic-3.1.2.8.5-4"></a>

###### Adverse events in the late-breaking abstract

> “For ABTECT2, TEAEs occurred in 61.0%, 50.9%, and 48.4% for Obe‐50, Obe‐25, and PBO, respectively.”
> “The overall rate of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for pts treated with Obe were similar to PBO.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: study limitations

- Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
- Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
- Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
- Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
- Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.

Source: [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216); [ClinicalTrials.gov NCT05507216 results](https://clinicaltrials.gov/study/NCT05507216?tab=results); [Abivax ABX464-106 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/16/NCT05507216/Prot_000.pdf); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 ABTECT Maintenance

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Objective in the UEG Week 2026 maintenance presentation

> “Assess obefazimod efficacy and safety vs. placebo in patients with moderately to severely active UC who responded to obefazimod induction after 52 weeks of treatment overall”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.1-2"></a>

###### Objective of the subgroup presentation by prior advanced therapy response

> “Assess obefazimod efficacy and safety vs. placebo in UC patients who responded to obefazimod induction ± prior inadequate response to advanced therapies (AT-IR) at Week 52”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Purpose and primary objectives of Part 1 and Part 2 in the ClinicalTrials.gov record

> “This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”
> “This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.”
> “The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission [SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1] at Week 44.”
> “The Part 2 primary objective is safety”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.1-4"></a>

###### Main objectives of Part 1, Part 2, and the long-term extension in the EU register

> “Part 1 (44 weeks): -To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”
> “Part 2 (44 weeks): -To assess the safety and tolerability of obefazimod 50 mg and 25 mg at Week 44.”
> “Long-Term Extension(4 years): -To evaluate the long-term safety and tolerability of obefazimod.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and number of locations in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-16”
> “Primary Completion (Actual) 2026-04-28”
> “Study Completion (Estimated) 2030-05”
> “This study has 413 locations”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.2-2"></a>

###### Countries, sites, and trial duration in the EU register

> “Trial duration 29 Aug 2023 → ongoing”
> “Locations 18 EU/EEA countries · 184 sites”
> “Rest of the world Mexico, Brazil, New Zealand, United Kingdom, China, Turkey, Israel, Korea, Republic of, Switzerland, Australia, Argentina, Bosnia and Herzegovina, Ukraine, United States, India, Japan, Serbia, Canada”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.2-3"></a>

###### Phase 3 program: 36 countries and over 600 sites, first U.S. participant in October 2022

> “These pivotal Phase 3 clinical trials consist of two induction trials (ABTECT-1 and ABTECT-2) and the subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50 mg across 36 countries in North America, Latin America, Europe and Asia Pacific, involving 1,275 moderately to severely active UC patients in over 600 sites.”
> “Enrollment of the first patient under this program in the United States occurred on October 11, 2022.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.3.2-4"></a>

###### Part 1 topline results announced June 1, 2026

> “PARIS, France – June 1, 2026 – 10:05 pm CEST”
> “today announced positive topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.2-5"></a>

###### Part 2 topline results announced June 29, 2026

> “PARIS, France – June 29, 2026 – 10:05 pm CEST”
> “today announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 UC maintenance program”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.2-6"></a>

###### Presentation at UEG Week 2026 in Barcelona

> “taking place October 17–20, 2026, in Barcelona, Spain”
> “Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance)”
> “Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies”

Source: [Abivax press release, UEG Week 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-united-european-gastroenterology)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-2"></a>

###### Two treatment phases: a 44-week maintenance phase (Part 1 and Part 2) and a 4-year long-term extension

> “This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.”
> “The maintenance phase is a 44-week double blind, placebo-controlled, phase. Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2.”
> “At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded.”
> “Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment. Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-3"></a>

###### Randomization by induction treatment and response status

> “Among both induction studies, subjects assessed as responders will be randomized as follows into Part 1 of the maintenance study according to their induction treatment: ABX464 Dose 50 mg QD ABX464 Dose 25 mg QD Placebo. All subjects with clinical response who were dosed with placebo in the induction studies will be randomized into the placebo group.”
> “Among both induction studies, subjects assessed as non-responders will be randomized as follows into Part 2 of the maintenance study according to their induction treatment: ABX464 Dose 50 mg QD (all subjects who received 50 mg in induction) ABX464 Dose 25 mg QD (all subjects who received 25 mg in induction) Subjects who were allocated to placebo in the induction study will be randomized to obefazimod 50 mg or 25 mg in a blinded manner.”
> “All eligible subjects will be randomized to either the double blind, placebo-controlled Part #1 (ABX464 50mg or 25mg or placebo) or randomized to double-blind Part #2 (ABX464 50mg or 25mg) depending on their clinical response at the end of induction.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-4"></a>

###### Part 1: re-randomization of obefazimod induction responders to 25 mg, 50 mg, or placebo

> “The Phase 3 ABTECT maintenance trial is a global 44-week multicenter, randomized, double-blind, placebo-controlled trial that evaluated the long-term efficacy and safety of obefazimod at 25 mg and 50 mg administered orally once-daily in adults with moderately to severely active UC. Participants who were clinical responders after the 8-week ABTECT-1 and ABTECT-2 induction trials (N=580) were re-randomized to receive 25 mg obefazimod, 50 mg obefazimod, or placebo.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.3-5"></a>

###### Responder definition, stratification factors, and placebo induction responders

> “ABTECT Phase 3 Responder Re-Randomized Maintenance Trial Design”
> “Induction Clinical Response defined as decrease in the MMS ≥ 2 points and ≥30% from baseline, with a decrease in RBS ≥ 1 or an absolute RBS ≤ 1”
> “Randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”
> “Placebo induction responders were maintained on blinded placebo in maintenance”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.3-6"></a>

###### Part 2: induction non-responders and Part 1 relapsers

> “Part 2 of the Phase 3 Maintenance trial enrolled patients who either did not achieve clinical response following induction treatment or who experienced disease relapse during the re-randomized maintenance trial (Part 1), expanding both the efficacy and safety results in a more refractory patient population than the registrational maintenance cohort.”
> “Patients who achieved clinical response with obefazimod during induction and relapsed after being re-randomized to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.3-7"></a>

###### Central endoscopy reading and primary endpoint at the end of the 44-week maintenance trial (52 weeks in total)

> “Each of the trials were randomized, double-blind and placebo-controlled, using independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance trial (total 52 weeks), as recommended by the FDA.”
> “After week 44, a long-term extension trial will follow for eligible and willing subjects for an additional for up to 4 years, or until the commercialization of obefazimod, whichever occurs first.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria for the maintenance phase in the ClinicalTrials.gov record

> “Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and patients' clinical response status must be available.”
> “Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1.”
> “16 Years and older”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria for the maintenance phase in the ClinicalTrials.gov record

> “Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106).”
> “Subjects who have developed any major illness/condition (eg. primary sclerosis cholangitis, Crohn's disease, colectomy, diverting ileostomy, colon cancer or colonic adenomas [low or high grade dysplasia]).”
> “Subjects with evidence of an unstable clinical condition (eg. toxic megacolon, fulminant colitis, bowel perforation, uncontrolled ischemic disease, congestive heart failure with NYHA class 3 or 4 symptoms) during the induction study that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.”
> “Male or female planning a pregnancy, or pregnant female subjects”
> “Introduction during induction study of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).”
> “Subject who is planning to receive live vaccine during the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.4-3"></a>

###### Minimum age of 16 years, or 18 years in the EU/EEA, Israel, Serbia, and Ukraine

> “Male or female (at birth) at least 16 years old, except in EU/EEA, Israel, Serbia and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment. Where enrolment of adolescents is allowed, adolescent subjects must weigh > 40 kg and meet the definition of Tanner stage 5 at screening.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.4-4"></a>

###### Long-term extension entry criteria

> “Subject must have completed the maintenance phase”
> “Investigator and subject must assess and agree that the subject has received, and will continue to receive benefit from being in the study”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Oral dosing once daily with food for 44 weeks

> “Subjects will be orally dosed during 44 weeks”
> “Administered once daily, preferably in the morning, with food”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.5-2"></a>

###### Long-term extension: continued allocated treatment for up to 4 years

> “At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.5-3"></a>

###### Investigational products: 25 mg and 50 mg hard capsules and matching placebo

> “Pharmaceutical form CAPSULE, HARD”
> “Maximum daily dose 25 mg milligram(s) Maximum total dose 7700 mg milligram(s) Maximum duration of treatment 44 week(s)”
> “Maximum daily dose 50 mg milligram(s) Maximum total dose 15400 mg milligram(s) Maximum duration of treatment 44 week(s)”
> “The placebo for the 25 and 50 mg ABX464 hard capsules.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.5-4"></a>

###### Dose escalation to open-label 50 mg after relapse in Part 1

> “Among patients who relapsed during Maintenance Part 1, re-treatment with 50 mg obefazimod resulted in clinically meaningful rates of clinical remission, clinical response, endoscopic improvement, HEMI and endoscopic remission by Week 44.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### FDA recommendation: proportion in clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “primary endpoint.”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “Stool frequency subscore = 0 or 1”
> “Rectal bleeding subscore = 0”
> “Centrally read endoscopy subscore = 0 or 1 (score of 1 modified to”
> “exclude friability)”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-2"></a>

###### FDA recommendation: induction followed by randomized withdrawal maintenance with evaluation at about 52 weeks

> “One approach (induction followed by randomized withdrawal maintenance) is to”
> “receive either active treatment or placebo, and efficacy is evaluated again at the end”
> “of the maintenance phase (e.g., 52 weeks).”
> “Placebo responders at the end of induction should continue to receive blinded placebo in maintenance.”
> “Although clinical response is not the final treatment goal, this definition may be used as a criterion at the end of induction to rerandomize subjects who are demonstrating improvement to continue into a maintenance phase in the induction/maintenance design.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-3"></a>

###### FDA recommendation: remission in participants entering maintenance in remission to show durability

> “induction phase are rerandomized in the maintenance phase, we recommend that”
> “sponsors assess remission within the subset of subjects who enter the maintenance”
> “phase in remission to support the ability of the therapy to maintain a durable state”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-4"></a>

###### Company definition of the primary endpoint and its basis in FDA guidance

> “The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1.”
> “At week 44 of the maintenance trial, secondary endpoints include endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.3.6.1-5"></a>

###### Primary endpoint and key secondary endpoints as presented at UEG Week 2026

> “Primary Endpoint Clinical Remission at Week 52”
> “Defined as SFS = 0 or 1 and RBS = 0, and MES = 0 or 1 (MES of 1 modified to exclude friability)”
> “Secondary Endpoints (Week 52)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.6.1-6"></a>

###### Definitions of the key secondary endpoints in the topline release

> “Clinical remission is defined as SFS = 0 or 1, and RBS = 0 and MES = 0 or 1; Endoscopic improvement is defined as MES = 0 or 1; Endoscopic remission is defined as MES = 0; HEMI is defined as MES = 0 or 1 and Geboes Index score <3.1; Corticosteroid-free clinical remission is defined as clinical remission (SFS = 0 or 1 and RBS = 0 and MES = 0 or 1) at Week 44 and corticosteroid free for at least 12 weeks immediately prior to Week 44; Sustained clinical remission is defined as clinical remission at Week 44 in the sub-population of subjects in clinical remission at Week 8 of the induction trial”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.6.1-7"></a>

###### Corticosteroid-free clinical remission: registered in the subpopulation receiving corticosteroids at maintenance entry

> “To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.6.1-8"></a>

###### EU register: endoscopic improvement and symptomatic remission as Part 1 primary endpoints, clinical remission as a secondary endpoint

> “Part 1 (44 weeks): Proportion of subjects who achieve endoscopic improvement at Week 44.”
> “Part 1 (44 weeks): Proportion of subjects with symptomatic remission at Week 44.”
> “Part 1: Proportion of subjects who achieve clinical remission at Week 44.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 1116”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.7.1-2"></a>

###### Planned participants in the EU register

> “Participants planned 1,241”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.7.1-3"></a>

###### Induction responders entering Part 1: 678 of 1,275

> “Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the maintenance trial.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.3.7.1-4"></a>

###### Part 1 analysis population: 580 obefazimod induction responders

| Group | Participants |
| --- | --- |
| Obefazimod induction responders | “Obefazimod Induction Responders (n=580)” |
| Placebo | “Placebo (n=192)” |
| Obefazimod 25 mg | “25 mg (n=193)” |
| Obefazimod 50 mg | “50 mg (n=195)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.7.1-5"></a>

###### Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy

> “Part 2 Induction Non-Responders – Exploratory Endpoints”
> “Part 1 Relapsers – Exploratory Endpoints”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

| Group | Participants |
| --- | --- |
| Induction non-responders, obefazimod 25 mg | “(N=81)” |
| Induction non-responders, obefazimod 50 mg | “(N=148)” |
| Part 1 relapsers, placebo then obefazimod 50 mg | “(N=109)” |
| Part 1 relapsers, obefazimod 25 mg then 50 mg | “(N=33)” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.7.1-6"></a>

###### Part 2 safety population: 186 participants on 25 mg and 447 on 50 mg

> “Includes combined induction non-responders on 50 mg in Part 2 (N=251) and Part 1 relapsers (N=196) who entered Part 2.”

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Treatment differences: Mantel-Haenszel common risk difference adjusted for the stratification factors

> “% Difference is for obefazimod minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting for the randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.7.2-2"></a>

###### Multiplicity control of the key secondary endpoints

> “Both obefazimod doses met all multiplicity-controlled key secondary endpoints (all p<0.0001)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Subgroup analyses by prior advanced therapy response: unadjusted differences and nominal p-values

> “Deltas are unadjusted numerical difference vs placebo (percentage points); not a Mantel-Haenszel stratified estimate.”
> “P-values are nominal and have not been adjusted for multiplicity; therefore, they should be interpreted as descriptive rather than confirmatory.”
> “Δ24% for 25mg in Sustained Clinical Remission endpoint only is based on the unadjusted numerical difference vs placebo (percentage points); not a Mantel-Haenszel stratified estimate. If the Mantel-Haenzel weights is used as described above for this dose and this endpoint, the delta becomes 8% due to the small sample size (n=15).”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Part 2 and integrated safety analyses: post-hoc, exposure-adjusted

> “The integrated post-hoc analyses presented today include the new Part 2 results, the combined Phase 3 maintenance program, and the broader Phase 2 and Phase 3 clinical development program.”
> “The post-hoc analyses below are presented progressively, from the combined Phase 2 and Phase 3 UC programs to the Phase 3 maintenance dataset (Part 1 + Part 2), and then to the Part 2 maintenance dataset, to illustrate how increasing cumulative patient-years strengthens the overall safety assessment.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Week 44 completion without relapse or treatment switch, by group

| Measure | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Study participants | “192” | “193” | “195” |
| Week 44 completion rate | “66 (34.3%)” | “152 (78.8%)” | “160 (82.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “Completion without relapse or treatment switch”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.1-2"></a>

###### Completion of the 44-week maintenance phase at the December 2025 data safety monitoring board review

> “The ABTECT Phase 3 DSMB meeting occurred on December 18, 2025, and reported no new safety signals with over 80% of participants having completed the 44-week double blind maintenance phase of the trial.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-3.1.3.8.1-3"></a>

###### Completion of the 44-week treatment period at the March 2026 data safety monitoring board review

> “completed a safety review of the ongoing Phase 3 ABTECT-UC maintenance trial and reported no new safety signals.”
> “Nearly 90% of enrolled participants have completed the 44-week treatment period.”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Part 1 baseline characteristics by group

| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Study participants | “192” | “193” | “195” |
| Age (years), mean (SD) | “41.3 (13.4)” | “43.0 (13.7)” | “42.3 (14.4)” |
| Induction baseline modified Mayo Score, mean (SD) | “6.9 (1.1)” | “6.7 (1.1)” | “6.9 (1.2)” |
| Duration of disease (years), mean (SD) | “8.1 (7.6)” | “8.1 (7.4)” | “7.8 (6.9)” |
| Induction baseline fecal calprotectin (mg/g), median | “1,202” | “1,585” | “1,568” |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |
| Clinical remission at maintenance baseline | “27.1%” | “37.8%” | “32.3%” |
| Prior advanced therapy failure | “37.5%” | “39.4%” | “46.2%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Higher proportion with prior advanced therapy failure in the 50 mg group

> “50 mg cohort had a higher percentage of patients with prior advanced therapy failure relative to patients on 25 mg and placebo”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.2-3"></a>

###### Definition of prior inadequate response to advanced therapy

> “AT-IR defined as: inadequate response, loss of response or intolerance to advanced therapies including biologics, JAKs, S1Ps with no upper limit”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Part 1 primary and key secondary endpoints at Week 44

| Endpoint at Week 44 | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) | Difference, 25 mg | Difference, 50 mg | P value (both doses) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission, n (%) | “20 (10.4%)” | “98 (50.8%)” | “100 (51.3%)” | “∆39.3%” | “∆40.3%” | “<0.0001” |
| Endoscopic improvement, n (%) | “24 (12.5%)” | “106 (54.9%)” | “125 (64.1%)” | “∆42.5%” | “∆51.0%” | “<0.0001” |
| Endoscopic remission, n (%) | “19 (9.9%)” | “80 (41.5%)” | “93 (47.7%)” | “∆31.4%” | “∆37.8%” | “<0.0001” |
| HEMI, n (%) | “20 (10.4%)” | “97 (50.3%)” | “112 (57.4%)” | “∆39.4%” | “∆46.5%” | “<0.0001” |
| Corticosteroid-free clinical remission, n (%) | “19 (9.9%)” | “87 (45.1%)” | “93 (47.7%)” | “∆35.1%” | “∆38.0%” | “<0.0001” |
| Sustained clinical remission, n/N (%) | “8/51 (15.7%)” | “49/73 (67.1%)” | “40/61 (65.6%)” | “∆52.8%” | “∆49.1%” | “<0.0001” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.3-2"></a>

###### Placebo clinical remission rate of 10.4% as characterized by the company

> “The trial also recorded a 10.4% placebo clinical remission rate, the lowest reported to date in a Phase 3 UC maintenance responder re-randomization trial.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.3-3"></a>

###### Week 52 reporting at UEG Week 2026: the same results expressed as 52 weeks of treatment overall

> “Week 52 includes the 8-week induction treatment with obefazimod”
> “Both obefazimod doses met the primary endpoint of clinical remission at Week 52 with 50.8% and 51.3% of patients receiving 25 mg and 50 mg, respectively, versus 10.4% receiving placebo (adjusted differences, 39.3 and 40.3 percentage points; both p<0.0001)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Other secondary endpoints at Week 52: clinical response and symptomatic remission

| Endpoint at Week 52 | Placebo, n/N | Placebo, % | Obefazimod 25 mg, n/N | Obefazimod 25 mg, % | Obefazimod 50 mg, n/N | Obefazimod 50 mg, % | Difference, 25 mg | Difference, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical response | “51/192” | “26.6%” | “135/193” | “69.9%” | “147/195” | “75.4%” | “∆ 42.8%” | “∆ 49.7%” |
| Symptomatic remission | “44/192” | “22.9%” | “129/193” | “66.8%” | “128/195” | “65.6%” | “∆ 42.5%” | “∆ 41.0%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “At Week 52, Higher Proportions of Patients Achieved Clinical Response and Symptomatic Remission With Both Obefazimod Doses than With Placebo”
> “defined as RBS=0, SFS <1”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.3-5"></a>

###### Clinical endpoints at Week 52 by prior inadequate response to advanced therapy

| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No prior AT-IR: clinical remission | “15/120” | “72/117” | “62/105” | “∆ 48%” | “p<0.0001” | “∆ 45%” | “p<0.0001” |
| No prior AT-IR: corticosteroid-free clinical remission | “15/120” | “64/117” | “59/105” | “∆ 42%” | “p<0.0001” | “∆ 43%” | “p<0.0001” |
| No prior AT-IR: sustained clinical remission | “5/38” | “42/58” | “27/38” | “∆ 62%” | “p<0.0001” | “∆ 55%” | “p=0.0003” |
| Prior AT-IR: clinical remission | “5/72” | “26/76” | “38/90” | “∆ 28%” | “p<0.0001” | “∆ 33%” | “p<0.0001” |
| Prior AT-IR: corticosteroid-free clinical remission | “4/72” | “23/76” | “34/90” | “∆ 26%” | “p=0.0001” | “∆ 31%” | “p<0.0001” |
| Prior AT-IR: sustained clinical remission | “3/13” | “7/15” | “13/23” | “∆ 24%” | “p=0.6873” | “∆ 30%” | “p=0.0915” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-6"></a>

###### Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy

| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N |
| --- | --- | --- | --- |
| No prior AT-IR: endoscopic improvement | “18/120” | “77/117” | “77/105” |
| No prior AT-IR: endoscopic remission | “15/120” | “62/117” | “58/105” |
| No prior AT-IR: HEMI | “15/120” | “71/117” | “68/105” |
| Prior AT-IR: endoscopic improvement | “6/72” | “29/76” | “48/90” |
| Prior AT-IR: endoscopic remission | “4/72” | “18/76” | “35/90” |
| Prior AT-IR: HEMI | “5/72” | “26/76” | “44/90” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-7"></a>

###### Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure

| Subgroup | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No prior AT-IR | “15/120” | “72/117” | “62/105” | “∆ 49%” | “p<0.0001” | “∆ 47%” | “p<0.0001” |
| One prior AT-IR | “4/27” | “12/31” | “17/41” | “∆ 24%” | “p=0.2785” | “∆ 27%” | “p=0.0584” |
| Two prior AT-IR | “0/24” | “7/22” | “8/19” | “∆ 32%” | “p=0.0215” | “∆ 42%” | “p=0.0014” |
| Three prior AT-IR | “1/12” | “4/12” | “10/21” | “∆ 25%” | “p=0.0771” | “∆ 39%” | “p=0.0968” |
| Four or more prior AT-IR | “0/9” | “3/11” | “3/9” | “∆ 27%” | “NC” | “∆ 33%” | “p=0.1967” |
| Prior JAK inhibitor inadequate response | “0/16” | “4/14” | “5/15” | “∆ 29%” | “p=0.0190” | “∆ 33%” | “p=0.0375” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-8"></a>

###### Conclusions of the subgroup presentation

> “Treatment differences favored obefazimod over placebo across clinical, endoscopic, symptomatic, and histologic-endoscopic outcomes in AT-IR naïve and in with patients with prior ATIR”
> “Placebo-adjusted treatment differences were generally numerically larger in AT-IR naïve vs. with patients with prior ATIR”
> “Clinical remission rates numerically favored both obefazimod doses across 0 to ≥4 prior AT-IR therapies and in JAK-IR patients”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-9"></a>

###### Part 2: induction non-responders continuing obefazimod, exploratory endpoints at Week 44

| Endpoint | Obefazimod 25 mg (N=81) | Obefazimod 50 mg (N=148) |
| --- | --- | --- |
| Clinical remission | “23.5%” | “37.2%” |
| Clinical response | “50.6%” | “61.5%” |
| Endoscopic improvement | “28.4%” | “48.0%” |
| HEMI | “23.5%” | “44.6%” |
| Endoscopic remission | “22.2%” | “34.5%” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.3-10"></a>

###### Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44

| Endpoint | Placebo in Part 1, then 50 mg (N=109) | Obefazimod 25 mg in Part 1, then 50 mg (N=33) |
| --- | --- | --- |
| Clinical remission | “45.0%” | “45.5%” |
| Clinical response | “69.7%” | “66.7%” |
| Endoscopic improvement | “54.1%” | “45.5%” |
| HEMI | “47.7%” | “39.4%” |
| Endoscopic remission | “32.1%” | “24.2%” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.3-11"></a>

###### No results posted in the registries

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

> “Summary of the results: not applicable: the trial has not ended.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### IBDQ response: long-term extension endpoint in the EU register, no results reported

> “Long-Term Extension (LTE) (4 years): Proportion of subjects with IBDQ response by visit.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Part 1 treatment-emergent adverse events over 44 weeks

| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Any TEAE | “96 (50.0%)” | “112 (58.0%)” | “140 (71.8%)” |
| TEAE leading to study drug discontinuation | “13 (6.8%)” | “5 (2.6%)” | “9 (4.6%)” |
| Serious TEAE | “8 (4.2%)” | “5 (2.6%)” | “11 (5.6%)” |
| Death | “0” | “0” | “0” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “2 (1.0%)” | “2 (1.0%)” | “1 (0.5%)” |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |
| Malignancy other than NMSC: prostate cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: breast cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: colonic dysplasia | “0” | “0” | “1 (0.5%)” |
| NMSC: basal cell carcinoma | “1 (0.5%)” | “0” | “2 (1.1%)” |
| NMSC: squamous cell carcinoma | “0” | “1 (0.5%)” | “2 (1.1%)” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-2"></a>

###### Part 1 malignancies and non-melanoma skin cancers as described by the company

> “Non-NMSC: The prostate, breast, and colon cancer cases were considered unrelated to treatment by investigators, and no organ-specific clustering was observed”
> “Two of the four 50 mg patients were deemed not/unlikely related to drug by investigators; of the remaining two cases, one had a medical history of skin cancer”
> “The mean age of observed NMSC cases was 62 years, compared with 42 years in the overall trial population, consistent with age-related NMSC risk”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-3"></a>

###### Part 1 serious or severe infections by group

> “Serious/Severe Infections and Opportunistic Infections: Placebo = Anal abscess, bronchitis & gastroenteritis, 25 mg = 1 Lymph node tuberculosis, 1 tonsillitis, 50 mg = 1 Appendicitis, focal peritonitis”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-4"></a>

###### Part 1 related serious adverse events, pregnancies, and colonic dysplasia as presented at UEG Week 2026

| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Patients with any related serious TEAE | “1 (0.5%)” | “0” | “0” |
| Pregnancy | “0” | “0” | “2 (1.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “One case of colonic dysplasia was reported in the obefazimod 50mg arm.”
> “No cases of acute pancreatitis were reported”
> “Overall favorable safety profile with no evidence of immunosuppression, consistent with the proposed mechanism of action of restoring immune balance while maintaining key components of immune surveillance”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.5-5"></a>

###### Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers

| Event, n (%) | Obefazimod 25 mg (N=186) | Obefazimod 50 mg (N=447) |
| --- | --- | --- |
| Any TEAE | “132 (71.0%)” | “307 (68.7%)” |
| TEAE leading to study drug discontinuation | “21 (11.3%)” | “27 (6.0%)” |
| Serious TEAE | “16 (8.6%)” | “23 (5.1%)” |
| Death, not treatment related | “1 (0.5%)” | “0” |
| Pregnancy | “1 (0.5%)” | “1 (0.2%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “5 (2.7%)” | “5 (1.1%)” |
| Malignancies excluding NMSC | “0” | “2 (0.4%)” |
| NMSC | “2 (1.1%)” | “2 (0.4%)” |
| Acute pancreatitis | “1 (0.5%)” | “1 (0.2%)” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” |

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-6"></a>

###### Part 2 death, infections, and malignancies: footnotes to the safety table

> “One death occurred in the 25 mg arm and was assessed by the investigator as unrelated to obefazimod. The suspected cause was pulmonary embolism in a 65+ patient with multiple pre-existing thromboembolic risk factors, including prior pulmonary embolism, and recent prolonged immobility.”
> “Serious/severe (grade ≥3) infections and opportunistic infections: 25 mg = Appendicitis, Bartonellosis, Cytomegalovirus gastrointestinal infection, Peritonsillar abscess, Sepsis; 50 mg (induction non-responder) = Clostridium difficile infection, pilonidal disease, Urethritis gonococcal; 50 mg Open Label (Part 1 relapsers = Appendicitis (Part 1 50 mg), Septic arthritis staphylococcal (Part 1 placebo).”
> “Part 1 relapsers previous on placebo: One case of Myoproliferative Neoplasm and one Prostate Cancer.”
> “Two cases of Basal Cell Carcinoma (25 mg | 50 mg) and two cases of Squamous Cell Carcinoma (25 mg | 50 mg).”

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-7"></a>

###### Part 2 malignancies and non-melanoma skin cancers: case characteristics and investigator assessment

| Case | Dose | Exposure to obefazimod | Age | Thiopurine history | Medical history of cancer or skin cancer | Investigator assessment |
| --- | --- | --- | --- | --- | --- | --- |
| Myeloproliferative neoplasm | “50 mg” | “7.4 months” | “40+” | “No” | “No” | “Determined not related to study drug by investigator” |
| Prostate cancer | “50 mg” | “3.4 months” | “55+” | “Yes azathioprine” | “No” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “50 mg” | “10.4 months” | “40+” | “Yes azathioprine” | “No” | “Determined probably related to study drug by investigator” |
| Squamous cell carcinoma | “50 mg” | “4.6 months” | “55+” | “Yes azathioprine” | “Yes” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “25 mg” | “8.1 months” | “50+” | “Yes azathioprine” | “No” | “Determined unlikely related to study drug by investigator” |
| Squamous cell carcinoma | “25 mg” | “8.3 months” | “75+” | “No” | “Yes” | “Determined probably related to study drug by investigator” |

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-8"></a>

###### Part 2 malignancies and non-melanoma skin cancers as described by the company

> “In Part 2, four total NMSC events were reported, two in the 25 mg arm and two in the 50 mg arm, which all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies. There were also two non-NMSC malignancies reported in the 50 mg arm, both deemed unrelated to obefazimod by the study investigators.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-9"></a>

###### Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range

| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
| --- | --- | --- | --- | --- | --- |
| Integrated UC program (phase 2 and phase 3) | “0.00” | “0.00” | “0.64” | “0.35” | “0.30 – 0.70” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.00” | “0.00” | “0.91” | “0.56” | “0.30 – 0.70” |
| Part 2 only | “-” | “0.00” | “0.69” | “0.48” | “0.30 – 0.70” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-10"></a>

###### Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range

| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
| --- | --- | --- | --- | --- | --- |
| Integrated UC program (phase 2 and phase 3) | “0.46” | “0.53” | “0.64” | “0.59” | “0.70 – 1.40” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.68” | “1.09” | “1.37” | “1.26” | “0.70 – 1.40” |
| Part 2 only | “-” | “1.52” | “0.69” | “0.95” | “0.70 – 1.40” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-11"></a>

###### Company interpretation of the exposure-adjusted malignancy analyses

> “Across the integrated Phase 2 and Phase 3 UC program (1,704 patient-years of exposure), exposure-adjusted incidence rates”
> “Because NMSCs and malignancies excluding NMSCs are uncommon events, incidence-rate estimates become more precise as cumulative exposure increases. The ABTECT Maintenance data should be interpreted using the totality of the exposure-adjusted evidence, together with patient characteristics and representative published UC epidemiologic reference ranges.”
> “The results in the tables below demonstrate that the exposure-adjusted incidence rate in the combined all active (25 mg + 50 mg) treatment arms for both NMSCs and malignancies excluding NMSCs are within the UC background reference range based on published UC studies.”
> “The overall safety results observed in Part 2 were consistent with those previously observed in the broader obefazimod clinical development program. No new safety pattern emerged with the additional cumulative exposure provided by Part 2.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-12"></a>

###### Interim data safety monitoring board reviews in December 2025 and March 2026

> “ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

> “ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trial”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

<a id="topic-3.1.3.8.5-13"></a>

###### Acute pancreatitis and cardiac abnormalities suggestive of cardiac fibrosis: ABTECT maintenance Part 1

| Event | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.

Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.

The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.

Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.

Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.

Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf); [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946); [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01); [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.4"></a>

#### 3.1.4 ABX464-103

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.”
> “A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.1-2"></a>

###### Aim stated in the published report

> “We aimed to assess ABX464 as a treatment for patients with moderate-to-severe, active ulcerative colitis.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.1-3"></a>

###### Primary objective in the protocol: dose selection

> “The primary objective of the study is to determine an optimal ABX464 dose to be used in moderate to severe active ulcerative colitis patients who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab, JAK inhibitors and/or corticosteroids by comparing the mean change from baseline in the MMS at week 8 between each ABX464 group and placebo.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.1-4"></a>

###### Selected secondary objectives in the protocol

> “To evaluate the effect of the different dose groups of ABX464 on clinical remission at Week 8 and at Week 16 (if available) versus placebo.”
> “To evaluate the effect of the different dose groups of ABX464 on Quality of Life (QoL) measured by the IBDQ at Week 8 and Week 16 versus placebo.”
> “To assess the pharmacokinetics of the ABX464 and its main active metabolite ABX464-N-Glu after oral administration of different daily doses of ABX464 using population approach.”
> “To evaluate the safety profile of the different dose groups of ABX464 versus placebo.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.1-5"></a>

###### Rationale for the study in the protocol: phase 2a results

> “A Phase IIa study (ABX464-101) aimed at evaluating the efficacy and safety of ABX464 given at a fixed dose of 50mg once daily versus Placebo in Patients with Moderate to Severe Active Ulcerative Colitis who have failed or are Intolerant to immunomodulators, Anti-TNFα or Corticosteroids was conducted in Belgium, France, Germany, Austria, Poland, Hungary.”
> “These efficacy and safety results warrant the continuation of the clinical development of ABX464 in this indication.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2019-08-13”
> “Primary Completion (Actual) 2021-04-01”
> “Study Completion (Actual) 2021-04-16”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.2-2"></a>

###### Results posting dates

> “Results First Submitted 2024-05-17”
> “Results First Posted 2025-11-28”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.2-3"></a>

###### Registered locations

> “This study has 130 locations”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.2-4"></a>

###### Centres, countries, and enrollment period in the published report

> “In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.”
> “Between Aug 13, 2019, and April 16, 2021, 254 patients were randomly allocated to ABX464 100 mg (n=64), ABX464 50 mg (n=63), ABX464 25 mg (n=63), or placebo (n=64).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.2-5"></a>

###### Planned sites in the protocol

> “Up to 244 patients will be randomized in this study. These patients will be enrolled in approximately 110 to 150 sites located in Europe, Canada and in the USA.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.2-6"></a>

###### Trial registration printed in the published abstract

> “This study is registered with ClinicalTrials.gov, NCT04023396.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomised, double-blind, placebo-controlled, four-group design

> “In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.”
> “Enrolled patients were randomly assigned (1:1:1:1) via an interactive voice and web response system to receive once daily oral ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, or matched placebo.”
> “Randomisation was stratified according to study site (US vs non-US) and to whether the patient had previous exposure to second-line treatment with biologics or JAK inhibitors.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.3-2"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double blind, placebo controlled, parallel groups” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Enrollment (actual) | “355” |

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.3-3"></a>

###### Treatment groups and duration in the ClinicalTrials.gov record

> “Eligible patients will be randomized into 4 parallel intervention/treatment groups: 100mg q.d of ABX464, 50mg q.d of ABX464, 25mg q.d of ABX464, or matching placebo and will be treated for 16 weeks.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.3-4"></a>

###### Limits on previous advanced therapy exposure, central endoscopy reading, and e-diaries

> “The proportion of patients with previous exposure to biologics or JAK inhibitors will be limited to 60%, including a maximal proportion of patients with previous treatment with vedolizumab of 20%. The maximal proportion of patients with previous exposure with JAK inhibitors will be limited to 10%.”
> “Patients will be treated for 16 Weeks in this induction study. All endoscopies (videos) will be centrally reviewed. E-Diaries will be used to collect frequency of stools, rectal bleedings, number of capsules taken and the intake time.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-5"></a>

###### Endoscopy schedule and exit for disease progression

> “Flexible sigmoidoscopy with rectal and sigmoidal (if the sigmoidal is inflamed) biopsies will be performed at screening, at Day 57 +/- 4 days (week 8) and at Day 113 +/- 4 days (week16). The Day 113 measurement will only be performed if patient does not experience endoscopic improvement at Day 57 (i.e.: endoscopy sub-score of 2 or 3).”
> “From Week 8 onwards, in the event of clinical progression of the disease defined as at least a 2-point increase from the screening in partial Modified Mayo Score (pMMS) with a Modified Mayo Score ≥ 4 confirmed by an endoscopy sub score of 2 points or higher, the patient will exit definitively the study.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-6"></a>

###### Duration of participation and roll-over to the open-label extension

> “Patients will be treated for 16 Weeks. At Week 16, regardless of their clinical/symptomatic response and the actual treatment/dose received, patients willing to continue the study treatment and eligible for enrollment will roll over in an Open Label Extension study (ABX464-104).”
> “Thus, the total duration of the study participation is 21 Weeks.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.3-7"></a>

###### Dose limiting toxicity rule and Data Safety Monitoring Board

> “A dose limiting toxicity (DLT) is defined as a grade 3 or higher adverse event as defined by the Common Terminology Criteria for Adverse Events (CTC-AE V5.0) considered by a safety review board as probably or definitely related to study treatment.”
> “The DSMB will meet every 2 months.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key eligibility criteria in the published report

> “Eligible patients were aged 18-75 years, with a diagnosis of moderate-to-severe, active ulcerative colitis and a modified Mayo Score (MMS) of 5 points or higher, and a documented non-response or intolerance to previous treatment.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record: disease activity and previous treatment

> “Men or women age 18 - 75 years;”
> “Moderate to severe active UC defined by Modified Mayo Score (MMS) of 5 to 9 inclusive (on a scale of 0-9). Moderate to severe active UC should be confirmed at screening visit with a centrally read endoscopy sub-score of at least 2 (on a scale of 0-3);”
> “Patients having either a documented inadequate response, no response, a loss of response, or an intolerance (defined as the occurrence of at least one Adverse Reaction leading to treatment discontinuation) to either immunosuppressant treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor [TNF] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment.”
> “18 Years to 75 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.4-3"></a>

###### Inclusion criteria in the ClinicalTrials.gov record: background therapy and washout

> “Patients receiving oral corticosteroids must have been on a stable dose of prednisone or prednisone equivalent (≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or on budesonide MMX (≤9 mg/day) for at least 2 Weeks prior to the screening visit;”
> “Patients who have received tumor necrosis factor [TNF] inhibitors, vedolizumab or other biologics must have discontinued therapy at least 8 Weeks prior to the screening visit due to lack or insufficient efficacy or intolerance;”
> “Patients previously treated with cyclosporine, tacrolimus or JAK inhibitors must have discontinued therapy at least 4 Weeks prior to the screening visit due to lack or insufficient efficacy or intolerance;”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.4-4"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Patients with Crohn's Disease (CD) or presence or history of fistula, indeterminate colitis (IC), infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis);”
> “History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or imminent colectomy, colonic malignancy;”
> “History of more than one episode of herpes zoster or a history (single episode) of disseminated zoster;”
> “Patients previously treated with ABX464;”
> “Acute, chronic or history of immunodeficiency or autoimmune disease;”
> “Pregnant or breast-feeding women;”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Arms and capsule regimens in the ClinicalTrials.gov record

> “ABX464 100 mg (two capsules of ABX464 50 mg) once daily for 16 weeks”
> “ABX464 50 mg (one capsule of ABX464 50 mg + one capsule of placebo) once daily for 16 weeks”
> “ABX464 25 mg (one capsule of ABX464 25 mg + one capsule of placebo) once daily for 16 weeks”
> “Two capsules of placebo once daily for 16 weeks”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.5-2"></a>

###### Formulation and administration in the protocol

> “For the proposed clinical trial, the IMP consists of size 01 capsules containing either 25mg or 50mg of ABX464 drug substance”
> “All patients regardless of the treatment group will receive 2 capsules every day.”
> “Patients will be orally dosed in a fed condition (regular meal) in the morning with a glass of water.”
> “No intra-patient dose escalation/dose adjustment are allowed.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.5-3"></a>

###### Allowed concomitant medications in the protocol

> “Corticosteroids at stable dose of prednisone or prednisone equivalent ≤20 mg/day; beclomethasone diproprionate (≤5mg/day) or budesonide MMX (≤9 mg/day);”
> “Oral 5-aminosalicylic acid at stable dose;”
> “Immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate at stable dose;”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.5-4"></a>

###### Prohibited medications in the protocol, including CYP1A2 substrates

> “JAK inhibitors with a wash-out period of at least 4 Weeks prior to the screening visit;”
> “Vaccination with live components during the study and up to 8 Weeks after the last dosing;”
> “The following CYP1A2 substrates with a narrow therapeutic margin are prohibited during the whole course of the study (Clozapine, theophylline, ropinirol, warfarin and methadone).”
> “Drugs that inhibit UGTIA9 activity and inhibitors of OATP1B1/1B3 transporters (cf. Appendix #1).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Change in Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint in the published report

> “The primary endpoint was the change from baseline in MMS at week 8.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.6.1-2"></a>

###### Registered primary outcome measure and the modified Mayo score

> “Reduction From Baseline in Modified Mayo Score (MMS) at Week 8”
> “MMS is a composite score of UC disease activity based on the following 3 subscores:”
> “The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="topic-3.1.4.6.1-3"></a>

###### Modified Mayo score compared with the total Mayo score in the protocol

> “The Stool and Rectal Bleeding frequency assessment will be based on the Mayo scoring system which is the most commonly used index in clinical trials.”
> “Total Mayo score consists of 4 items: stool frequency, rectal bleeding, flexible sigmoidoscopic examination, and a physician global assessment (Appendix #3). Modified Mayo Score (MMS) consists of 3 items (stool frequency, rectal bleeding, flexible sigmoidoscopic examination).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.6.1-4"></a>

###### Secondary endpoint definitions in the protocol: clinical remission, clinical response, endoscopic improvement, and mucosal healing

> “Clinical remission, based on the Mayo Scoring system, is defined as stool frequency subscore = 0 or 1 and rectal bleeding subscore = 0 and endoscopy subscore = 0 or 1 (modified to exclude friability).”
> “Clinical Response is defined as a reduction in Mayo Score of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.”
> “Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability) and endoscopic remission defined as sub score of 0.”
> “Mucosal healing is defined as both endoscopic remission and histological remission (Geboes score < 2.0).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.6.1-5"></a>

###### Central reading of endoscopy in the registered secondary outcomes

> “Endoscopies were assessed by a blinded central reader and scored according to the following scale:”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size assumptions in the protocol

> “mean reduction in MMS (ABX464): 2.5”
> “mean reduction in MMS (placebo): 1.0”
> “pooled standard deviation of reduction in MMS: 2.1”
> “If the above assumptions hold true, then a total sample size of 232 subjects will be required to be randomized (58 subjects randomized to each study treatment arm).”
> “Due to the SARS Cov-2 pandemic the drop-out rate of the study is expected to be somewhat higher than originally estimated. Therefore, an additional 12 subjects are planned to be recruited in the study leading to an overall sample size of 244 patients (61 subjects randomized to each study treatment arm).”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants consented, randomized, treated, and analyzed in the posted results

> “A total of 355 patients consented to participate, 254 patients were randomized. A total of 253 patients were treated, 222 patients completed study treatment.”
> “A total of 252 patients were included in the FAS (64: ABX464 100mg q.d, 63: ABX464 50mg q.d, 61: ABX464 25mg q.d and 64: placebo).”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.7.1-3"></a>

###### Exclusions from the full analysis set in the published report

> “Two patients, both in the ABX464 25 mg group, were excluded from the FAS.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.7.1-4"></a>

###### Participants analyzed for the primary outcome in the posted results

| Group | Participants analyzed, change in MMS at week 8 |
| --- | --- |
| ABX464 100 mg | “58” |
| ABX464 50 mg | “54” |
| ABX464 25 mg | “59” |
| Matching placebo | “60” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Full analysis set and safety population in the published report

> “The primary efficacy analysis was done in the full analysis set (FAS), defined as all randomly assigned patients who received at least one dose of study treatment and had baseline data for at least one efficacy variable, and was analysed according to the principles of intention-to-treat.”
> “Safety analyses included patients who had been randomly assigned and who received at least one dose of study treatment.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.7.2-2"></a>

###### Analysis sets in the statistical analysis plan

> “The Safety Analysis Set (SAF) will include all randomized patients who have received at least one dose of the study treatment.”
> “The Full Analysis Set (FAS) will include all patients included in the study who have received at least one dose of the study treatment, and who have baseline data for at least one efficacy variable.”
> “The Per Protocol Analysis Set (PPAS) will include all patients in the FAS who do not have major PDs that would affect the evaluation of the primary efficacy endpoint.”

Source: [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf)

<a id="topic-3.1.4.7.2-3"></a>

###### Handling of missing week 8 data

> “A subject’s missing efficacy data viz. MMS (or any components of MMS missing) at Week 8, will be imputed and the subject will be considered as a non-responder for clinical remission and response.”

Source: [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf)

<a id="topic-3.1.4.7.2-4"></a>

###### Primary analysis model and fixed testing sequence in the protocol

> “This change will be compared between subjects who received ABX464 and placebo for each ABX464 treatment arm separately using an ANCOVA model adjusting for randomized study treatment arm, previous biological or JAK inhibitors treatment use (i.e. randomization strata), and baseline MMS.”
> “The dose testing will commence with comparing the ABX464 50mg dose with placebo. If this is significant at a 5% two-sided level (i.e. p<0.05) a comparison against placebo will be carried out at the ABX464 100mg dose. Again, if significance at a 5% level for this test is observed the procedure will be repeated at the ABX464 25mg dose.”
> “Analysis of efficacy data will be carried out in the Full Analysis Set in which subjects who prematurely discontinue the study due to adverse reaction(s) will be considered treatment failures.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Participant flow in the posted results

| Measure | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Started | “64” | “63” | “63” | “64” |
| Treated | “64” | “63” | “62” | “64” |
| Full analysis set | “64” | “63” | “61” | “64” |
| Completed | “54” | “53” | “58” | “57” |
| Not completed | “10” | “10” | “5” | “7” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

###### Discontinuations and exclusions in the posted results

> “32 patients discontinued and 1 patient was randomized but did not receive study drug. One further patient was excluded from the Full Analysis Set (FAS) due to noncompliance with inclusion/exclusion criteria.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline characteristics in the posted results

| Characteristic | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo | Total |
| --- | --- | --- | --- | --- | --- |
| Participants | “64” | “63” | “61” | “64” | “252” |
| Age, years, mean (SD) | “42.2(12.34)” | “40.2(13.94)” | “41.5(14.16)” | “41.1(14.43)” | “41.2(13.67)” |
| Female | “23” | “36” | “21” | “24” | “104” |
| Male | “41” | “27” | “40” | “40” | “148” |
| Baseline MMS 5 to 6 | “17” | “16” | “17” | “21” | “71” |
| Baseline MMS 7 to 9 | “47” | “47” | “44” | “42” | “180” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.2-2"></a>

###### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.2-3"></a>

###### Disease severity and refractoriness of the induction population

> “Of the 252 patients treated in the induction trial, baseline disease activity was severe (MMS of 7–9) in 71.4% of patients, and more than 45% of patients were refractory to 2 or more advanced targeted therapies at baseline.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.4.8.2-4"></a>

###### Participants enrolled by country in the posted results, selected countries

| Country | Total participants |
| --- | --- |
| Poland | “70” |
| Ukraine | “32” |
| France | “30” |
| Hungary | “22” |
| Italy | “20” |
| United States | “2” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Induction results reported in the maintenance study publication

> “More than 45% had failed at least 2 prior advanced targeted therapies (biologics or JAK inhibitors). Obefazimod (25, 50, or 100 mg) significantly reduced the modified Mayo score (MMS) at week 8, meeting the primary endpoint. Improvements were seen in both naïve and bio/JAK refractory patients in key secondary outcomes, including clinical remission, response, endoscopic, and histologic–endoscopic mucosal improvement.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.4.8.3-2"></a>

###### Primary endpoint: change from baseline in modified Mayo score at week 8

> “In the FAS at week 8, the least squares mean (LSM) change from baseline in MMS was -2·9 (95% CI -3·4 to -2·5) for the ABX464 100 mg group, -3·2 (-3·7 to -2·7) for the ABX464 50 mg group, -3·1 (-3·6 to -2·6) for the ABX464 25 mg group, and -1·9 (-2·4 to -1·5) for placebo group; the magnitude of the difference in MMS from baseline was significantly greater in all three ABX464 groups compared with placebo (p=0·0039 for ABX464 100 mg vs placebo, p=0·0003 for ABX464 50 mg vs placebo, and p=0·0010 for ABX464 25 mg vs placebo).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.3-3"></a>

###### Investigators' interpretation

> “All doses of ABX464 significantly improved moderate-to-severe, active ulcerative colitis compared with placebo, as measured by changes in MMS from baseline to week 8.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.3-4"></a>

###### Primary outcome in the posted results: least squares mean change in MMS at week 8

| Group | Least squares mean | 95% confidence interval |
| --- | --- | --- |
| ABX464 100 mg | “-2.9” | “(-3.4 to -2.5)” |
| ABX464 50 mg | “-3.2” | “(-3.7 to -2.7)” |
| ABX464 25 mg | “-3.1” | “(-3.6 to -2.6)” |
| Matching placebo | “-1.9” | “(-2.4 to -1.5)” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-5"></a>

###### Secondary outcomes at week 8 in the posted results: number of participants

| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Clinical remission per MMS (64, 63, 61, 64) | “16” | “11” | “16” | “8” |
| Clinical response (64, 63, 61, 64) | “32” | “37” | “38” | “22” |
| Endoscopic improvement (54, 53, 58, 59) | “24” | “21” | “20” | “8” |
| Endoscopic remission (54, 53, 58, 59) | “2” | “5” | “4” | “5” |
| Mucosal healing (64, 63, 61, 64) | “0” | “1” | “0” | “2” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-6"></a>

###### Secondary outcomes at week 16 in the posted results: number of participants

| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| Clinical remission per MMS (31, 30, 37, 46) | “7” | “6” | “9” | “6” |
| Clinical response (31, 30, 37, 46) | “19” | “20” | “25” | “20” |
| Endoscopic improvement (32, 31, 38, 46) | “11” | “12” | “11” | “9” |
| Endoscopic remission (32, 31, 38, 46) | “1” | “1” | “2” | “3” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.3-7"></a>

###### Analysis population for the week 16 outcomes

> “Number of patients in the category with data available for baseline and the respective visit.”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### IBDQ planned as a secondary endpoint in the protocol

> “The scores and changes from baseline in IBDQ at Week 8 and Week 16 per intervention treatment group.”
> “The Inflammatory Bowel Disease Questionnaire (IBDQ) is a widely used questionnaire for HRQoL assessment in patients with inflammatory bowel diseases (IBDs).”
> “IBDQ will be filled in by the patients at Day 1, Day 57 and Day 113 prior to any study procedures.”

Source: [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf)

<a id="topic-3.1.4.8.4-2"></a>

###### Stool frequency and rectal bleeding recorded in an electronic diary

> “Participants recorded stool frequency using an electronic subject diary on a daily basis.”
> “Participants recorded rectal bleeding in an electronic subject diary on a daily basis.”

Source: [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Headache and serious adverse events in the published report

> “The most frequently reported adverse event was headache, which was reported for 27 (42%) of 64 patients in the ABX464 100 mg group, 19 (30%) of 63 in the 50 mg group, 13 (21%) of 62 in the 25 mg group, and five (8%) of 64 in the placebo group.”
> “Severe (grade 3) headache was reported for three (5%) patients in the ABX464 group 100 mg group, two (3%) in the ABX464 50 mg group, one (2%) in the ABX464 25 mg group, and none in the placebo group.”
> “The only serious adverse event reported for two or more patients in any group was ulcerative colitis (one in each of the ABX464 100 mg and 50 mg groups, and three [5%] in the placebo group).”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-3.1.4.8.5-2"></a>

###### Adverse events in the posted results: participants affected / at risk (%)

| Event | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
| --- | --- | --- | --- | --- |
| All-cause mortality | “0/64 (0.00%)” | “0/63 (0.00%)” | “0/62 (0.00%)” | “0/64 (0.00%)” |
| Serious adverse events, total | “4/64 (6.25%)” | “4/63 (6.35%)” | “1/62 (1.61%)” | “4/64 (6.25%)” |
| Other adverse events, total | “45/64 (70.31%)” | “38/63 (60.32%)” | “33/62 (53.23%)” | “30/64 (46.88%)” |
| Headache | “27/64 (42.19%)” | “19/63 (30.16%)” | “13/62 (20.97%)” | “5/64 (7.81%)” |
| Nausea | “9/64 (14.06%)” | “4/63 (6.35%)” | “5/62 (8.06%)” | “4/64 (6.25%)” |
| Vomiting | “5/64 (7.81%)” | “2/63 (3.17%)” | “1/62 (1.61%)” | “1/64 (1.56%)” |
| Abdominal pain upper | “4/64 (6.25%)” | “3/63 (4.76%)” | “3/62 (4.84%)” | “0/64 (0.00%)” |

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.8.5-3"></a>

###### Adverse event collection period in the posted results

> “TEAEs and SAEs were collected from enrollment to end of study: up to 24 weeks in total, including 4 weeks screening (prior the first dose of study drug), 16 weeks of treatment, and 4 weeks safety follow-up (28 days after last dose of study drug).”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/); [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results); [Abivax ABX464-103 protocol (2020)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/Prot_000.pdf); [Abivax ABX464-103 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/03/NCT03760003/SAP_001.pdf); [ClinicalTrials.gov NCT03760003](https://clinicaltrials.gov/study/NCT03760003); [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.4.9-2"></a>

###### Limitations and caveats field in the posted results

> “Limitations and Caveats [Not Specified]”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="topic-3.1.4.9-3"></a>

###### Publication agreement disclosed in the posted results

> “There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed”

Source: [ClinicalTrials.gov NCT03760003 results](https://clinicaltrials.gov/study/NCT03760003?tab=results)

<a id="heading-3.1.5"></a>

#### 3.1.5 ABX464-104

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.”
> “A Phase 2b, Open-label, Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.1-2"></a>

###### Objectives stated in the published report

> “The objectives of the OLM study were to assess the long-term safety and efficacy of obefazimod 50 mg od.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.1-3"></a>

###### Primary objective in the protocol

> “The primary objective of the study is to assess in all patients the long-term efficacy of ABX464 given at 50 mg QD on clinical remission at week 48 compared to the induction study (ABX464-103) baseline (ISB).”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.1-4"></a>

###### Selected secondary objectives in the protocol, including cardiac function

> “To evaluate the proportion of patients with glucocorticoid-free clinical remission at week 48.”
> “To evaluate the effect of ABX464 50 mg QD on patients’ quality of Life (QoL) measured by the Inflammatory Bowel Disease Questionnaire (IBDQ) at week 24 and week 48 compared to BOLS.”
> “To evaluate the long-term safety profile of ABX464 50 mg QD.”
> “To evaluate the effect of ABX464 on cardiac function as assessed through echocardiograms.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2020-01-13”
> “Primary Completion (Actual) 2023-02-23”
> “Study Completion (Actual) 2023-02-23”
> “Results First Posted 2025-04-27”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.2-2"></a>

###### Registered locations

> “This study has 120 locations”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.2-3"></a>

###### Centers and countries in the published report

> “Patients were enrolled at 69 study centers in 14 countries (Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Serbia, Slovakia, Slovenia, Spain, and Ukraine).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.2-4"></a>

###### Planned sites in the protocol

> “Patients will be enrolled in 69 sites located in Europe, US and Canada.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.2-5"></a>

###### Conduct in Ukraine during the war

> “The Phase 2b 12-month assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still on-going.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “217” |

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.3-2"></a>

###### Open-label design described in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-103 clinical study (induction study) and who are willing to continue their treatment.”
> “All subjects will receive ABX464 given at 50mg o.d regardless of their previous treatment and dose received in the ABX464-103 study (i.e. ABX464 100mg, ABX464 50mg, ABX464 25mg or Placebo).”
> “Subjects will be treated with ABX464 for an overall period of 48 weeks. Subjects will be followed up on a monthly basis.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.3-3"></a>

###### Entry regardless of induction response, continuation to week 96, and visit schedule

> “Patients who had completed the induction study phase and who were willing to continue treatment could enter the OLM and receive treatment with obefazimod 50 mg od, regardless of the patient’s clinical response or randomized treatment (placebo or obefazimod 25, 50, or 100 mg od) during induction (Figure 1).”
> “After week 48, patients who had shown clinical response (defined as a decrease in MMS ≥2 points and ≥30% from baseline (induction), plus a decrease in rectal bleeding subscore [RBS] ≥1 or an absolute RBS ≤1) were eligible for continued participation in the extension for a total period of 96 weeks.”
> “From day 1 onwards, patients were seen at the investigational site every 4 weeks up to week 48, then at weeks 60, 72, 84, and 96; flexible sigmoidoscopy with rectal and/or sigmoidal biopsies was performed at weeks 48 and 96 (both central and blinded reading of endoscopies were assessed).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.3-4"></a>

###### Safety follow-up, exit for disease progression, and roll-over to ABX464-108 in the protocol

> “Patients will be treated for a maximum of 96 weeks in this maintenance study. After the treatment period, patients will be followed for 4 additional weeks for safety purposes. Alternatively, eligible subjects willing to continue study treatment will be offered to take part in a long term follow up safety study (ABX464-108) at the end of treatment (ie Week 96).”
> “During the open label maintenance phase, in the event of clinical progression of the disease, defined as at least a 2-point increase from the screening partial Modified Mayo Score (pMMS) with a pMMS ≥ 4 confirmed by an endoscopy sub score of 2 points or higher, the patient will exit the study.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.3-5"></a>

###### Data and Safety Monitoring Board and Independent Cardiovascular Safety Committee

> “A Data and Safety Monitoring Board (DSMB) with expertise and experience in the management in UC will review the safety of the trial every 2 months during the entire study period.”
> “An Independent Cardiovascular Safety Committee (ICVSC), comprised of 3 cardiologists with experience from drug development, will be formed as detailed in the Charter.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.3-6"></a>

###### Echocardiography added after enrollment was complete

> “Since enrolment is completed at the time of this amendment, drug-free baseline measurements are not available. Echocardiography will be performed at the earliest opportunity (Week 24 or Week 48 or Week 72) and will be repeated every six months.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Patients must have completed the 16-week induction treatment period (ABX464-103);”
> “Patients are able and willing to comply with study visits and procedures as per protocol;”
> “18 Years to 75 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-2"></a>

###### Criteria for a second 48 weeks of treatment

> “Criteria that should be met by patients at week 48 to be eligible for 48 additional weeks of study treatment.”
> “Patients should be in clinical response. Clinical response is defined as: a reduction in Modified Mayo Score ≥ 2 points and ≥ 30 % from baseline (induction) with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Patients who had major protocol deviation(s) in the induction study;”
> “Patients who permanently discontinued study the treatment in induction study (ABX464-103) because of an adverse event (AE) regardless of relatedness to investigational product;”
> “Patients who are participating or plan to participate in other investigational studies (other than induction study) during the study.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.4-4"></a>

###### Induction population described in the published report

> “The study design and results from the induction trial, as well as the eligibility and exclusion criteria for patients aged 18–75 with moderate-to-severely active UC, have been reported previously.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.5-2"></a>

###### Administration in the protocol

> “Patients will be treated with a daily dose of 50mg of ABX464. Patients will receive 1 capsule every day.”
> “All patients will be orally dosed in a fed condition (regular meal) with a glass of water.”
> “No intra-patient dose escalation/dose adjustment are allowed.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.5-3"></a>

###### Allowed and prohibited concomitant medications and corticosteroid tapering

> “Allowed concomitant medications were continued from the baseline of the induction trial. These included corticosteroids (CS; ≤20 mg per day of prednisone or prednisone equivalent, ≤5 mg per day of beclomethasone dipropionate, or ≤9 mg per day budesonide MMX), oral 5-ASA, immunosuppressants such as azathioprine and 6-mercaptopurine, and antidiarrheals.”
> “The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study. At the start of the OLM study, CS-tapering was recommended in all patients but was not mandatory.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered primary outcome measure

> “Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)”
> “Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.6.1-2"></a>

###### Primary endpoint and remission definition in the protocol

> “Proportion of patients with clinical remission at week 48 compared to induction study baseline.”
> “Clinical remission, based on the Mayo Scoring system, is defined as stool frequency sub score = 0 or 1 and rectal Bleeding sub score = 0 and endoscopy sub score = 0 or 1 (modified to exclude friability).”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.6.1-3"></a>

###### Efficacy endpoints and definitions in the published report

> “Endpoints included rate of clinical remission (defined as stool frequency subscore [SFS] ≤1 and rectal bleeding = 0 and endoscopic score of 0 or 1), rate of clinical response (defined as a decrease from baseline in MMS ≥2 points and ≥30% from baseline, plus a decrease in RBS ≥1 or an absolute RBS ≤1), rate of endoscopic improvement (endoscopic subscore ≤1), rate of endoscopic remission (endoscopic subscore = 0), change from baseline of OLM study by visit up to week 96 for stool frequency, and fecal calprotectin (FCP).”
> “CS-free status, defined as the cessation of CS for at least 12 weeks prior to each assessment time point in this analysis, was evaluated for efficacy outcomes at weeks 48 and 96 within the subgroup of patients receiving concomitant CS at the induction baseline.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.6.1-4"></a>

###### Glucocorticoid-free clinical remission defined in the protocol

> “Glucocorticoid-free clinical remission is defined as clinical remission in addition to not requiring any treatment with glucocorticoids for at least 8 weeks prior to week 48.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.6.1-5"></a>

###### Registered secondary outcome: clinical response definition

> “Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="topic-3.1.5.6.1-6"></a>

###### Endoscopic improvement and fecal calprotectin as treatment targets

> “Endoscopically determined improvement in mucosal appearance has been associated with more favorable long-term outcomes in patients with UC.”
> “FCP levels below 150 µg/g typically indicate remission with a high degree of accuracy according to Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### No sample size calculation in the protocol

> “This study is an open label extension study. Sample size calculation is therefore not applicable.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants enrolled and analyzed in the published report

> “Of the 222 eligible patients who completed the induction trial, 217 (97.7%) were enrolled in the OLM study (Figure S1).”
> “The primary analysis set for efficacy was the full analysis set (FAS, N = 217), and analysis of safety parameters was carried out using the safety analysis set (SAF, N = 217).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.7.1-3"></a>

###### Participants analyzed in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “217” |
| Overall number of baseline participants | “217” |
| Overall number of participants analyzed, clinical remission at week 48 | “217” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Full analysis set, safety analysis set, baseline, and nonresponder imputation in the published report

> “The FAS included all patients who received at least 1 dose of obefazimod 50 mg and had a baseline of OLM data for at least 1 efficacy variable; the SAF included all patients who received at least 1 dose of obefazimod 50 mg.”
> “Baseline of OLM was defined as the last non-missing measurement after induction (week 8 or 16) taken prior to the first dose of obefazimod 50 mg of the OLM study.”
> “The proportions of patients in clinical remission, clinical response, with endoscopic improvement, or endoscopic remission were summarized descriptively using nonresponder imputation (NRI) analysis at weeks 48 and 96 (patients with missing data were imputed as nonresponders).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.7.2-2"></a>

###### Analysis sets in the protocol

> “The Safety dataset (SAF population) is defined as those patients included in the study, who have received at least one dose of the study treatment.”
> “The Full Analysis dataset (FAS population) is defined as those patients included in the study, who have received at least one dose of the study treatment, and who have at least one efficacy baseline data.”
> “The Per Protocol dataset (PP population) is defined as those patients of the FAS population without any major protocol deviation.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.7.2-3"></a>

###### Two baselines and missing data rules in the statistical analysis plan

> “ISB (Induction Study Baseline) is the baseline measurement for the Induction (ABX464-103) study.”
> “BOLS (Baseline of Open Label Study) is the Day 113 (Week 16) measurement of the Induction (ABX464-103) study.”
> “Patients discontinued prior to Week 96 are considered as non-responders at Week 96 i.e. not achieving clinical endpoint at Week 96. LOCF method is used to impute completers (not discontinued but missing Week 96 assessment) by carrying forward the results from Week 48.”

Source: [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf)

<a id="topic-3.1.5.7.2-4"></a>

###### Descriptive statistics and interim analysis at week 48

> “Descriptive statistics were presented for all efficacy and safety variables.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “An interim analysis will be performed when all the subjects reach Week 48 visit.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Participant flow in the posted results

| Measure | Participants |
| --- | --- |
| Started | “217” |
| Completed | “164” |
| Not completed | “53” |
| Adverse event | “16” |
| Death | “1” |
| Lack of efficacy | “3” |
| Lost to follow-up | “1” |
| Other reason (e.g., Ukraine Crisis) | “10” |
| Physician decision | “4” |
| Pregnancy | “4” |
| Withdrawal by subject | “14” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.1-2"></a>

###### Discontinuations by year in the published report

> “Of 222 eligible patients, 217 were enrolled and 164 (75.6%) completed week 96 of the OLM study.”
> “Thirty of 217 (13.8%) discontinued prior to week 48, 6 patients did not meet eligibility criteria for the second year of treatment (did not achieve clinical response at week 48 or were unwilling to continue) and 17/181 (9.4%) patients discontinued between weeks 48 and 96. All discontinuations were considered as treatment failures for the NRI analysis of efficacy at weeks 48 and 96.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.1-3"></a>

###### Enrollment and completion in the Form 20-F

> “Of the 222 patients who completed our 16-week Phase 2b induction trial, 217 patients (98%) enrolled in the subsequent open-label maintenance trial to evaluate the long-term safety and efficacy profile of obefazimod for up to two years, irrespective of treatments or treatment outcome during the induction phase.”
> “Of the patients included in the maintenance trial, 164 patients (76%) completed two years of once-daily oral dosing with 50 mg obefazimod.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographic and baseline characteristics in the published report

| Characteristic | Total (N = 217) |
| --- | --- |
| Age, years, mean (SD) | “42.1 (13.8)” |
| Male, n (%) | “133 (61.3)” |
| Female, n (%) | “84 (38.7)” |
| Obefazimod 25 mg during induction, n (%) | “58 (26.7)” |
| Obefazimod 50 mg during induction, n (%) | “51 (23.5)” |
| Obefazimod 100 mg during induction, n (%) | “53 (24.4)” |
| Placebo during induction, n (%) | “55 (25.3)” |
| Naïve to biologics or JAK inhibitors, n (%) | “119 (54.8)” |
| Inadequate response to biologics or JAK inhibitors, n (%) | “98 (45.2)” |
| Inadequate response to 2 or more biologics or JAK inhibitors, n (%) | “70 (71.4)” |
| Concomitant corticosteroids, n (%) | “120 (55.3)” |
| Concomitant 5-ASA, n (%) | “159 (73.3)” |
| Fecal calprotectin, µg/g, mean (SD) | “900.1 (1574.5)” |

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.2-2"></a>

###### Baseline characteristics described in the text of the published report

> “At baseline of OLM, the mean age was 42.1 years; 61.3% of patients were men; 162 patients were randomized to 1–3 doses of obefazimod and 55 patients to placebo in the induction trial.”
> “At baseline of OLM, 98 patients (45.2%) had prior inadequate response to biologics or JAK inhibitors (70 of these 98 (71.4%) patients had inadequate response to ≥2 biologics or JAK inhibitors), 119/217 patients (54.8%) were naive to biologics or JAK inhibitors and 120/217 patients (55.3%) were using concomitant corticosteroids (Table 1).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.2-3"></a>

###### Race and ethnicity not collected, and participants by country in the posted results

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

| Country | Participants |
| --- | --- |
| Poland | “63” |
| Ukraine | “30” |
| France | “24” |
| Hungary | “17” |
| Italy | “17” |
| Canada | “5” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Clinical and endoscopic outcomes at weeks 48 and 96, all participants (nonresponder imputation)

> “Among the 217 patients who enrolled in the OLM study and received 50 mg od oral dosing with obefazimod, 177/217 (81.6%) and 158/217 (72.8%) achieved clinical response at weeks 48 and 96, respectively, and 119/217 (54.8%) and 114/217 (52.5%) patients achieved clinical remission at weeks 48 and 96, respectively. Furthermore, 133/217 (61.3%) and 128/217 (59.0%) patients had endoscopic improvement at weeks 48 and 96, while 72/217 (33.2%) and 78/217 (35.9%) patients attained endoscopic remission at weeks 48 and 96, respectively (Figure 2).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-2"></a>

###### Primary outcome in the posted results: clinical remission at week 48 (of 217)

| Outcome | Participants |
| --- | --- |
| Clinical remission at week 48 | “119” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.3-3"></a>

###### Secondary outcomes in the posted results: number of participants (of 217)

| Outcome | Week 48 | Week 96 |
| --- | --- | --- |
| Clinical response | “177” | “158” |
| Endoscopic improvement | “133” | “128” |
| Endoscopic remission | “72” | “78” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.3-4"></a>

###### Week 48 and week 96 outcomes reported in the Form 20-F

> “At week 48, of those 217 patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients (82%) had clinical response, 119 patients (55%) were in clinical remission, 133 patients (61%) had endoscopic improvement and 72 patients (33%) had endoscopic remission.”
> “Of all 217 patients who entered the Phase 2b open-label maintenance trial, regardless of their status at the end of the 8-week induction period, 119 patients (55%) achieved clinical remission at week 48 and 114 patients (53%) achieved clinical remission at week 96.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.5.8.3-5"></a>

###### Outcomes by clinical response at week 8 of induction

> “Among the 124 patients with clinical response at week 8 of the induction trial, 82/124 (66.1%) and 74/124 (59.7%) achieved clinical remission at weeks 48 and 96, respectively (Figure 3).”
> “Among the 93 patients that did not achieve clinical response at week 8 of the induction trial, 37/93 (39.8%) and 40/93 (43.0%) achieved clinical remission at weeks 48 and 96, respectively.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-6"></a>

###### Outcomes by induction treatment: obefazimod or placebo

> “Overall, 162 patients treated with obefazimod during induction entered the OLM. Among this subgroup, 103/162 (63.6%) achieved clinical response at W8 of the induction trial, while 59/162 (36.4%) did not.”
> “For example, clinical remission was achieved by 69/103 (67.0%) and 65/103 (63.1%) among W8 clinical responders at W48 and W96, respectively, compared to 20/59 (33.9%) and 24/59 (40.7%) among W8 nonresponders.”
> “Among the 55 patients receiving placebo during induction and entering the OLM, 21/55 (38.2%) achieved clinical response at W8 of the induction trial, while 34/55 (61.8%) did not. Clinical remission was achieved by 13/21 (61.9%) and 9/21 (42.9%) of W8 clinical responders at W48 and W96, respectively, compared to 17/34 (50.0%) and 16/34 (47.1%) of nonresponders.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-7"></a>

###### Outcomes by previous biologic or JAK inhibitor exposure

> “Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).”
> “Among the 119 patients naïve to biologics or JAK inhibitors at the induction study baseline, 103/119 (86.6%) and 92/119 (77.3%) achieved a clinical response at weeks 48 and 96. In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-8"></a>

###### Corticosteroid-free outcomes in participants receiving corticosteroids at induction baseline

> “Among the 115 patients enrolled in the OLM who received concomitant CS at induction baseline, 64/115 (55.7%) were in clinical remission rates at week 48 and 60/115 (52.2%) at week 96. While the protocol did not require CS-tapering upon entry to the OLM study, 12-week CS-free clinical remission was attained by 43/115 patients (37.4%) at week 48 and by 40/115 patients (34.8%) at week 96.”
> “Notably, among the patients that met clinical endpoints but not the corresponding CS-free clinical endpoints, many investigators chose not to attempt the optional CS-tapering.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-9"></a>

###### Fecal calprotectin

> “The median FCP concentration decreased from 204.7 µg/g at baseline of OLM, to 86.6 µg/g at week 48 and 89.6 µg/g at week 96 (Table 2). Of the 167 patients with available data at week 48, 122/167 (73.1%) achieved FCP levels below 250 µg/g, and 109/167 (65.3%) achieved FCP levels below 150 µg/g. At week 96, 102 (69.4%) of the 147 patients with available data achieved FCP levels below 250 µg/g, and 91/147 (61.9%) achieved FCP levels below 150 µg/g.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-10"></a>

###### miR-124 expression in blood and rectal tissue

> “Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.3-11"></a>

###### Comparison with week 8 induction results

> “Efficacy rates increased during the maintenance treatment period with obefazimod 50 mg relative to week 8 of the induction trial.”
> “At week 48 of the OLM study, these percentages increased to 82% for clinical response and 61% for endoscopic improvement.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

###### IBDQ planned as a secondary endpoint in the protocol

> “Scores and changes from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) domains at week 24 and 48.”

Source: [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf)

<a id="topic-3.1.5.8.4-2"></a>

###### Missing IBDQ scores not imputed in the statistical analysis plan

> “Missing Fecal calprotectin, CRP scores and IBDQ scores will not be imputed.”

Source: [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf)

<a id="topic-3.1.5.8.4-3"></a>

###### Stool frequency subscore at weeks 48 and 96

> “The mean SFS decreased from 1.4 at OLM baseline to 0.7 at week 48 and 0.6 at week 96, with most patients having an SFS of 0 or 1 (87.9%) at week 96.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.4-4"></a>

###### Stool frequency and rectal bleeding recorded in a paper diary

> “Participants recorded stool frequency using a paper subject diary on a daily basis.”
> “Participants recorded rectal bleeding in a paper subject diary on a daily basis.”

Source: [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396)

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events over 96 weeks

> “At least 1 TEAE was reported for 148 (68.2%) of 217 obefazimod-treated patients (Table 3). The most common TEAEs reported in at least 5% of patients were COVID-19 (14.3%), headache (11.5%), UC (7.8%), nasopharyngitis (6.9%), back pain (5.5%), and arthralgia (5.1%). TESAEs were reported by 18 patients (8.3%).”
> “There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident). TEAEs leading to study discontinuation were reported in 17 patients (7.8%) (Table 4). These events included the worsening of disease (coded as colitis ulcerative and colitis), which resulted in the discontinuation of 9 patients.”
> “Infections and infestations TESAEs, reported for 4 patients, comprised COVID-19/COVID-19 pneumonia (2 patients, 1.0%), urosepsis (1 patient, 0.5%), and appendicitis (1 patient, 0.5%).”
> “Laboratory results revealed no new or unexpected safety signals, and there were no clinically meaningful changes in laboratory parameters compared to week 8.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-2"></a>

###### Headache after switching dose at entry

> “Ten of the 25 patients who reported headache experienced them within the first 7 days after switching from placebo to obefazimod or from 25 to 50 mg upon entering the OLM study.”
> “Headache appears to be associated with the introduction to obefazimod treatment, as the rate was reduced to 11.5% of patients who received up to 96 weeks obefazimod 50 mg compared to 30.2% of patients who received obefazimod 50 mg during induction.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-3"></a>

###### Treatment-emergent adverse events leading to discontinuation

| Event | n (%) |
| --- | --- |
| Any TEAE | “17 (7.8)” |
| Colitis ulcerative | “7 (3.2)” |
| Colitis | “2 (0.9)” |
| Ischemic stroke | “1 (0.5)” |
| Left ventricular dysfunction | “1 (0.5)” |
| Alanine aminotransferase increased | “1 (0.5)” |

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.8.5-4"></a>

###### Adverse events in the posted results: participants affected / at risk (%)

| Event | ABX464 50 mg |
| --- | --- |
| All-cause mortality | “1/217 (0.46%)” |
| Serious adverse events, total | “18/217 (8.29%)” |
| Other adverse events, total | “148/217 (68.20%)” |
| COVID-19 | “31/217 (14.29%)” |
| Headache | “25/217 (11.52%)” |
| Colitis ulcerative | “17/217 (7.83%)” |
| Nasopharyngitis | “15/217 (6.91%)” |

Source: [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results)

<a id="topic-3.1.5.8.5-5"></a>

###### Long-term safety: phase 2b open-label maintenance study through 96 weeks

> “In total, 148/217 patients (68.2%) reported at least 1 treatment-emergent adverse event (TEAE).”
> “The most frequent TEAEs were COVID-19 (14.3%), headache (11.5%), UC (7.8%), and nasopharyngitis (6.9%).”
> “There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident).”
> “AESIs reported in more than 1 patient were headache, rash, and eczema, which were reported in 4 (1.8%), 3 (1.4%), and 2 patients (0.9%), respectively.”
> “No new safety risks emerged over 96 weeks.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/); [ClinicalTrials.gov NCT04023396](https://clinicaltrials.gov/study/NCT04023396); [ClinicalTrials.gov NCT04023396 results](https://clinicaltrials.gov/study/NCT04023396?tab=results); [Abivax ABX464-104 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/Prot_000.pdf); [Abivax ABX464-104 statistical analysis plan (2023)](https://cdn.clinicaltrials.gov/large-docs/96/NCT04023396/SAP_001.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.5.9-2"></a>

###### Limitations stated by the investigators

> “Although the central evaluation of endoscopy data reduced the risk of bias in this open-label study, the results must be interpreted with caution due to the absence of a control group. Furthermore, steroid cycling was not accounted for in the NRI method, potentially limiting the interpretation of CS-free outcomes.”
> “CS-free efficacy rates might have been higher had CS-tapering been required during the OLM study.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-3.1.5.9-3"></a>

###### Role of the funder

> “Personnel from Abivax designed the trial in conjunction with the principal academic investigators. A contract research organization collected the trial data, Abivax analyzed the data, and all of the authors jointly interpreted the data.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="heading-3.1.6"></a>

#### 3.1.6 ABX464-101

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.”
> “Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.1-2"></a>

###### Proof-of-concept purpose described by the sponsor

> “ABX464-101 is an ongoing Phase 2a proof-of-concept study aimed at evaluating the safety and efficacy of ABX464 50 mg given once daily versus placebo for two months in subjects with moderate-to-severe active ulcerative colitis who have failed or are intolerant to immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2017-11-16”
> “Primary Completion (Actual) 2018-07-25”
> “Study Completion (Actual) 2019-02-04”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.2-2"></a>

###### Results posting date

> “Results First Posted 2023-02-08”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.2-3"></a>

###### Registered locations

> “This study has 19 locations”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.2-4"></a>

###### Centers and countries reported by the sponsor

> “This clinical study was conducted in 15 centers in six European countries: Belgium, France, Germany, Austria, Hungary and Poland.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.2-5"></a>

###### Centers and countries at the time of the extension study authorization

> “This clinical study is being conducted in 18 centers in eight European countries. Full regulatory and ethics committee authorizations already have been obtained in Belgium, France, Hungary, Poland, Czech Republic, Spain and Germany.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “Double-blind, placebo-controlled, randomized study” |
| Masking description | “Double-Blind Treatment” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “32” |

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.3-2"></a>

###### Randomization ratio and treatment period

> “Eligible subjects will be randomized according to a 2/1 ratio in two different groups of treatment. Randomized subjects who will receive 50 mg ABX464 orally once daily for 56 days.”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.3-3"></a>

###### Randomized, double-blind design and central endoscopy reading described by the sponsor

> “ABX464-101 was a randomized, double-blind, placebo-controlled Phase 2a study evaluating the safety and efficacy of ABX464 50mg given orally once-daily for two months in subjects with moderate-to-severe active ulcerative colitis who have failed on immunomodulators, anti-TNFα, vedolizumab and/or corticosteroids.”
> “Twenty-nine of the 32 recruited patients, randomized 2:1 to receive ABX464 as a once daily oral tablet or placebo, have completed the study per protocol, which employed state-of-the art technologies for monitoring potential treatment effects, including numerical recording of the colonoscopies with centralized reading.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.3-4"></a>

###### Optional roll-over into the open-label extension

> “In four countries, patients who completed the ABX464-101 study had the option to roll over into study ABX464-102, a 12-month open-label follow-up study.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.3-5"></a>

###### Induction phase of the phase 2 program

> “Obefazimod 50 mg (n=23)”
> “Placebo (n=9)”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Disease activity and background therapy in the ClinicalTrials.gov record

> “Diagnosis of moderate to severe active UC confirmed by endoscopy and histology at least 12 weeks prior to screening visit. Moderate to severe active UC defined by Mayo Clinic Score (MCS) of 6 to 12 inclusive (on a scale of 0-12). Moderate to severe active UC should be confirmed at screening visit with a centrally read MCS endoscopy score of at least 2 (on a scale of 0-3);”
> “Subjects receiving oral corticosteroids must have been on a stable dose of prednisone or prednisone equivalent ≤20 mg/day) or on beclomethasone diproprionate (≤5mg/day) or on budesonide MMX (≤9mg/day), for ≥2 weeks before first dosing (i.e. baseline);”
> “Subjects who have previously received anti-tumor necrosis factor (TNF) therapy or vedolizumab must have discontinued therapy ≥8 weeks before first dosing (i.e. baseline);”
> “18 Years to 70 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Subject with Crohn's Disease (CD), indeterminate colitis (IC) or presence or history of fistula with CD;”
> “History of toxic megacolon, abdominal abscess, symptomatic colonic stricture or stoma; history or is at imminent risk of colectomy;”
> “History or current evidence of colonic dysplasia or adenomatous colonic polyps.”
> “Subject with significant and known active infections at screening such as Infected abscess, positive for Clostridium difficile (stool antigen and toxin), CMV, TB and recent infectious hospitalization;”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.4-3"></a>

###### Prior treatment failure described by the sponsor

> “This clinical trial was conducted in 32 patients for induction treatment of moderate-to-severe ulcerative colitis (UC), refractory to anti-TNF monoclonal antibodies or corticosteroids.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Arms in the ClinicalTrials.gov record

> “Subjects will receive 50 mg of ABX464 orally once daily for 56 days.”
> “Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.”
> “Placebo matching with ABX464”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.5-2"></a>

###### Capsule dosage form in the posted adverse event groups

> “Participants received 1 oral capsule containing ABX464 daily for 56 days”
> “Participants received 1 oral capsule containing placebo daily for 56 days”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.5-3"></a>

###### Permitted background therapy at stable doses

> “Subjects who are on oral 5-aminosalicylic acid must have been on a stable dose ≥4 weeks before first dosing (i.e. baseline);”
> “Subjects who are receiving immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate needed to be on a stable dose for 4 weeks before first dosing (i.e. baseline).”
> “Topical corticosteroids and topical 5-aminosalicylic acid preparations must have been withdrawn ≥2 weeks before first dosing (i.e. baseline);”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Registered primary outcome measure

> “Number of Subjects With Treatment-emergent Adverse Events”
> “Number of treatment-emergent adverse events in the ABX464 treated subjects compared to placebo”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.6.1-2"></a>

###### Clinical remission registered as the primary efficacy endpoint among secondary outcomes

> “Percentage of subjects receiving ABX464 with clinical remission according to the Total Mayo Score at Week 8 compared to placebo (primary efficacy endpoint)”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

<a id="topic-3.1.6.6.1-3"></a>

###### Other registered secondary outcome measures

> “Percentage of patients with fecal calprotectin levels > 50µg/g at Week 8 compared to placebo”
> “Change from baseline in Total Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 12; 12 being the worst score) - 4-component Scale: Rectal bleeding, Stool frequency, Mucosal appearance and Physician Global Assessment”
> “Change from baseline in Partial Mayo Score in subjects receiving ABX464 compared to placebo. The scale ranges from 0 to 9, with 9 indicating the worst score. It is a three-component scale assessing rectal bleeding, stool frequency, and the physician's global assessment.”

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259)

Additional sources: [Abivax ABX464-101 protocol (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/Prot_000.pdf)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned sample size stated in the ABX464-102 protocol

> “Not applicable / Maximum 30 subjects (i.e. ABX464-101’s sample size)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.7.1-2"></a>

###### Participants randomized

> “32 patients were randomized (23 ABX464 patients/9 placebo).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.7.1-3"></a>

###### Participants analyzed in the posted results

| Analysis | ABX464 | Placebo |
| --- | --- | --- |
| Baseline and safety analysis | “23” | “9” |
| Efficacy outcomes (total Mayo score, partial Mayo score, fecal calprotectin) | “20” | “9” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

Additional sources: [Abivax ABX464-101 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/SAP_001.pdf)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Analysis populations in the posted results

> “The safety analysis set included all participants who received at least 1 dose of ABX464.”
> “All subjects who received at least 1 dose of study treatment”
> “Subjects in the FAS without any major protocol deviations and who completed the study (Day 56)”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.7.2-2"></a>

###### Statistical tests in the posted results

| Outcome | Method |
| --- | --- |
| Treatment-emergent adverse events | “Chi-squared” |
| Clinical remission | “Chi-squared” |
| Fecal calprotectin | “ANCOVA” |
| Total Mayo score | “ANCOVA” |
| Partial Mayo score | “ANCOVA” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

Additional sources: [Abivax ABX464-101 statistical analysis plan (2018)](https://cdn.clinicaltrials.gov/large-docs/59/NCT03093259/SAP_001.pdf)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Participant flow in the posted results

| Milestone | ABX464 | Placebo |
| --- | --- | --- |
| Started | “23” | “9” |
| Completed | “21” | “9” |
| Not completed | “2” | “0” |
| Reason not completed: adverse event | “1” | “0” |
| Reason not completed: withdrawal by subject | “1” | “0” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.1-2"></a>

###### Participants completing per protocol, as reported by the sponsor

> “Twenty-nine of the 32 recruited patients, randomized 2:1 to receive ABX464 as a once daily oral tablet or placebo, have completed the study per protocol”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.8.1-3"></a>

###### Roll-over into the ABX464-102 extension

> “At the end of the completed 2 months induction treatment study, 22 Patients (15 previously treated with ABX464 and 7 on placebo) were enrolled into the open-label maintenance study with ABX464 50mg daily (ABX464-102) regardless of what treatment they had previously received.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Age, sex, and race in the posted results

| Characteristic | ABX464 (N=23) | Placebo (N=9) | Total (N=32) |
| --- | --- | --- | --- |
| Age between 18 and 65 years | “19” | “9” | “28” |
| Age 65 years or older | “4” | “0” | “4” |
| Female | “11” | “1” | “12” |
| Male | “12” | “8” | “20” |
| White | “23” | “9” | “32” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.2-2"></a>

###### Baseline disease activity, disease duration, and prior advanced therapy

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Clinical remission, clinical response, and endoscopic outcomes at week 8 reported by the sponsor

> “At the end of the eight-week induction of the phase 2a proof-of-concept clinical study in ulcerative colitis, 35% and 70% of patients in the ABX464 active group achieved clinical remission and clinical response versus 11.1% and 33.3% in the placebo group, respectively. Endoscopic improvement and remission were observed in 50% and 10% of patients receiving ABX464, respectively, versus 11.1% each for placebo.”

Source: [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance)

<a id="topic-3.1.6.8.3-2"></a>

###### Week 8 results stated in the ABX464-102 protocol

> “Clinical Remission rate of 35.0 % of ABX464 patients (Placebo = 11.1%)”
> “Mucosal Healing rate of 50.0 % (p=0.03) of ABX464 patients (Placebo = 11.1%)”
> “Clinical Response rate of 70.0 % of ABX464 patients (Placebo = 33.0%)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.8.3-3"></a>

###### Statistical comparisons of week 8 outcomes reported by the sponsor

> “The proportion of subjects achieving clinical remission was greater in the ABX464 group than in the placebo group (35.0% vs. 11.1%, p=ns). The difference between ABX464 and placebo treated patients in colorectal mucosal healing was statistically significant (50% vs. 11%, p=0.034).”
> “Furthermore, the onset of the therapeutic effect of ABX464 was rapid, with a reduction of the pMS between ABX464 and placebo being observed at the first assessment following treatment for two weeks, which became significant at eight weeks (-3.9 vs. -1.8, p=0.029; likelihood ratio CHI-square test). Similarly, the difference of the reduction of the total Mayo Score (tMS) after eight weeks was statistically significant (-4.6 vs. -2.1, p=0.029).”

Source: [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative)

<a id="topic-3.1.6.8.3-4"></a>

###### Topline statistical comparisons and fecal calprotectin reported in 2018

> “The difference between ABX464 and placebo in colorectal mucosal healing was statistically significant (p<0.03).”
> “Similarly, the difference of the reduction of the total Mayo score”
> “after eight weeks was statistically significant (p<0.03).”
> “Calprotectin, the best studied biomarker in ulceratice colitis, was markedly reduced (4.4-fold) in patients who received ABX464 in comparison to placebo (1.6-fold) after 4 weeks of treatment.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

<a id="topic-3.1.6.8.3-5"></a>

###### Clinical remission at week 8 in the posted results, with arm titles as the record lists them

| Field | First arm listed | Second arm listed |
| --- | --- | --- |
| Arm/group title | “ABX464 Matching Placebo Treatment Arm” | “ABX464 Treatment Arm” |
| Overall number of participants analyzed | “20” | “9” |
| Participants in clinical remission | “7” | “1” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.3-6"></a>

###### Mayo score change and fecal calprotectin at week 8 in the posted results

| Outcome | ABX464 (n=20) | Placebo (n=9) |
| --- | --- | --- |
| Change from baseline in total Mayo score, mean (SD) | “-4.6(2.8)” | “-2.1(2.5)” |
| Change from baseline in partial Mayo score, mean (SD) | “-3.9(2.2)” | “-1.8(2.0)” |
| Participants with fecal calprotectin above 50 µg/g | “15” | “8” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.3-7"></a>

###### miR-124 expression in blood during ABX464-101 and ABX464-102

> “The measurement of miR124 relative gene expression by qPCR using whole blood samples was included in both ABX464-101 and -102.”
> “A total of 19 patients were sampled on day 0, 28, 56 of ABX464-101 and on day 365 (while in ABX464-102). Statistically significant increases of miR124 expression were observed at all these time points.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.6.8.3-8"></a>

###### Review summary of the proof-of-concept study

> “In vivo, in a proof-of-concept clinical study, ABX464 showed robust and consistent efficacy in ulcerative colitis (UC).”

Source: [Tazi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33387693/)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Participants with treatment-emergent adverse events (primary outcome)

| Measure | ABX464 | Placebo |
| --- | --- | --- |
| Overall number of participants analyzed | “23” | “9” |
| Participants with treatment-emergent adverse events | “18” | “5” |
| Time frame | “Week 8” | “Week 8” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-2"></a>

###### Deaths, serious adverse events, and other adverse events in the posted results

| Measure, affected / at risk (%) | ABX464 | Placebo |
| --- | --- | --- |
| All-cause mortality | “0/23 (0.00%)” | “0/9 (0.00%)” |
| Serious adverse events, total | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Nephrolithiasis left side (serious) | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Other (not including serious) adverse events, total | “18/23 (78.26%)” | “5/9 (55.56%)” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-3"></a>

###### Other adverse events in at least two participants of either group

| Event, affected / at risk (%) | ABX464 | Placebo |
| --- | --- | --- |
| Abdominal pain | “4/23 (17.39%)” | “1/9 (11.11%)” |
| Headache | “4/23 (17.39%)” | “0/9 (0.00%)” |
| Abdominal pain upper | “3/23 (13.04%)” | “0/9 (0.00%)” |
| Nausea | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Chest pain | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Influenza like illness | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Hypophosphataemia | “1/23 (4.35%)” | “2/9 (22.22%)” |

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-4"></a>

###### Adverse event collection period

> “From baseline up to 4 weeks post last dose of study drug (up to 63 Days)”

Source: [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results)

<a id="topic-3.1.6.8.5-5"></a>

###### Sponsor statement on safety

> “As observed in the other studies with ABX464, the product candidate was considered to be safe and well tolerated in ABX464-101. No severe adverse events attributed to ABX464 were reported in the trial.”

Source: [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.

Source: [ClinicalTrials.gov NCT03093259](https://clinicaltrials.gov/study/NCT03093259); [ClinicalTrials.gov NCT03093259 results](https://clinicaltrials.gov/study/NCT03093259?tab=results); [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf); [Abivax press release, phase 2a induction results (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-results-clinical-phase-2a-trial-abx464); [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative); [Abivax press release, phase 2a Gastroenterology publication (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-publishes-data-abx464-induction-and-long-term-maintenance)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.7"></a>

#### 3.1.7 ABX464-102

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue their treatment.”
> “A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.1-2"></a>

###### Primary, secondary, and echocardiography objectives in the protocol

> “The primary objective of the study is to evaluate the long-term safety of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.”
> “To evaluate the long-term effect of ABX464 on clinical and endoscopic remission in subjects with Moderate to Severe Active Ulcerative Colitis assessed by the MCS.”
> “To evaluate the long-term effect of ABX464 on inflammatory markers (CRP, Calprotectin and ESR)”
> “To evaluate the effect of ABX464 on cardiac function as assessed through echocardiograms.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2018-01-20”
> “Primary Completion (Actual) 2022-07-12”
> “Study Completion (Actual) 2022-08-15”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.2-2"></a>

###### Results posting date

> “Results First Posted 2025-03-05”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.2-3"></a>

###### Registered location

> “This study has 1 location”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.2-4"></a>

###### Sites, study period, and EudraCT number in the protocol

> “Active sites from previous study (ABX464-101) located in Belgium, Hungary and Poland.”
> “Q4 2017 – Q3 2022”
> “2017-003284-35”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.2-5"></a>

###### Region of enrollment in the posted results

| Country | Participants |
| --- | --- |
| Belgium | “3” |
| Poland | “10” |
| Hungary | “9” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “22” |

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.3-2"></a>

###### Open-label treatment for 48 months regardless of induction assignment

> “All subjects will receive ABX464 given at 50 mg o.d irrespective of their previous treatment received in the ABX464-101 study (i.e. ABX464 or Placebo).”
> “The actual treatment received by a subject throughout the previous study (ABX464-101) will not be known at the time the subjects enter this follow-up study.”
> “Subjects will be treated with ABX464 for an overall period of 48 months. Subjects will be followed up weekly during the first month, every two weeks during the second month and then on a monthly basis until M24, then quarterly from M24 to M48.”
> “At M48, depending on their clinical response, eligible patients willing to continue study treatment will be offered to take part into a long term follow up study (ABX464-108 study).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.3-3"></a>

###### Data safety monitoring board and cardiovascular safety committee

> “The DSMB will meet on a monthly basis until December 2019 and then quarterly from January 2020 onwards.”
> “An Independent Cardiovascular Safety Committee (ICVSC), comprised of 3 cardiologists with experience from drug development, will be formed as detailed in the Charter.”
> “Patients included with a history of cardiac ischemic disease and/or congestive heart failure will be discontinued from the study, will perform the End of Study Visit 4 weeks after last study drug administration and will then be treated according to the standard of care upon study treatment interruption.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.3-4"></a>

###### Planned treatment duration of 12 months, January 2018, superseded in March 2019

> “ABX464-102 is a twelve-month open label follow-up study for patients with ulcerative colitis benefiting from the administration of ABX464 in the ABX464-101 study.”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="topic-3.1.7.3-5"></a>

###### Planned treatment duration of 24 months, March 2019, superseded in February 2022

> “These data have also convinced the study’s DSMB to recommend an additional 12-month extension to the study, increasing the total maintenance to 24 months.”

Source: [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Subjects previously enrolled in the ABX464-101 clinical study who have completed the initial 2-month treatment phase;”
> “Hemoglobin > 9.0 g dL-1;”
> “Creatinine clearance > 50 mL min-1 by the Cockcroft-Gault equation;”
> “Alkaline phosphatase, AST (SGOT) and ALT (SGPT) < 1.5 x ULN;”
> “Any condition, which in the opinion of the investigator, could compromise the subject's safety or the adherence to the study protocol.”
> “18 Years to 70 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.4-2"></a>

###### Enrollment based on willingness and investigator judgement

> “The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator’s judgement.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.4-3"></a>

###### Enrollment of responders planned at authorization, January 2018

> “The new study will recruit patients from the ongoing ulcerative colitis proof-of-concept study (ABX464-101) who are responding to treatment with ABX464 into the 12-month open label follow-up study (ABX464-102).”

Source: [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.5-2"></a>

###### Formulation

> “The study drug is formulated as hard gelatin, powder-filled capsules (size 01).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.5-3"></a>

###### Allowed and prohibited concomitant medications

> “Oral 5-aminosalicylic acid at stable dose.”
> “Immunosuppressants in the form of azathioprine, 6-mercaptopurine, or methotrexate at stable dose.”
> “Topical corticosteroids and topical 5-aminosalicylic acid preparations.”
> “Drugs that could interact with ABX464 should be avoided especially the CYP1A2 inducers/inhibitors. The following CYP1A2 inducers/inhibitors are prohibited during the whole course of the study (ciprofloxacin, enoxacin, fluvoxamine, montelukast, phenytoin, rifampicin, ritonavir, teriflunomide).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.5-4"></a>

###### Withdrawal for worsening ulcerative colitis

> “Worsening of the UC defined as a 2-point increase in the pMMS, with pMMS ≥ 4 on 2 separate occasions 7 day-apart and confirmed by an endoscopy sub score of 2 points or higher;”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary endpoint in the protocol

> “The primary endpoint of this study is defined as the number of incidences of treatment-emergent adverse events in the ABX464 treated subjects.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.6.1-2"></a>

###### Registered outcome measures

> “Number of Treatment-emergent Adverse Events”
> “Through subject study treatment, up to 48 months”
> “Number of Subjects With Clinical Remission at Month 48”
> “SF-36 Quality of Life Questionnaire (SF-36 Physical Component)”

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118)

<a id="topic-3.1.7.6.1-3"></a>

###### Adverse events of special interest

> “Due to safety signals in nonclinical toxicology studies, the following events are monitored as adverse events of special interest in ongoing and future studies with ABX464: anemia, liver function tests abnormalities, serious grade 3 infections and opportunistic infections, malignancies including non-melanoma skin cancers and cardiac events, including biomarkers (blood levels of AST, troponin, CPK and NT-proBNP).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.6.1-4"></a>

###### Efficacy definitions in the statistical analysis plan

> “Clinical remission is achieved when all the following criteria are met in the components of the Mayo Score:”
> “rectal bleeding sub-score = 0”
> “central or local endoscopy sub-score <= 1”
> “Endoscopic improvement is achieved if the Mayo central endoscopic sub-score is 0 or 1.”
> “Endoscopic remission is defined as Mayo central endoscopic sub-score = 0.”
> “Worsening of the UC is defined as a 2-point increase from the screening TMS with 3 days of continuous rectal bleeding confirmed by flexible sigmoidoscopy with an endoscopy sub-score of 2 points or higher.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.6.1-5"></a>

###### Changes from the protocol in the statistical analysis plan

> “In the definition of clinical response (Section 11.3.1.6), Modified Mayo Score is used instead of Total Mayo Score for consistency with other Abivax studies.”
> “The echocardiography secondary endpoints will be included in a separate report.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.6.1-6"></a>

###### Clinical response definition in the posted results

> “reduction in Total Mayo Score (TMS) of at least 2 points and >= 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of >= 1 point or absolute rectal bleeding sub-score of <= 1 point.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Planned sample size

> “Not applicable / Maximum 30 subjects (i.e. ABX464-101’s sample size)”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

> “Not applicable. All patients in this study are those who were included in the ABX464-101 study.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.7.1-2"></a>

###### Participants enrolled and analyzed in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “22” |
| Overall number of baseline participants | “22” |
| Overall number of participants analyzed, each outcome | “22” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Observed cases and non-responder imputation sets

> “The Observed Cases (OC) Set is defined as those subjects included in the study, who have received at least one dose of the study treatment. This set will use all data available at timepoints without any imputations for missing dichotomous values, and with Last Observation Carried Forward (LOCF) imputation (described in section 10.4) for missing continuous values.”
> “The OC Set will be used for all safety and efficacy analyses.”
> “Efficacy analyses will be repeated for the NRI Set.”
> “Observed Cases (OC) Set and Non-responder Imputation (NRI) Set are defined for populations instead of the populations defined in the protocol.”
> “No stratification or covariate adjustment will be used in this study.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="topic-3.1.7.7.2-2"></a>

###### Descriptive efficacy analysis planned in the protocol

> “Analysis of safety will be performed on the safety data set consisting in all subjects who received at least one dose of ABX464 in the study.”
> “Efficacy results will be presented descriptively; proper tests will be performed if appropriate.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.7.2-3"></a>

###### Month 12 interim analysis set

> “The interim analysis used the Month 12 Per Protocol (M12 PP) dataset which included all subjects that had a Month 12 visit. Of the 22 subjects, 3 subjects were excluded from the M12 PP Set: 2 subjects from the ABX464 induction group (one who withdrew due to lack of efficacy at M1 of the maintenance study and one who was lost to follow-up) and 1 subject from the placebo induction group (grade 2 headache at month 4), resulting in 19 subjects analyzed in the efficacy M12 PP set at baseline. Of the nineteen subjects in the set, sixteen had had a Month 12 endoscopy performed which forms part of the Total Mayo score (TMS).”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.7.2-4"></a>

###### Analysis populations in the posted results

> “Non responder Imputation (NRI) population”
> “Observed cases population”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Participant flow in the posted results

| Milestone | ABX464 50 mg |
| --- | --- |
| Started | “22” |
| Completed | “11” |
| Not completed | “11” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.1-2"></a>

###### Participants entering from the obefazimod and placebo induction groups

> “At the end of the completed 2 months induction treatment study, 22 Patients (15 previously treated with ABX464 and 7 on placebo) were enrolled into the open-label maintenance study with ABX464 50mg daily (ABX464-102) regardless of what treatment they had previously received.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.8.1-3"></a>

###### Participants remaining on treatment through year 2

> “Out of 32 patients included in the active or placebo arm of the initial induction phase, 22 were enrolled in the 50mg once-daily open label ABX464 Phase 2a maintenance study. 19/22 patients stayed on treatment for 52 weeks and 16/19 patients completed the second year of ABX464 maintenance treatment.”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

<a id="topic-3.1.7.8.1-4"></a>

###### Participants completing year 3

> “15 out of the 22 patients who were initially enrolled into the phase 2a maintenance study in 2018, completed the third year of treatment with once-daily oral 50mg ABX464.”

Source: [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Demographics in the posted results

| Characteristic | ABX464 50 mg (N=22) |
| --- | --- |
| Age, years, mean (SD) | “42.4(14.3)” |
| Female | “9” |
| Male | “13” |
| White | “22” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.2-2"></a>

###### Clinical remission status at entry among participants remaining at month 12

> “Detailed analysis showed that of the 7/19 patients in clinical remission at the end of the two-month induction study, 5 patients were still in clinical remission at the end of the maintenance study and 2 patients missed endoscopy and could therefore not be assessed. Of the 12/19 patients NOT in clinical remission at the end of the induction study, 7 patients (58%) achieved clinical remission at the end of the maintenance study, while 4 patients had no remission and 1 had no endoscopy.”

Source: [Abivax press release, phase 2a 12-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-12-month-efficacy-and-safety-data)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Month 48 outcomes with non-responder imputation in the posted results

| Outcome (N=22) | Quoted record |
| --- | --- |
| Participants with clinical response | “11” |
| Participants with clinical remission | “9” |
| Participants with endoscopic improvement | “9” |
| Participants with endoscopic remission | “6” |
| Change in total Mayo score, mean (SD) | “-3.0(3.4)” |
| Change in partial Mayo score, mean (SD) | “-2.2(2.4)” |
| Change in fecal calprotectin, µg/g, mean (SD) | “-299.69(472.28)” |
| Change in CRP, mg/L, mean (SD) | “2.29(4.82)” |
| Change in ESR, mm/hour, mean (SD) | “2.90(8.62)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.3-2"></a>

###### Ulcerative colitis worsening reported as an adverse event (post hoc)

> “Proportion of subjects with UC worsening based on adverse events”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

| Measure | Quoted record |
| --- | --- |
| Overall number of participants analyzed | “22” |
| Participants with UC worsening | “7” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.3-3"></a>

###### Month 12 interim results

> “A total of 19 patients completed the one year ABX464 open label maintenance study and showed good long-term safety and tolerability of 50mg given orally over 52 weeks.”
> “At month 12, an endoscopy to assess clinical remission status (the critical parameter for regulatory authorities) was performed in 16/19 patients. During treatment with ABX464, patients reduced their total Mayo Score (mean) from 8.7 to 1.9 (-78%), their endoscopic subscore from 2.3 to 0.25 (-89%) and the fecal calprotectin biomarker (median) from 1044 microg/g to 27.9 microg/g (-97%).”
> “All 16 patients with endoscopy showed an endoscopic subscore of 0 or 1, indicative of mucosal healing and in total 12/16 (75%) of the patients undergoing endoscopy achieved clinical remission.”

Source: [Abivax press release, phase 2a 12-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-impressive-12-month-efficacy-and-safety-data)

<a id="topic-3.1.7.8.3-4"></a>

###### Month 12 interim results stated in the protocol

> “Clinical remissions obtained at the end of the induction study were durable and the rates further improved during the maintenance phase, as additional subjects achieved clinical remission for 12 months treatment.”
> “All patients who had an endoscopy performed, had an endoscopic sub-score of 0 or 1. 12/16 patients were in clinical remission at month 12.”
> “Mean and median fecal calprotectin and CRP showed continued declines during the maintenance study, though the large variability and small patient numbers requires that the results should be interpreted with caution.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

<a id="topic-3.1.7.8.3-5"></a>

###### Month 24 interim results with central endoscopy reading

> “Readings for all endoscopies were performed centrally by independent reviewers. The data showed that 11/16 (69%) patients were in clinical remission and 15/16 (94%) benefited from a clinical response. 7/16 (44%) had endoscopic remission consisting of complete disappearance of colon/rectum lesions (endoscopic Mayo score=0). Median fecal calprotectin, the key biological marker of UC disease activity, which was normalized during the first year of treatment, remained at 31.6 µg/g (normal levels are below 50 µg/g).”
> “Especially as the central and independent endoscopy readings after two years confirm the good one-year maintenance results, where endoscopies were read locally.”
> “Stool frequency sub score = 0 or 1 and rectal bleeding sub score = 0 and endoscopy sub score = 0 or 1 (modified to exclude friability).”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

<a id="topic-3.1.7.8.3-6"></a>

###### Month 36 interim results

> “Among the 13 patients who underwent centrally read endoscopies at the completion of year 3, 11 patients (85%) were still in clinical remission, among which 7 patients (54%) had an endoscopic remission (endoscopic subscore=0) and 11 patients had an endoscopic improvement (endoscopic subscore=0 or 1).”

Source: [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

###### SF-36 component scores at up to 24 months in the posted results

| Outcome (N=22, non-responder imputation) | Change from day 0, mean (SD) |
| --- | --- |
| SF-36 physical component | “4.82(4.23)” |
| SF-36 mental component | “6.38(3.40)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.4-2"></a>

###### SF-36 instrument and assessment schedule

> “Change from Day 0 up to 24 months in SF-36 Questionnaire scores; The SF-36 questionnaire is a self-administered questionnaire containing 36 items.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

> “SF-36 Questionnaire is assessed at the following visits: D28, D56/M2, and M3 to M24 on a monthly basis.”

Source: [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf)

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Adverse event counts in the posted results

| Outcome (N=22) | Events |
| --- | --- |
| Treatment-emergent adverse events | “145” |
| Treatment-emergent serious adverse events | “3” |
| Treatment-emergent adverse events of special interest | “15” |
| Adverse events leading to investigational product discontinuation | “1” |
| Specific laboratory abnormalities, first 12 months | “17” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-2"></a>

###### Deaths and serious adverse events in the posted results

| Measure | Affected / at risk (%) |
| --- | --- |
| All-cause mortality | “0/22 (0.00%)” |
| Serious adverse events, total | “3/22 (13.64%)” |
| Myocardial infarction | “1/22 (4.55%)” |
| Enteropathic spondylitis | “1/22 (4.55%)” |
| Benign ovarian tumor | “1/22 (4.55%)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-3"></a>

###### Investigator assessment of the serious adverse events

> “The event was considered not related to study treatment and resolved without sequelae 5 days after onset date. No action was taken with study treatment”
> “The subject admitted to hospital due to spondyloarthropathy caused by inflammatory bowel disease (HLA-B27+). The event considered not related to study treatment and resolved without sequelae. No action was taken with study treatment.”
> “subject underwent total hysterectomy. Event considered not related to study treatment and resolved without sequelae. Study treatment was temporarily discontinued.”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-4"></a>

###### Other adverse events in at least 3 participants

| Event | Affected / at risk (%) |
| --- | --- |
| Other (not including serious) adverse events, total | “20/22 (90.91%)” |
| Colitis ulcerative | “7/22 (31.82%)” |
| Abdominal pain | “5/22 (22.73%)” |
| Nasopharyngitis | “5/22 (22.73%)” |
| Diarrhoea | “4/22 (18.18%)” |
| Vomiting | “3/22 (13.64%)” |
| Headache | “3/22 (13.64%)” |

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-5"></a>

###### Adverse event collection period

> “Adverse event were collected from first day of dosing (baseline) up to last safety visit (up to 49 months : 48 months on treatment and one month safety follow-up)”

Source: [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="topic-3.1.7.8.5-6"></a>

###### Sponsor statements on safety at month 12 and year 2

> “No severe or serious adverse reactions were reported. Most adverse events were of mild to moderate intensity.”

Source: [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf)

> “ABX464 was safe and well tolerated and there were no serious adverse drug reactions reported. No patients were prematurely discontinued due to adverse event during this second year of ABX464 treatment.”

Source: [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.

Source: [ClinicalTrials.gov NCT03368118](https://clinicaltrials.gov/study/NCT03368118); [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results); [Abivax ABX464-102 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/Prot_000.pdf); [Abivax ABX464-102 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/18/NCT03368118/SAP_001.pdf); [Abivax press release, ABX464-102 authorization (2018)](https://ir.abivax.com/news-releases/news-release-details/abivax-initiate-long-term-extension-study-abx464-patients); [Abivax press release, phase 2a six-month maintenance data (2019)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-impressive-new-phase-2a-abx464-ulcerative); [Abivax press release, phase 2a two-year maintenance data (2020)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-long-lasting-two-year-efficacy-and-safety-data); [Abivax press release, phase 2a three-year maintenance data (2021)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-update-abx464-clinical-data-and-development)

Additional sources: [Vermeire et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33662385/)

<a id="heading-3.1.8"></a>

#### 3.1.8 ABX464-108

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies (OLE and maintenance studies) and who are willing to continue their treatment.”
> “A Follow-up Phase II Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 25 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis”
> “To evaluate the long-term safety of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis.”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.1-2"></a>

###### Objective of the three-year interim analysis

> “Evaluate maintenance of efficacy through 3 years following dose reduction to obefazimod 25 mg during long-term extension after Phase 2 induction and maintenance studies, overall and by prior advanced therapy exposure”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Active, not recruiting”
> “Study Start (Actual) 2021-12-03”
> “Primary Completion (Estimated) 2028-03”
> “Study Completion (Estimated) 2028-04”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.2-2"></a>

###### Registered locations

> “This study has 46 locations”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.2-3"></a>

###### Data cutoff of the three-year interim analysis

> “A total of 130 patients entered the trial and as of the January 5, 2026 cutoff date, 80% (104/130) were still enrolled and completed the full 144-week evaluation.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

> “data transfer date: February 13, 2026”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Open Label Follow-up Study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (estimated) | “203” |

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.3-2"></a>

###### Treatment period and follow-up in the ClinicalTrials.gov record

> “Subjects will be treated with ABX464 for a maximum period of 54 months. Subjects will be followed up quarterly. After the treatment period, subjects will be followed for 4 additional weeks for safety purposes.”
> “From Baseline to a maximum period of 78 months”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.3-3"></a>

###### Dose de-escalation after the phase 2a and phase 2b open-label maintenance studies

> “patients who had completed the four-year Phase 2a or two-year Phase 2b OLM trials, where they had received 50 mg of once-daily obefazimod, were given the opportunity to continue receiving obefazimod at a reduced dose of 25 mg daily for up to five additional years (provided they met the eligibility criteria of Mayo Endoscopic Subscore = 0 or 1).”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.3-4"></a>

###### Design described in the congress poster

> “Patients with UC received Obe 50 mg in the Phase 2 trials for 2 to 4 years; those who achieved endoscopic improvement (Mayo Endoscopic subscore = 0 or 1 and rectal bleeding subscore = 0) were eligible to enroll in an OLM study (Fig 1)”
> “Patients enrolled can receive Obe 25 mg for up to an additional 78 months”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.3-5"></a>

###### Phase 2 program schema

> “Obefazimod 50 mg (n=22)”
> “48 months ~4 years of treatment”
> “Obefazimod 50 mg (n=217)”
> “48 + 48 weeks ~2 years of treatment”
> “Up to 78 months”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Subjects who previously completed the ABX464-102 or ABX464-104 clinical studies”
> “Subjects should be in endoscopic improvement with a rectal bleeding sub-score = 0 point at the end of treatment period in the previous study (ABX464-102 or ABX464-104). Endoscopic improvement is defined as: a Mayo endoscopic sub score of ≤1 ;”
> “Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (except UC) that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study”
> “18 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.4-2"></a>

###### Eligibility criteria shown in the congress presentation

> “Mayo Endoscopic subscore = 0 or 1 AND Rectal bleeding subscore = 0”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Intervention in the ClinicalTrials.gov record

> “All subjects will receive ABX464 given at 25 mg QD.”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.5-2"></a>

###### Prior obefazimod 50 mg exposure

> “Patients with UC received Obe 50 mg for approximately four years in the Phase 2a OLM study and for approximately two years in the Phase 2b OLM study”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.5-3"></a>

###### Total duration of obefazimod treatment

> “Patients in Study 108 were treated with obefazimod for up to seven years, with no new safety signals observed”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Registered primary and secondary outcome measures

> “Number of adverse events in ABX464 treated subjects”
> “Percentage of subjects reaching clinical remission at yearly visits.”
> “Percentage of subjects reaching endoscopic remission at yearly visits”
> “Percentage of subjects reaching clinical response at yearly visits”
> “Percentage of subjects reaching endoscopic improvement at yearly visits”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.6.1-2"></a>

###### Efficacy endpoint definitions in the interim analysis

> “Clinical remission: SFS = 0 or 1, RBS = 0, and MES = 0 or 1. Symptomatic remission: SFS = 0 or 1 and RBS = 0. Endoscopic improvement: MES = 0 or 1. Endoscopic remission: MES = 0.”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Planned enrollment

> “Enrollment (Estimated) 203”

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835)

<a id="topic-3.1.8.7.1-2"></a>

###### Participants eligible and treated

> “Out of 174 pts who completed these studies (10 in Phase 2a OLM, 164 in Phase 2b OLM), 138 were eligible”
> “Overall, 130 pts received treatment in the Obe-25 OLM”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.7.1-3"></a>

###### Participants analyzed in the congress presentation

| Analysis | Quoted record |
| --- | --- |
| Safety, all participants | “n = 130” |
| Week 144 completers | “n=104” |
| Week 144 completers naive to advanced therapy inadequate response | “57” |
| Week 144 completers with prior advanced therapy inadequate response | “47” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.7.1-4"></a>

###### Participants evaluated at the September 2024 data cutoff

> “A total of 130 patients entered the trial, as of September 11, 2024, the data cut-off date, 113 patients have been evaluated out to 48 weeks and 74 patients have undergone the full 96-week evaluation.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

###### Intent-to-treat analysis with non-responder imputation

> “Clinical remission, inclusive of endoscopic subscore, was evaluated in the ITT population using non-responder imputation.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.7.2-2"></a>

###### Non-responder imputation and as-observed analyses

> “This interim analysis (data transfer date: February 13, 2026) reports efficacy outcomes through the Week 144 visit (clinical remission, endoscopic improvement, endoscopic remission, and symptomatic remission), using both a non-responder imputation and as observed analysis”
> “Treatment emergent adverse events (TEAEs), serious TEAEs, and study discontinuation rates were examined”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.7.2-3"></a>

###### Week 144 completer population and definition of prior advanced therapy inadequate response

> “Here we present efficacy and safety in patients completing Week 144 of 25 mg treatment stratified by prior inadequate response to advanced therapies”
> “primary refractoriness to biologics or JAK inhibitors”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

###### Discontinuations and visit completion through week 144

> “Among this cohort, 16 pts (12%) discontinued prior to W48, including 4 who were subsequently found to be ineligible after enrollment”
> “7 pts (5%) discontinued between W48 and W96; and 3 pts (2%) discontinued between W96 and W144”
> “As of the data transfer date, 113 pts (87%) completed the W48 visit, 107 (82%) the W96 visit and 104 (80%) the W144 visit”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.1-2"></a>

###### Participants at each timepoint in the program schema

| Timepoint | Quoted record |
| --- | --- |
| Week 48 | “n= 114” |
| Week 96 | “n=107” |
| Completed week 144 | “n=104” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.1-3"></a>

###### Retention reported by the sponsor

> “Following two to four years of open-label treatment with 50 mg, 130 patients de-escalated to 25 mg, and at week 144, 68% (88/130) were in clinical remission and 80% (104/130) completed 144 weeks of treatment”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.1-4"></a>

###### Retention at the September 2024 data cutoff

> “Patient retention rates were high, with only 12% (16/130) of patients discontinuing in the first year and 5% (6/114) discontinuing during the second year of treatment.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Clinical remission at study baseline

> “At study baseline, 89% (116/130) of patients were in clinical remission.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.2-2"></a>

###### Characteristics at the start of the 25 mg dose among week 144 completers

| Characteristic | Week 144 completers (n=104) |
| --- | --- |
| Age, years, mean (SD) | “45.4 (12.74)” |
| Male, n (%) | “65 (62.5)” |
| UC duration, years, mean (SD) | “11.2 (7.02)” |
| Modified Mayo score 0 to 4, n (%) | “104 (100)” |
| C-reactive protein, mg/L, median | “2.2” |
| Fecal calprotectin, µg/g, median | “57.0” |
| Concomitant corticosteroids, n (%) | “6 (5.8)” |
| Concomitant 5-ASA, n (%) | “79 (76.0)” |
| Prior refractoriness to biologics, n (%) | “49 (47.1)” |
| Primary non-response, n (%) | “19 (38.8)” |
| Loss of response, n (%) | “30 (61.2)” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Clinical remission at weeks 48, 96, and 144 with non-responder imputation

> “At weeks 48, 96 and 144 of treatment, 73% (95/130), 69% (90/130), and 68% (88/130) of patients evaluated were in clinical remission, respectively.”
> “Similar trends were observed with other efficacy analyses, and no new safety signals were observed.”

Source: [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports)

<a id="topic-3.1.8.8.3-2"></a>

###### Clinical and symptomatic remission in the non-responder imputation and as-observed analyses

> “Following treatment with Obe-25, rates of clinical remission were 73% at W48, 69% at W96 and 68% at W144, while symptomatic remission rates ranged from 72% to 79% (NRI analysis)”
> “In the as-observed analysis among Week 144 completers, clinical remission rates were 84-85% through W144, while symptomatic remission rates ranged from 89% to 91%.”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.3-3"></a>

###### Efficacy endpoints among week 144 completers

| Endpoint (n=104) | Baseline | Week 48 | Week 96 | Week 144 |
| --- | --- | --- | --- | --- |
| Clinical remission | “91%” | “85%” | “85%” | “85%” |
| Symptomatic remission | “92%” | “90%” | “88%” | “90%” |
| Endoscopic improvement | “99%” | “92%” | “93%” | “92%” |
| Endoscopic remission | “66%” | “66%” | “72%” | “72%” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.3-4"></a>

###### Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response

| Endpoint and subgroup | Baseline | Week 48 | Week 96 | Week 144 |
| --- | --- | --- | --- | --- |
| Clinical remission, AT-IR naive (N=57) | “97%” | “91%” | “88%” | “90%” |
| Clinical remission, prior AT-IR (N=47) | “85%” | “77%” | “80%” | “79%” |
| Symptomatic remission, AT-IR naive (N=57) | “97%” | “97%” | “91%” | “95%” |
| Symptomatic remission, prior AT-IR (N=47) | “87%” | “83%” | “85%” | “85%” |
| Endoscopic improvement, AT-IR naive (N=57) | “100%” | “93%” | “95%” | “95%” |
| Endoscopic improvement, prior AT-IR (N=47) | “98%” | “92%” | “91%” | “89%” |
| Endoscopic remission, AT-IR naive (N=57) | “84%” | “77%” | “84%” | “81%” |
| Endoscopic remission, prior AT-IR (N=47) | “45%” | “53%” | “57%” | “62%” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.3-5"></a>

###### Fecal calprotectin through week 144

> “Median fecal calprotectin (FCP) ranged from 48 to 98 µg/g over the 144-week study period”
> “Among pts with available FCP data at W144, 81% (72/89) had FCP levels <250 µg/g and 69% (61/89) had levels <150 µg/g (Fig 3)”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.3-6"></a>

###### Two-year interim analysis among participants evaluated, September 2024 data cutoff

> “At study baseline, 89% (116/130) of patients were in clinical remission. At weeks 48 and 96 of treatment, 84% (95/113) and 87% (64/74) of patients evaluated were in clinical remission, respectively. Similarly, 92% (119/130) of patients were in symptomatic remission at study baseline. At weeks 48 and 96, 91% (103/113) and 92% (68/74) of patients evaluated were in symptomatic remission, respectively.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Treatment-emergent adverse events in all 130 participants

| Event | N (%) [IR/100 PY] |
| --- | --- |
| Any TEAE | “96 (73.8) [87.9]” |
| TEAE leading to discontinuation | “9 (6.9) [4.25]” |
| Serious TEAE | “8 (6.2) [3.86]” |
| Ulcerative colitis | “15 (11.5) [7.3]” |
| Nasopharyngitis | “11 (8.5) [5.4]” |
| Upper respiratory tract infection | “10 (7.7) [4.9]” |
| COVID-19 | “11 (8.5) [5.4]” |
| Hypertension | “7 (5.4) [3.4]” |
| Diarrhea | “5 (3.8) [2.4]” |
| Arthralgia | “5 (3.8) [2.4]” |
| Gastroenteritis | “4 (3.1) [1.9]” |
| Non-melanoma skin cancer | “1 (0.8) [0.5]” |

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.5-2"></a>

###### Deaths, opportunistic infections, and laboratory findings

> “Death 0 Opportunistic infections 0”
> “This table does not include laboratory findings.”

Source: [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf)

<a id="topic-3.1.8.8.5-3"></a>

###### Infections and malignancies across up to 7 years of treatment

> “No safety signals were identified over the 144-week period”
> “Across up to 7 years of treatment, no safety signal for infections or malignancies emerged”

Source: [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf)

<a id="topic-3.1.8.8.5-4"></a>

###### Safety at the September 2024 data cutoff

> “The safety results were consistent with previous trials, with no new safety signals detected.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.

Source: [ClinicalTrials.gov NCT05177835](https://clinicaltrials.gov/study/NCT05177835); [Abivax first quarter 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-quarter-2026-financial-results-and-reports); [UEG Week poster, Study 108 three-year analysis (2026)](https://www.abivax.com/wp-content/uploads/2026/10/Final-Poster-3.-Verstockt-OLE-3-yr-Dose-De-Esc.pdf); [Sands et al. (2026b)](https://www.abivax.com/wp-content/uploads/2026/10/OP107_Obe-3yr-LTE-ATIR-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-BES.pdf); [ClinicalTrials.gov NCT03368118 results](https://clinicaltrials.gov/study/NCT03368118?tab=results)

<a id="heading-3.1.9"></a>

#### 3.1.9 ABX464-906

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Purpose stated in the EU register title

> “A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin in healthy male participants.”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

<a id="topic-3.1.9.2-1"></a>

###### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-906” |
| Location | “Locations France” |
| Start of trial | “Start of trial 13/06/2024” |
| End of trial | “End of trial 20/02/2025” |

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.2-2"></a>

###### Trial site

> “Eurofins Optimed”
> “clinical pharmacology unit, 1 Rue Des Essarts, 38610, Gieres”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Phase 1, two-part, open-label, single-sequence design

> “A Phase 1, 2-part, open-label, single-sequence study”
> “Trial Phase Human Pharmacology (Phase I)- Other”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.3-2"></a>

###### Drug-drug interaction trials described in the Form 20-F

> “In addition, three Phase 1 clinical trials have been completed in 2025 to assess the tolerability and safety profile of obefazimod”
> “two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Participant type, age, and sex in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
| Population named in the title | “healthy male participants” |

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Single and multiple doses of obefazimod with rosuvastatin

> “the effect of single and multiple doses of obefazimod on the pharmacokinetics of rosuvastatin”

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00)

<a id="topic-3.1.9.5-2"></a>

###### Investigational medicinal product details not yet public

> “Details of the investigational medicinal products, including ATC codes”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Rosuvastatin Pharmacokinetics as the Study Endpoint

No evidence found.

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Planned participants in the EU register

> “France: Ended. Planned participants: 24”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="topic-3.1.9.7.1-2"></a>

###### Enrollment in the two drug-drug interaction trials stated in the Form 20-F

> “for which we enrolled 24 and 36 healthy volunteers respectively”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

ABX464-906 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (13 June 2024 to 20 February 2025), one site in France, and 24 planned healthy volunteers aged 18 to 64 years; the 20-F reports two drug-drug interaction trials with 24 and 36 enrolled healthy volunteers. The objectives, endpoints, doses, and eligibility criteria are not public, and the summary of results is deferred under the rules for category 1 trials until 20 August 2027. The register limits the population to healthy men. No pharmacokinetic or safety result has been published.

Source: [EU Clinical Trials Information System 2023-509226-21-00](https://euclinicaltrials.eu/ctis-public/view/2023-509226-21-00); [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.9.9-2"></a>

###### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 20 Aug 2027 (EMA/263067/2023).”
> “Protocol and documents: deferred: documents of adult category 1 trials (mostly phase I) are not public while the deferral applies, until 20 Aug 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-509226-21-00](https://ctis.eu/trial/2023-509226-21-00)

<a id="heading-3.1.10"></a>

#### 3.1.10 ABX464-910

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Purpose stated in the EU register title

> “A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-910” |
| Location | “Locations Belgium” |
| Start of trial | “Start of trial 10/10/2023” |
| End of trial | “End of trial 31/08/2024” |

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="topic-3.1.10.2-2"></a>

###### Trial site

> “Advanced Technology Corporation”
> “ATC, Avenue Hippocrate 15, 4000, Liege”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

###### Phase 1 drug-drug interaction design

> “Trial Phase Human Pharmacology (Phase I)- Other”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="topic-3.1.10.3-2"></a>

###### Drug-drug interaction trials described in the Form 20-F

> “two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

###### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Medical condition | “Medical condition(s) Healthy female participants of childbearing potential.” |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Multiple doses of obefazimod with ethinyl estradiol and drospirenone

> “multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone)”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Combined Oral Contraceptive Pharmacokinetics as the Study Endpoint

No evidence found.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

###### Planned participants in the EU register

> “Belgium: Ended. Planned participants: 36”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="topic-3.1.10.7.1-2"></a>

###### Enrollment in the two drug-drug interaction trials stated in the Form 20-F

> “for which we enrolled 24 and 36 healthy volunteers respectively”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

No evidence found.

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00); [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.10.9-2"></a>

###### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 28 Feb 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="heading-3.1.11"></a>

#### 3.1.11 ABX464-902

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

###### Primary and secondary objectives in the protocol

> “Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the PK of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.”
> “Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on its PK in the presence and absence of fluvoxamine.”
> “Evaluate the safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.1-2"></a>

###### Purpose stated in the registry record

> “A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2020-12-17” |
| Primary completion (actual) | “2021-05-18” |

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.2-2"></a>

###### Results reporting dates in the registry record

| Field | Registry entry |
| --- | --- |
| Results first submitted | “2022-05-06” |
| Results first posted | “2026-11-09” |
| Other study ID numbers | “ABX464-902” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.2-3"></a>

###### Single site in Wales, United Kingdom

> “Study recruitment for this study was undertaken in South Wales in the United Kingdom. The recruitment process began in December 2020 and concluded in April 2021.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

> “The study will be conducted in 60 healthy volunteers (males and females) at Simbec-Orion Clinical Pharmacology Unit in Merthyr Tydfil, South Wales.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

###### Phase 1, two-part, fixed-sequence, open-label crossover design

> “This is a Phase 1, 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine) and a known CYP1A2 inhibitor (fluvoxamine).”
> “Separate cohorts of subjects will be enrolled for Part A (up to 24 subjects enrolled to allow 22 subjects required to complete Part A ) and Part B (up to 36 subjects enrolled to allow 32 subjects were to complete Part B).”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.3-2"></a>

###### Perpetrator and victim roles in each part

> “In Part A of the study ABX464 is considered the ‘perpetrator’ drug and caffeine the ‘victim’ drug.”
> “In Part B of the study ABX464 is considered the victim drug and fluvoxamine the perpetrator drug.”
> “The co-administration on Day 4 is to evaluate the potential for inhibition of CYP1A2 by the perpetrator drug (ABX464) following a single dose, while the co-administration on Day 17 is to evaluate the potential for induction of CYP1A2 by the perpetrator following multiple dosing for 14 days”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.3-3"></a>

###### Rationale for the open-label design

> “As the PK parameters investigated are objective, it was considered that there was only minimal risk of introducing bias into the study.”
> “The crossover design permits within-subject comparison, which results in reduced variability of the data obtained.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

###### Key inclusion and exclusion criteria in the registry record

> “Healthy, male or female subject, between 18 and 55 years of age, inclusive.”
> “Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, or any product known to interact with CYP1A2 within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP.”
> “Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to first dose administration with the study medication or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).”
> “Experiences regular headaches (i.e., experiences headaches more than weekly).”
> “Clinically significant history of depression or anxiety.”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Part A: caffeine with and without obefazimod

> “Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days). Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.5-2"></a>

###### Part B: obefazimod with and without fluvoxamine

> “Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days). ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.5-3"></a>

###### Dose selection and administration with food

> “The dose of 50 mg ABX464 was chosen as this is anticipated as the recommended clinical dose during subsequent clinical trials. In addition, given the established significant effect of food on the PK of ABX464, all doses of ABX464 will be administered within 30 minutes (mins) of the consumption of a standardised breakfast.”
> “Fluvoxamine: 100 mg once daily for 10 days followed by tapering period of 50 mg for 7 days then 25 mg for 7 days.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Caffeine and Obefazimod Cmax and AUC as the Primary Endpoints

<a id="topic-3.1.11.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Part A - Day 1 Peak Plasma Concentration of Caffeine” | “Day 1” |
| Primary | “Part A - Day 17 AUC of Caffeine & ABX464” | “Day 17” |
| Primary | “Part B - Day 1 - Peak Plasma Concentration of ABX464” | “Day 1” |
| Primary | “Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)” | “Day 11” |
| Secondary | “Number of Adverse Events (AEs)” | “From baseline up to Day 25” |

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.6.1-2"></a>

###### In vitro basis for a CYP1A2 interaction study

> “Oxidative metabolism via the cytochrome (CYP) P450 pathway was also identified as a route of metabolism for ABX464, with cytochrome P450 1A2 (CYP1A2) identified as the major contributing isoform. Subsequent studies also demonstrated that ABX464 was a strong inhibitor of CYP1A2 in human liver microsomes and induced its expression in human hepatocytes.”
> “These findings indicate a potential clinically significant interaction with co-administered CYP1A2 substrates and are the basis for this clinical study to evaluate potential CYP1A2-mediated drug interactions.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.6.1-3"></a>

###### Choice of caffeine and fluvoxamine as probe drugs

> “Caffeine was chosen as the probe victim drug for Part A as it is a well-established substrate for CYP1A2, and therefore its PK are sensitive to either inhibition or induction of CYP1A2 by a perpetrator drug.”
> “Fluvoxamine was chosen as the probe perpetrator drug for Part B as it is a well-established inhibitor of CYP1A2”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

###### Sample size calculation in the protocol

> “a sample size of 22 subjects is considered sufficient to detect a 20% treatment difference with a power of 80% and alpha of 5%, based upon a geometric mean ratio of 1. To allow for a higher CV%, dropouts or subjects who otherwise fail to complete the study, 24 subjects will be enrolled in Part A of the study.”
> “a sample size of 32 subjects is considered sufficient to detect a 20% treatment difference with a power of 80% and alpha of 5%, based upon a geometric mean ratio of 1. To allow for a higher CV%, dropouts or subjects who otherwise fail to complete the study, 36 subjects will be enrolled in Part B of the study.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.7.1-2"></a>

###### Participants screened, enrolled, and analyzed

> “164 volunteers were screened for 59 eligible participants enrolled.”
> “Total number of Part A and Part B is 59 (24 and 35 respectively).”
> “Of the 24 participants enrolled into Part A of the study, 2 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for non-adherence with pre-dose caffeine restrictions.”
> “Of the 35 participants enrolled into Part B of the study, 9 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for a vomiting episode within 2 x median Tmax on either Day 1 or Day 11 and 1 participant was excluded as an early withdrawal from the study”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

<a id="topic-3.1.11.7.2-1"></a>

###### Safety and pharmacokinetic sets in the protocol

> “Safety Set: All enrolled subjects who receive at least 1 dose of IMP/NIMP will be included in the safety analysis.”
> “PK Set: Subjects will be included in the PK Set where they have received all doses of IMP/NIMP up to and including Day 17 for Part A and Day 11 for Part B and comply with the following criteria:”
> “Do not have an occurrence of vomiting (that occurs at or before 2 times median time to maximum observation concentration (Cmax; Tmax) of the appropriate treatment) or diarrhoea which renders the concentration profile unreliable;”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.7.2-2"></a>

###### Planned statistical comparison

> “The primary pharmacokinetic endpoints of AUC0-inf, AUC0-t and Cmax will be log-transformed and analysed using an analysis of variance (ANOVA) model including fixed effects for treatment and subject.”
> “These estimates will then be back-transformed to provide estimates of the ratios of the geometric LSMeans and corresponding 90% confidence intervals.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

<a id="topic-3.1.11.8.1-1"></a>

###### Participant flow in the registry results

| Milestone | Part A | Part B |
| --- | --- | --- |
| Started | “24” | “35” |
| Completed | “24” | “34” |
| Withdrawal by subject | “0” | “1” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

<a id="topic-3.1.11.8.2-1"></a>

###### Age and sex by study part

| Characteristic | Part A (24 participants) | Part B (35 participants) |
| --- | --- | --- |
| Age, mean (standard deviation), years | “33.7(9.44)” | “36.8(9.75)” |
| Sex, participants | “Part A Number Analyzed 24 participants Female 5 Male 19” | “Part B Number Analyzed 35 participants Female 13 Male 22” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.2-2"></a>

###### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)

| Measure, mean (standard deviation) | Day 1, caffeine alone | Day 4, caffeine and ABX464 | Day 17, caffeine and ABX464 |
| --- | --- | --- | --- |
| Caffeine Cmax, ng/mL | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL | “7420(4760)” | “5460(2740)” | “1560(719)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.3-2"></a>

###### Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)

| Measure, mean (standard deviation) | Day 1, ABX464 alone | Day 11, ABX464 and fluvoxamine |
| --- | --- | --- |
| ABX464 Cmax, ng/mL | “23.2(12.5)” | “33.4(19.0)” |
| ABX464 AUC, h*ng/mL | “55.2(25.7)” | “73.0(34.2)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.3-3"></a>

###### Plain-language summary of the interaction results

> “ABX464 does not demonstrate any drug-drug interactions for drugs which are broken down (metabolised) by the enzyme CYP1A2 as the levels of caffeine and fluvoxamine in the blood remained similar in both the presence and absence of ABX464.”
> “ABX464 may be metabolised in the same pathway as fluvoxamine, as the levels of ABX464 in the blood showed increases in the presence of fluvoxamine.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

###### Adverse events, serious adverse events, and deaths

| Measure | Part A overall | Part B overall |
| --- | --- | --- |
| Participants with any other (nonserious) adverse event | “16/24 (66.67%)” | “30/35 (85.71%)” |
| Participants with a serious adverse event | “0/24 (0.00%)” | “0/35 (0.00%)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.5-2"></a>

###### Most frequent adverse events by study part

| Adverse event | Part A overall | Part B overall |
| --- | --- | --- |
| Headache | “13/24 (54.17%)” | “25/35 (71.43%)” |
| Nausea | “7/24 (29.17%)” | “20/35 (57.14%)” |
| Vomiting | “2/24 (8.33%)” | “11/35 (31.43%)” |
| Decreased appetite | “1/24 (4.17%)” | “15/35 (42.86%)” |
| Fatigue | “3/24 (12.50%)” | “14/35 (40.00%)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.5-3"></a>

###### Plain-language safety summary

> “With respect to the safety objectives of the study, it was determined ABX464 was considered to be safe and well tolerated at a 50 mg dose strength, both in the presence and absence of caffeine and fluvoxamine respectively. All adverse events (side effects) which were reported were considered to be mild to moderate in severity and resolved before the study completed.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 h*ng/mL on Day 1 alone and 1560 h*ng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results); [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf); [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers); [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.9-2"></a>

###### Limitations and caveats stated in the registry results

> “N/A - although a number of participants were excluded from the PK analysis sets, this did not impact on the overall evaluation of the study objectives.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.12"></a>

#### 3.1.12 ABX464-908

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Purpose stated in the EU register title

> “A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.1-2"></a>

###### Purpose stated in the Form 20-F

> “a trial in participants with mild and moderate hepatic impairment compared to matched control normal liver function participants, for the purposes of assessing pharmacokinetics, safety and tolerability in this population”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

###### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-908” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/10/2023” |
| End of trial | “End of trial 11/09/2024” |

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.2-2"></a>

###### Trial site

> “CRS Clinical Research Services Management GmbH”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Phase 1 multiple-dose design with matched controls

> “Trial Phase Human Pharmacology (Phase I)- Other”
> “multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

###### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Patients” |
| Age range | “Age range 65+ years, 18-64 years” |

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="topic-3.1.12.4-2"></a>

###### Hepatic impairment groups and controls

> “participants with mild and moderate hepatic impairment compared to matched control normal liver function participants”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

###### Multiple oral doses of obefazimod

> “multiple oral doses of obefazimod”

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Obefazimod Pharmacokinetics in Hepatic Impairment as the Study Endpoint

No evidence found.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Planned participants in the EU register

> “Germany: Ended. Planned participants: 32”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

<a id="topic-3.1.12.7.1-2"></a>

###### Enrollment stated in the Form 20-F

> “for which we enrolled 30 participants”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Company statement on the completed Phase 1 trials

> “The results of these Phase 1 clinical trials provide supportive data for our further clinical development and New Drug Application (“NDA”) submission.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

ABX464-908 has only an EU register record and a sentence in the Form 20-F. The register gives the title, the dates (9 October 2023 to 11 September 2024), one site in Germany, and 32 planned participants; the 20-F reports 30 enrolled participants with mild or moderate hepatic impairment or matched normal liver function. The 20-F states that the trial was completed in 2025, whereas the register gives 11 September 2024 as its end. The classification method for hepatic impairment, the dose, the number per group, and the endpoints are not public, severe hepatic impairment was not studied, and the summary of results is deferred until 11 March 2027. The 20-F describes the results only as “supportive data” for the NDA, so no exposure ratio or safety result is available to inform dosing in hepatic impairment.

Source: [EU Clinical Trials Information System 2023-505299-31-00](https://euclinicaltrials.eu/ctis-public/view/2023-505299-31-00); [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.12.9-2"></a>

###### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 11 Mar 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

<a id="heading-3.1.13"></a>

#### 3.1.13 ABX464-907

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

<a id="topic-3.1.13.1-1"></a>

###### Purpose stated in the EU register title

> “A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

<a id="topic-3.1.13.2-1"></a>

###### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-907” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/09/2024” |
| End of trial | “End of trial 14/10/2025” |

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-3.1.13.2-2"></a>

###### Trial site

> “CRS Clinical Research Services Management GmbH”
> “Clinical Unit, Lornsenstrasse 7, Brunswik, Kiel”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

<a id="topic-3.1.13.3-1"></a>

###### Phase 1 multiple-dose design with matched controls

> “Trial Phase Human Pharmacology (Phase I)- Other”
> “multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-3.1.13.3-2"></a>

###### Additional Phase 1 trials described in the Form 20-F

> “Furthermore, additional Phase 1 clinical trials to support NDA submission are ongoing.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

<a id="topic-3.1.13.4-1"></a>

###### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Participants type | “Participants type Healthy volunteers, Patients” |
| Age range | “Age range 18-64 years, 65+ years” |

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

<a id="topic-3.1.13.5-1"></a>

###### Multiple oral doses of obefazimod

> “multiple oral doses of obefazimod”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Obefazimod Pharmacokinetics in Renal Impairment as the Study Endpoint

No evidence found.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.13.7.1-1"></a>

###### Planned participants in the EU register

> “Germany: Ended. Planned participants: 48”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

No evidence found.

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

###### Summary

ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00); [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.13.9-2"></a>

###### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 14 Apr 2028 (EMA/263067/2023).”

Source: [CTIS.eu 2024-514561-20-00](https://ctis.eu/trial/2024-514561-20-00)

<a id="heading-3.1.14"></a>

#### 3.1.14 ABX464-FE-001

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

<a id="topic-3.1.14.1-1"></a>

###### Objectives stated in the publication

> “The objectives of this study were to assess the relative bioavailability of single and repeated oral doses of 50 mg of ABX464 under fed or fasted conditions and to assess the clinical and biological tolerability of ABX464.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.1-2"></a>

###### Purpose stated in the registry record

> “The goal of this study is to determine the impact of the food on the absorption of the ABX464.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

<a id="topic-3.1.14.2-1"></a>

###### Single site in Mauritius, October 2014 to June 2015

> “The study (protocol no. ABX464-FE-001) was approved by the Clinical Research Regulatory Council in Mauritius and conducted between October 2014 and June 2015 in accordance with the Declaration of Helsinki and good clinical practice guidelines.”
> “performed at a single site (CAP Research, Phoenix, Mauritius)”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.2-2"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start | “2014-09” |
| Primary completion (actual) | “2015-06” |
| Other study ID numbers | “ABX464-FE-001” |

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

<a id="topic-3.1.14.3-1"></a>

###### Open-label, randomized food-effect design in two groups

> “This phase I study consisted of an open-label, food-effect, randomized study divided into 2 groups and performed at a single site (CAP Research, Phoenix, Mauritius).”
> “In the first group, a crossover design, 24 subjects received a single dose of 50 mg of ABX464 on 2 occasions (once under fasted conditions [treatment A] and once under fed conditions [treatment B]), separated by a washout period of at least 45 days. In the second group, a parallel design, 24 subjects received 50 mg of ABX464 every 3 days during 10 days under the fasted (treatment A) or fed (treatment B) condition.”
> “The second group involved the repeated-dose investigation with a conservative interval of 3-day dosing being chosen primarily because of safety considerations and also to assess whether this regimen was sufficient to maintain the metabolite at high levels.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

<a id="topic-3.1.14.4-1"></a>

###### Healthy men aged 18 to 55 years

> “Forty-eight healthy male subjects in good health on the basis of medical history, physical examination, vital signs, electrocardiogram (ECG), and routine laboratory safety tests, aged from 18 to 55 years, with BMIs of 17 to 28 kg/m2, and who were nonsmokers or light smokers (≤5 cigarettes per day) without history of frequent headache and/or migraine, recurrent nausea, and/or vomiting were included after having given their written informed consent.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.4-2"></a>

###### Key criteria in the registry record

> “Healthy Caucasian male subjects, 18-55 years of age”
> “Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

<a id="topic-3.1.14.5-1"></a>

###### Obefazimod 50 mg fasted or after a high-fat breakfast

> “In group 1, a single oral dose of ABX464 (50 mg; two 25-mg capsules) was administered on the morning of day 0 of each period either after overnight fasting or after a high-fat breakfast.”
> “In group 2, ABX464 (50 mg) was administered on days 1, 4, 7, and 10 either after overnight fasting or after a high-fat breakfast.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Single-dose AUC and Cmax Under Fed and Fasted Conditions as the Primary Endpoints

<a id="topic-3.1.14.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Area under the plasma concentration versus time curve (AUC) of single oral dose of 50mg of ABX464 in fed or fasted condition.” | “45 days” |
| Primary | “Peak Plasma Concentration (Cmax) of single oral dose of 50mg of ABX464 in fed or fasted condition.” | “45 days” |
| Secondary | “Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0” | “Up to 45 days” |

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="topic-3.1.14.6.1-2"></a>

###### Reason for studying the food effect

> “Food influence can be very important in the absorption of medicines, because food can lead to inefficiency in treatment or an increase in adverse events (AEs). It is important to investigate the food effect on the plasma levels of the drug in order to accordingly adapt doses for patients and optimize the treatment.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.14.7.1-1"></a>

###### Planned and enrolled participants

> “Twenty-four subjects were enrolled in each group in order to have 20 evaluable subjects per group (data not shown).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.7.1-2"></a>

###### Planned enrollment in the registry record

> “This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

<a id="topic-3.1.14.7.2-1"></a>

###### Safety and pharmacokinetic populations

> “All of the included subjects received the treatment as planned in the protocol and were analyzed in the safety analysis.”
> “This was considered to have no impact on PK parameters, and thus all the subjects/periods were kept in the PK population except a subject in group 1 with no quantifiable ABX464 plasma concentrations after administration of ABX464 without food (treatment A).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.7.2-2"></a>

###### Statistical comparison of fed and fasted conditions

> “In 2 groups, for each parameter, a point estimate for the ratio of geometric means (GMs) (treatment B to treatment A) was obtained by calculating the difference of least-square means on the logarithmic scale and subsequent back-transformation with the exponential function.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

<a id="topic-3.1.14.8.1-1"></a>

###### Vomiting episodes and treatment received as planned

> “Regarding the PK analysis set, 6 subjects (5 in group 1 and 1 in group 2) experienced vomiting episodes on day 1 more than 2 h after administration.”
> “No AEs led to premature discontinuation.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

<a id="topic-3.1.14.8.2-1"></a>

###### Age and body mass index by group

> “Twenty-four male subjects aged from 20 to 53 years (mean, ∼35 years) and with a body mass index (BMI) of 17.4 to 28.2 kg/m2 were included in group 1, and 24 male subjects aged from 18 to 53 years (mean, ∼34 years) and with a BMI of 17.9 to 28.0 kg/m2 were included in group 2.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

<a id="topic-3.1.14.8.3-1"></a>

###### Single-dose obefazimod exposure, fed versus fasted (group 1)

| Parameter | Fasted, geometric mean | Fed, geometric mean | Point estimate (fed/fasted) | 90% CI |
| --- | --- | --- | --- | --- |
| Cmax, ng/ml | “13.70” | “43.71” | “3.16” | “2.45–4.07” |
| AUC0–t, ng · h/ml | “34.52” | “109.27” | “3.12” | “2.55–3.82” |

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-2"></a>

###### Food increased obefazimod exposure and delayed absorption

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively). The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h. The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-3"></a>

###### Repeated dosing (group 2)

> “Day 1 GM values for Cmax and AUC0–t were 42.92 ng/ml and 105.22 ng · h/ml under fed conditions compared to 10 ng/ml and 26.92 ng · h/ml, respectively, under fasted conditions, i.e., 329% and 291% higher.”
> “With concomitant food intake, GM values of Cmax and AUC0–t were also substantially higher (415% and 294% higher, respectively).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-4"></a>

###### Smaller food effect on the N-glucuronide metabolite

> “The GM value of the Cmax of ABX464-NGlc given under fed conditions (2,401.52 ng/ml) was 7% lower than that when ABX464 was given under fasted conditions (2,572.81 ng/ml), while the GM AUC0–∞ was 6% lower.”
> “The GM values for Cmax and t1/2 were approximately 190- and 120-fold higher, respectively, than those for the parent compound under fasted conditions.”
> “After the fourth administration, differences in ABX464-NGlc PK parameters under fasted and fed conditions were somewhat larger than those after the first, with GM values for the Cmax and AUC0–t being 35% and 33% higher, respectively, when ABX464 was given with food (Table 5).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

<a id="topic-3.1.14.8.5-1"></a>

###### Treatment-emergent adverse events

> “A total of 50 treatment-emergent AEs (TEAEs) (27 under fasted conditions and 23 under fed conditions) were reported by 21 subjects out of 48 (data not shown). All of them were of mild to moderate intensity except for 1 case of severe abdominal injury not related to ABX464. The most frequent TEAEs consisted of headaches (29% of the subjects), nausea (12.5% of the subjects), and vomiting (12.5% of the subjects).”
> “Concomitant food intake did not appear to reduce this side effect, as 4 subjects vomited under fed conditions and 2 under fasting conditions.”
> “There was 1 serious AE (SAE) in each group resulting from an accident and an intercurrent disease (acute gastroenteritis 26 days after the last dosing). None of these could be reasonably related to ABX464.”
> “No changes or clinically significant abnormalities in either laboratory parameters, vital signs, or ECG parameters were observed.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

<a id="topic-3.1.14.9-1"></a>

###### Summary

ABX464-FE-001 enrolled 48 healthy men in Mauritius in 2014 and 2015, 24 per group; the registry described 40 healthy Caucasian men. The repeated-dose group received 50 mg every 3 days, a schedule the authors chose for safety reasons, and compared fed and fasted conditions in a parallel design. The authors state that the study “does have a number of intrinsic limitations”: women were excluded, no age effects could be analyzed, and the terminal elimination rate constant after a single dose could be determined in only 17 participants fasted and 13 fed. One participant without quantifiable fasted concentrations was excluded from the pharmacokinetic analysis, and four authors are Abivax employees.

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/); [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="topic-3.1.14.9-2"></a>

###### Limitations stated by the authors

> “Also, as this study was the first to investigate food effect and repeated dosing, it does have a number of intrinsic limitations.”
> “In addition, in order to eliminate any potential risk in the event of contraceptive failure, female subjects were not included in this study. The study is further limited in that no age effects could be analyzed, as the study was done with low subject numbers (n = 24 in each group), in the 18- to 55-year age group, as is standard for such early studies.”
> “With treatment A (single treatment under fasted conditions), the terminal plasma elimination rate constant (kel) could be properly determined in only 17 subjects.”
> “With treatment B (single treatment under fed conditions), the kel could be properly determined in only 13 subjects.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.9-3"></a>

###### Funding and author affiliations

> “This work was funded by Abivax, a publicly listed company (formerly known as Splicos).”
> “D.S., J.-M.S., P.G., and H.J.E. are Abivax employees and hold Abivax stock options.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.15"></a>

#### 3.1.15 ABX464-001

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

<a id="topic-3.1.15.1-1"></a>

###### Objective stated in the publication abstract

> “A first-in-man study was conducted to determine the pharmacokinetic and safety profiles of ABX464.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

<a id="topic-3.1.15.2-1"></a>

###### Single site in Montpellier, France

> “This study is an open label, parallel group, single ascending dose, exploratory study performed in a single site (Centre Cap, Montpellier, France).”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.2-2"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start | “2014-03” |
| Primary completion (actual) | “2014-07” |
| Other study ID numbers | “ABX464-001” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

<a id="topic-3.1.15.3-1"></a>

###### Open-label, single ascending dose design with sentinel dosing

> “Six subjects per dose group were enrolled into 1 of 4 groups with escalating doses of ABX464 (50, 100, 150 and 200 mg). For each dose group, a first subject was treated, if no adverse event (AE) occurred, a second subject was dosed one hour later. The four last subjects were dosed the day after if no clinically significant AE occurred. Escalation to the following dose level was decided after review of PK and safety data (laboratory results, ECG, vital signs and AEs)”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

<a id="topic-3.1.15.4-1"></a>

###### Healthy men without HIV infection

> “Twenty-four male subjects in good health without HIV infection, aged from 18 to 55 years old, with BMIs of 18-27 kg/m 2 were included.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-3.1.15.4-2"></a>

###### Key criteria in the registry record

> “Non smokers or light smokers of less than 10 cigarettes per day”
> “Subject with any on-going infection or disease”

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

<a id="topic-3.1.15.5-1"></a>

###### Single oral dose of 50 to 200 mg after overnight fasting

> “A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using the Percentage of Participants With at Least One Adverse Event as the Primary Endpoint

<a id="topic-3.1.15.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Percentage of patients experiencing at least one Adverse Event” | “Up to 45 days post dosing” |
| Secondary | “Peak Plasma Concentrations (Cmax) of ABX464 and metabolite” | “Up to 45 days post dosing” |
| Secondary | “Area Under the Curve (AUC) of Plasma Concentrations of ABX464 and metabolite” | “Up to 45 days post dosing” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.6.1-2"></a>

###### Safety assessments and pharmacokinetic analytes

> “Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464- N -glucuronide (ABX464-NGlc).”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.15.7.1-1"></a>

###### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “24” |

Source: [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

<a id="topic-3.1.15.8.3-1"></a>

###### Pharmacokinetics of obefazimod and its N-glucuronide metabolite

> “ABX464's Cmax was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGlc. The Cmax of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t1/2 (90-110 h). The ratio of metabolite to parent drug was consistent across the complete dose range.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

<a id="topic-3.1.15.8.5-1"></a>

###### Tolerability across the 50 to 200 mg doses

> “ABX464 was well tolerated; the most frequent related treatment-emergent adverse events were headaches, nausea and vomiting; they were not considered as treatment-limiting effects.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-3.1.15.8.5-2"></a>

###### Description of the first-in-human results in the food-effect publication

> “This study was carried out with a single dose of 50, 100, 150, or 200 mg after overnight fasting, and the product was reported to be safe and well tolerated at all doses.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

<a id="topic-3.1.15.9-1"></a>

###### Summary

ABX464-001 gave a single oral dose of 50, 100, 150, or 200 mg after overnight fasting to 24 healthy men, 6 per dose group. It had no placebo group and no repeated dosing, enrolled men only, and all doses were given fasted. The full article is closed access, and the abstract gives no numerical pharmacokinetic parameters by dose, no adverse event counts, and no dose-proportionality analysis beyond stating that the metabolite-to-parent ratio “was consistent across the complete dose range”. The registry record posts no results, and four of eight authors list Abivax as their affiliation.

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/); [ClinicalTrials.gov NCT02792686](https://clinicaltrials.gov/study/NCT02792686)

<a id="topic-3.1.15.9-2"></a>

###### Author affiliations in the abstract record

> “Scherrer D(1), Rouzier R(2), Noel Barrett P(3), Steens JM(1), Gineste P(1), Murphy RL(4), Tazi J(5), Ehrlich HJ(1).”
> “(1)ABIVAX, 5 Rue de la Baume, 75008 Paris, France.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
